(ROOT (S (NP (NN Hypertension)) (VP (VP (VBZ is) (NP (NP (DT the) (ADJP (RBS most) (JJ common)) (NN condition)) (VP (VBN seen) (PP (IN in) (NP (JJ primary) (NN care)))))) (CC and) (VP (VBZ leads) (PP (TO to) (NP (NP (JJ myocardial) (NN infarction)) (, ,) (NP (NN stroke)) (, ,) (NP (JJ renal) (NN failure)) (, ,) (CC and) (NP (NN death)))) (SBAR (IN if) (S (RB not) (VP (VBN detected) (NP (NP (ADJP (JJ early))) (CC and) (NP (JJ treated))) (ADVP (RB appropriately))))))) (. .)))
(ROOT (S (NP (NNS Patients)) (VP (VBP want) (S (VP (TO to) (VP (VB be) (VP (VBN assured) (SBAR (IN that) (S (NP (NP (NP (NN blood) (NN pressure)) (PRN (-LRB- -LRB-) (NP (NN BP)) (-RRB- -RRB-))) (NN treatment)) (VP (MD will) (VP (VB reduce) (NP (PRP$ their) (NN disease) (NN burden)) (, ,) (SBAR (IN while) (S (NP (NNS clinicians)) (VP (VBP want) (NP (NP (NN guidance)) (PP (IN on) (NP (NN hypertension) (NN management)))) (S (VP (VBG using) (NP (DT the) (JJS best) (JJ scientific) (NN evidence)))))))))))))))) (. .)))
(ROOT (S (NP (DT This) (NN report)) (VP (VBZ takes) (NP (DT a) (JJ rigorous) (, ,) (JJ evidence-based) (NN approach)) (S (VP (TO to) (VP (VB recommend) (NP (NP (NN treatment) (NNS thresholds)) (, ,) (NP (NNS goals)) (, ,) (CC and) (NP (NP (NNS medications)) (PP (IN in) (NP (NP (DT the) (NN management)) (PP (IN of) (NP (NP (NN hypertension)) (PP (IN in) (NP (NNS adults))))))))))))) (. .)))
(ROOT (S (NP (NN Evidence)) (VP (VBD was) (VP (VBN drawn) (PP (IN from) (S (VP (VBN randomized) (NP (NP (JJ controlled) (NNS trials)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBP represent) (NP (NP (DT the) (JJ gold) (NN standard)) (UCP (UCP (IN for) (S (VP (VBG determining) (NP (NN efficacy)))) (CC and)) (NP (NN effectiveness))))))))))))) (. .)))
(ROOT (S (NP (NN Evidence) (NN quality) (CC and) (NNS recommendations)) (VP (VBD were) (VP (VBN graded) (S (VP (VBN based) (PP (IN on) (NP (NP (PRP$ their) (NN effect)) (PP (IN on) (NP (JJ important) (NNS outcomes))))))))) (. .)))
(ROOT (S (S (NP (EX There)) (VP (VBZ is) (NP (NP (JJ strong) (NN evidence)) (SBAR (S (VP (TO to) (VP (VB support) (S (VP (VBG treating) (S (NP (JJ hypertensive) (NNS persons)) (VP (JJ aged) (SBAR (S (NP (NP (NP (CD 60) (NNS years)) (CC or) (NP (JJR older))) (PP (TO to) (NP (NP (DT a) (NN BP) (NN goal)) (PP (IN of) (NP (NP (QP (JJR less) (IN than) (CD 150/90)) (NN mm) (NN Hg)) (CC and) (NP (JJ hypertensive) (NNS persons))))))) (VP (CD 30) (PP (IN through) (NP (NP (CD 59) (NNS years)) (PP (IN of) (NP (NN age))))) (PP (TO to) (NP (NP (DT a) (JJ diastolic) (NN goal)) (PP (IN of) (NP (QP (JJR less) (IN than) (CD 90)) (NN mm) (NN Hg))))))))))))))))))) (: ;) (RB however) (, ,) (S (NP (EX there)) (VP (VBZ is) (NP (NP (JJ insufficient) (NN evidence)) (PP (IN in) (NP (NP (JJ hypertensive) (NNS persons)) (ADJP (JJR younger) (PP (IN than) (NP (CD 60) (NNS years))))))) (PP (IN for) (NP (NP (DT a) (JJ systolic) (NN goal)) (, ,) (CC or) (PP (IN in) (NP (DT those) (ADJP (JJR younger) (PP (IN than) (NP (CD 30) (NNS years)))))) (PP (IN for) (NP (DT a) (JJ diastolic) (NN goal))))))) (, ,) (IN so) (S (NP (DT the) (NN panel)) (VP (VBZ recommends) (NP (NP (DT a) (NN BP)) (PP (IN of) (NP (NP (QP (JJR less) (IN than) (CD 140/90)) (NN mm) (NN Hg)) (PP (IN for) (NP (DT those) (NNS groups)))))) (PP (VBN based) (PP (IN on) (NP (JJ expert) (NN opinion)))))) (. .)))
(ROOT (S (NP (DT The) (JJ same) (NNS thresholds) (CC and) (NNS goals)) (VP (VBP are) (VP (VBN recommended) (PP (IN for) (NP (NP (JJ hypertensive) (NNS adults)) (PP (IN with) (NP (NP (NN diabetes)) (CC or) (NP (NP (JJ nondiabetic) (JJ chronic) (NN kidney) (NN disease)) (PRN (-LRB- -LRB-) (NP (NN CKD)) (-RRB- -RRB-))))))) (PP (IN as) (PP (IN for) (NP (NP (DT the) (JJ general) (JJ hypertensive) (NN population)) (ADJP (JJR younger) (PP (IN than) (NP (CD 60) (NNS years))))))))) (. .)))
(ROOT (S (NP (EX There)) (VP (VBZ is) (S (NP (JJ moderate) (NN evidence)) (VP (TO to) (VP (VB support) (S (VP (VBG initiating) (NP (NN drug) (NN treatment)) (PP (IN with) (FRAG (NP (NP (DT an) (JJ angiotensin-converting) (NN enzyme) (NN inhibitor)) (, ,) (NP (NP (NN angiotensin) (NN receptor) (NN blocker)) (, ,) (NP (NN calcium) (NN channel) (NN blocker)) (, ,) (CC or) (NP (JJ thiazide-type) (JJ diuretic)))) (PP (IN in) (NP (DT the) (JJ nonblack) (JJ hypertensive) (NN population))) (, ,) (PP (VBG including) (NP (NP (DT those)) (PP (IN with) (NP (NN diabetes))))))))))))) (. .)))
(ROOT (FRAG (PP (IN In) (NP (DT the) (JJ black) (JJ hypertensive) (NN population))) (, ,) (PP (VBG including) (SBAR (S (NP (NP (NP (DT those)) (PP (IN with) (NP (NN diabetes)))) (, ,) (NP (NP (DT a) (NN calcium) (NN channel) (NN blocker)) (CC or) (NP (JJ thiazide-type) (JJ diuretic)))) (VP (VBZ is) (VP (VBN recommended) (PP (IN as) (NP (JJ initial) (NN therapy)))))))) (. .)))
(ROOT (S (NP (EX There)) (VP (VBZ is) (NP (NP (JJ moderate) (NN evidence)) (SBAR (S (VP (TO to) (VP (VB support) (NP (NP (JJ initial) (CC or) (JJ add-on) (JJ antihypertensive) (NN therapy)) (PP (IN with) (NP (NP (DT an) (JJ angiotensin-converting) (NN enzyme) (NN inhibitor)) (CC or) (NP (NP (NN angiotensin) (NN receptor) (NN blocker)) (PP (IN in) (NP (NNS persons))))))) (PP (IN with) (NP (NP (NN CKD)) (SBAR (S (VP (TO to) (VP (VB improve) (NP (NN kidney) (NNS outcomes)))))))))))))) (. .)))
(ROOT (S (SBAR (IN Although) (S (NP (DT this) (NN guideline)) (VP (VP (VBZ provides) (NP (NP (JJ evidence-based) (NNS recommendations)) (PP (IN for) (NP (NP (DT the) (NN management)) (PP (IN of) (NP (JJ high) (NN BP))))))) (CC and) (VP (MD should) (VP (VB meet) (NP (NP (DT the) (JJ clinical) (NNS needs)) (PP (IN of) (NP (JJS most) (NNS patients))))))))) (, ,) (S (NP (DT these) (NNS recommendations)) (VP (VBP are) (RB not) (NP (NP (DT a) (NN substitute)) (PP (IN for) (NP (JJ clinical) (NN judgment)))))) (, ,) (CC and) (S (NP (NP (NNS decisions)) (PP (IN about) (NP (NN care)))) (VP (MD must) (ADVP (RB carefully)) (VP (VB consider) (CC and) (VP (VP (VB incorporate) (NP (DT the) (JJ clinical) (NNS characteristics))) (CC and) (NP (NP (NNS circumstances)) (PP (IN of) (NP (DT each) (JJ individual) (NN patient)))))))) (. .)))
(ROOT (S (NP (NN Hypertension)) (VP (VBZ remains) (NP (NP (CD one)) (PP (IN of) (NP (NP (NP (DT the) (ADJP (RBS most) (JJ important)) (JJ preventable) (NNS contributors)) (PP (TO to) (NP (NN disease)))) (CC and) (NP (NN death)))))) (. .)))
(ROOT (S (NP (NP (JJ Abundant) (NN evidence)) (PP (IN from) (NP (VBN randomized) (NP (NP (JJ controlled) (NNS trials)) (PRN (-LRB- -LRB-) (NP (NNS RCTs)) (-RRB- -RRB-)))))) (VP (VBZ has) (VP (VBN shown) (NP (NP (NP (NN benefit)) (PP (IN of) (NP (JJ antihypertensive) (NN drug) (NN treatment))) (PP (IN in) (S (VP (VBG reducing) (NP (JJ important) (NN health) (NNS outcomes)))))) (PP (IN in) (NP (NNS persons))) (PP (IN with) (NP (NN hypertension)))))) (. .)))
(ROOT (S (NP (JJ Clinical) (NNS guidelines)) (VP (VBP are) (PP (IN at) (NP (DT the) (NN intersection))) (PP (IN between) (NP (NP (NN research) (NN evidence)) (CC and) (NP (NP (JJ clinical) (NNS actions)) (SBAR (WHNP (WDT that)) (S (VP (MD can) (VP (VB improve) (NP (NN patient) (NNS outcomes)))))))))) (. .)))
(ROOT (S (S (NP (NP (DT The) (NNP Institute)) (PP (IN of) (NP (NNP Medicine) (NNP Report)))) (NP (NP (JJ Clinical) (NNP Practice) (NNS Guidelines)) (SBAR (S (NP (PRP We)) (VP (MD Can) (SBAR (S (NP (NNP Trust)) (VP (VP (VBD outlined) (NP (DT a) (NN pathway)) (PP (TO to) (NP (NN guideline) (NN development)))) (CC and) (VP (VBZ is) (NP (DT the) (NN approach) (SBAR (IN that) (S (NP (DT this) (NN panel)) (VP (VBD aspired) (PP (TO to) (PP (IN in) (NP (NP (DT the) (NN creation)) (PP (IN of) (NP (DT this) (NN report))))))))))))))))))) (. .)))
(ROOT (S (NP (NP (NP (DT The) (NN panel) (NNS members)) (VP (VBN appointed) (PP (TO to) (NP (DT the) (NNP Eighth) (NNP Joint) (NNP National) (NNP Committee))))) (PRN (-LRB- -LRB-) (NP (NNP JNC) (CD 8)) (-RRB- -RRB-))) (VP (VBN used) (NP (JJ rigorous) (JJ evidence-based) (NNS methods)) (, ,) (S (VP (VBG developing) (NP (NP (NP (NN Evidence) (NNS Statements) (CC and) (NNS recommendations)) (PP (IN for) (NP (NP (NP (NN blood) (NN pressure)) (PRN (-LRB- -LRB-) (NP (NN BP)) (-RRB- -RRB-))) (NN treatment)))) (VP (VBN based) (PP (IN on) (NP (NP (DT a) (JJ systematic) (NN review)) (PP (IN of) (NP (DT the) (NN literature))))))) (S (VP (TO to) (VP (VB meet) (NP (NN user) (NNS needs))))) (, ,) (NP (NP (RB especially) (DT the) (NNS needs)) (PP (IN of) (NP (DT the) (JJ primary) (NN care) (NN clinician))))))) (. .)))
(ROOT (S (NP (DT This) (NN report)) (VP (VP (VBZ is) (NP (NP (DT an) (NN executive) (NN summary)) (PP (IN of) (NP (DT the) (NN evidence))))) (CC and) (VP (VBZ is) (VP (VBN designed) (S (VP (TO to) (VP (VB provide) (NP (NP (JJ clear) (NNS recommendations)) (PP (IN for) (NP (DT all) (NNS clinicians)))))))))) (. .)))
(ROOT (S (NP (NP (JJ Major) (NNS differences)) (PP (IN from) (NP (DT the) (JJ previous) (NN JNC) (NN report)))) (VP (VBP are) (VP (VBN summarized) (PP (IN in) (NP (NNP Table) (CD 1))))) (. .)))
(ROOT (S (NP (NP (DT The) (JJ complete) (NN evidence) (NN summary)) (CC and) (NP (NP (JJ detailed) (NN description)) (PP (IN of) (NP (DT the) (NN evidence) (NN review) (CC and) (NNS methods))))) (VP (VBP are) (VP (VBN provided) (NP (NP (NN online)) (PRN (-LRB- -LRB-) (S (VP (VB see) (NP (NN Supplement)))) (-RRB- -RRB-))))) (. .)))
(ROOT (S (NP (NP (DT The) (NN panel) (NNS members)) (VP (VBN appointed) (PP (TO to) (NP (NN JNC) (CD 8))))) (VP (VBD were) (VP (VBN selected) (PP (IN from) (NP (QP (JJR more) (IN than) (CD 400)) (NNS nominees))) (PP (VBN based) (PP (IN on) (NP (NP (NN expertise)) (PP (IN in) (NP (NP (NP (NN hypertension)) (PRN (-LRB- -LRB-) (S (NP (NN n)) (VP (JJ =) (NP (CD 14)))) (-RRB- -RRB-))) (, ,) (NP (NP (JJ primary) (NN care)) (PRN (-LRB- -LRB-) (S (NP (NN n)) (VP (JJ =) (NP (CD 6)))) (-RRB- -RRB-)) (, ,) (PP (VBG including) (NP (NP (NP (NNS geriatrics)) (PRN (-LRB- -LRB-) (S (NP (NN n)) (VP (JJ =) (NP (CD 2)))) (-RRB- -RRB-))) (, ,) (NP (NP (NN cardiology)) (PRN (-LRB- -LRB-) (S (NP (NN n)) (VP (JJ =) (NP (CD 2)))) (-RRB- -RRB-))) (, ,) (NP (NP (NN nephrology)) (PRN (-LRB- -LRB-) (S (NP (NN n)) (VP (JJ =) (NP (CD 3)))) (-RRB- -RRB-))) (, ,) (NP (NP (NN nursing)) (PRN (-LRB- -LRB-) (NP (NP (NN n)) (ADJP (JJ =) (NP (CD 1)))) (-RRB- -RRB-))) (, ,) (NP (NP (NN pharmacology)) (PRN (-LRB- -LRB-) (S (NP (NN n)) (VP (JJ =) (NP (CD 2)))) (-RRB- -RRB-))) (, ,) (NP (NP (JJ clinical) (NNS trials)) (PRN (-LRB- -LRB-) (S (NP (NN n)) (VP (JJ =) (NP (CD 6)))) (-RRB- -RRB-))) (, ,) (NP (NP (JJ evidence-based) (NN medicine)) (PRN (-LRB- -LRB-) (S (NP (NN n)) (VP (JJ =) (NP (CD 3)))) (-RRB- -RRB-))) (, ,) (NP (NP (NN epidemiology)) (PRN (-LRB- -LRB-) (NP (NP (NN n)) (ADJP (JJ =) (NP (CD 1)))) (-RRB- -RRB-))) (, ,) (NP (NP (NNS informatics)) (PRN (-LRB- -LRB-) (S (NP (NN n)) (VP (JJ =) (NP (CD 4)))) (-RRB- -RRB-))) (, ,) (CC and) (NP (NP (DT the) (NP (NP (NN development)) (CC and) (NP (NN implementation)))) (PP (IN of) (NP (NP (NP (JJ clinical) (NNS guidelines)) (PP (IN in) (NP (NP (NNS systems)) (PP (IN of) (NP (NN care)))))) (PRN (-LRB- -LRB-) (S (NP (NN n)) (VP (JJ =) (NP (CD 4)))) (-RRB- -RRB-))))))))))))))) (. .)))
(ROOT (S (NP (DT The) (NN panel)) (ADVP (RB also)) (VP (VBD included) (NP (NP (NP (DT a) (JJ senior) (NN scientist)) (PP (IN from) (NP (NP (DT the) (NNP National) (NNP Institute)) (PP (IN of) (NP (NP (NNP Diabetes)) (CC and) (NP (NP (JJ Digestive) (CC and) (NN Kidney) (NNS Diseases)) (PRN (-LRB- -LRB-) (NP (NN NIDDK)) (-RRB- -RRB-)))))))) (, ,) (NP (NP (DT a) (JJ senior) (JJ medical) (NN officer)) (PP (IN from) (NP (NP (NP (DT the) (NNP National) (NNP Heart)) (, ,) (NP (NN Lung)) (, ,)) (CC and) (NP (NP (NNP Blood) (NNP Institute)) (PRN (-LRB- -LRB-) (NP (NNP NHLBI)) (-RRB- -RRB-)))))) (, ,) (CC and) (NP (NP (DT a) (JJ senior) (NN scientist)) (PP (IN from) (NP (NP (NNP NHLBI)) (SBAR (WHNP (WP who)) (S (VP (VBD withdrew) (PP (IN from) (NP (NN authorship))) (ADVP (RB prior) (PP (TO to) (NP (NN publication)))))))))))) (. .)))
(ROOT (S (NP (CD Two) (NNS members)) (VP (VBD left) (NP (DT the) (NN panel)) (ADVP (RB early) (PP (IN in) (NP (NP (DT the) (NN process)) (PP (IN before) (NP (DT the) (NN evidence) (NN review)))))) (PP (IN because) (IN of) (NP (NP (JJ new) (NN job) (NNS commitments)) (SBAR (WHNP (WDT that)) (S (VP (VBD prevented) (NP (PRP them)) (PP (IN from) (S (VP (VBG continuing) (S (VP (TO to) (VP (VB serve))))))))))))) (. .)))
(ROOT (S (NP (NN Panel) (NNS members)) (VP (VBD disclosed) (NP (NP (DT any) (JJ potential) (NNS conflicts)) (PP (IN of) (NP (NN interest))) (PP (VBG including) (NP (NP (NNS studies)) (VP (VBN evaluated) (PP (IN in) (NP (NP (DT this) (NN report) (CC and) (NNS relationships)) (PP (IN with) (NP (NN industry)))))))))) (. .)))
(ROOT (S (S (NP (NP (DT Those)) (PP (IN with) (NP (NNS conflicts)))) (VP (VBD were) (VP (VBN allowed) (S (VP (TO to) (VP (VB participate) (PP (IN in) (ADVP (NP (NNS discussions)) (ADVP (ADVP (RB as) (RB long)) (SBAR (IN as) (S (NP (PRP they)) (VP (VBD declared) (NP (PRP$ their) (NNS relationships)))))) (, ,))))))))) (CC but) (S (NP (PRP they)) (VP (VBD recused) (NP (PRP themselves)) (PP (IN from) (S (VP (VBG voting) (PP (IN on) (NP (NP (NN evidence) (NNS statements) (CC and) (NNS recommendations)) (ADJP (JJ relevant) (PP (TO to) (NP (PRP$ their) (NNS relationships) (CC or) (NNS conflicts))))))))))) (. .)))
(ROOT (S (NP (NP (CD Four) (NN panel) (NNS members)) (PRN (-LRB- -LRB-) (NP (CD 24) (NN %)) (-RRB- -RRB-))) (VP (VBD had) (S (NP (NP (NNS relationships)) (PP (IN with) (NP (NP (NN industry)) (CC or) (NP (JJ potential) (NNS conflicts))))) (VP (TO to) (VP (VB disclose) (PP (IN at) (NP (NP (DT the) (NN outset)) (PP (IN of) (NP (DT the) (NN process))))))))) (. .)))
(ROOT (S (PP (IN In) (NP (NNP January) (CD 2013))) (, ,) (S (NP (DT the) (NN guideline)) (VP (VBD was) (VP (VBN submitted) (PP (IN for) (NP (JJ external)))))) (VP (VBP peer) (NP (NN review)) (PP (IN by) (NP (NP (NP (NNP NHLBI)) (PP (TO to) (NP (CD 20) (NNS reviewers)))) (, ,) (SBAR (WHNP (WHNP (DT all)) (WHPP (IN of) (WHNP (WP whom)))) (S (VP (VBD had) (NP (NP (NN expertise)) (PP (IN in) (NP (NN hypertension)))))))))) (, ,) (CC and) (PP (TO to) (NP (CD 16) (JJ federal) (NNS agencies))) (. .)))
(ROOT (S (NP (NNS Reviewers)) (ADVP (RB also)) (VP (VBD had) (NP (NP (NP (NN expertise)) (PP (IN in) (NP (NP (NN cardiology)) (, ,) (NP (NN nephrology)) (, ,) (NP (JJ primary) (NN care)) (, ,) (NP (NN pharmacology)) (, ,) (NP (NN research) (-LRB- -LRB-) (PP (VBG including) (NP (JJ clinical) (NNS trials))) (-RRB- -RRB-))))) (, ,) (NP (NNS biostatistics)) (, ,) (CC and) (NP (JJ other) (JJ important) (JJ related) (NNS fields)))) (. .)))
(ROOT (S (NP (NP (CD Sixteen) (JJ individual) (NNS reviewers)) (CC and) (NP (CD 5) (JJ federal) (NNS agencies))) (VP (VBD responded)) (. .)))
(ROOT (S (NP (NP (NNS Reviewers) (POS ')) (NNS comments)) (VP (VP (VBD were) (VP (VBN collected) (, ,) (VP (VBN collated)))) (, ,) (CC and) (VP (VBN anonymized))) (. .)))
(ROOT (S (NP (NNS Comments)) (VP (VP (VBD were) (VP (VBN reviewed))) (CC and) (VP (VP (VBN discussed) (PP (IN by) (NP (NP (DT the) (NN panel)) (PP (IN from) (NP (NNP March))))) (PP (IN through) (NP (NNP June) (CD 2013)))) (CC and) (VP (VBN incorporated) (PP (IN into) (NP (DT a) (VBN revised) (NN document)))))) (. .)))
(ROOT (S (-LRB- -LRB-) (NP (NP (NP (NNS Reviewers) (POS ')) (NNS comments) (CC and) (NNS suggestions)) (, ,) (CC and) (NP (NP (NP (NNS responses)) (CC and) (NP (NN disposition))) (PP (IN by) (NP (DT the) (NN panel))))) (VP (VBP are) (ADJP (JJ available)) (PP (IN on) (NP (NP (NN request)) (PP (IN from) (NP (DT the) (NNS authors)))))) (. .) (-RRB- -RRB-)))
(ROOT (S (NP (DT This) (JJ evidence-based) (NN hypertension) (NN guideline)) (VP (VBZ focuses) (PP (IN on) (NP (NP (NP (DT the) (NN panel) (POS 's)) (CD 3) (JJ highest-ranked) (NNS questions)) (ADJP (VBN related) (PP (TO to) (NP (NP (JJ high) (NN BP) (NN management)) (VP (VBN identified) (PP (IN through) (NP (DT a) (VBN modified) (NNP Delphi) (NN technique)))))))))) (. .)))
(ROOT (S (NP (CD Nine) (NNS recommendations)) (VP (VBP are) (VP (VBN made) (S (VP (VBG reflecting) (NP (DT these) (NNS questions)))))) (. .)))
(ROOT (S (NP (DT These) (NNS questions)) (VP (VBP address) (NP (NP (NP (NNS thresholds) (CC and) (NNS goals)) (PP (IN for) (NP (NP (JJ pharmacologic) (NN treatment)) (PP (IN of) (NP (NN hypertension)))))) (CC and) (SBAR (IN whether) (S (NP (ADJP (ADJP (JJ particular)) (ADJP (JJ antihypertensive))) (NNS drugs) (CC or) (NN drug) (NNS classes)) (VP (VBP improve) (NP (JJ important) (NN health) (NNS outcomes)) (PP (VBN compared) (PP (IN with) (NP (JJ other) (NN drug) (NNS classes))))))))) (. .)))
(ROOT (S (PP (IN In) (NP (NP (NNS adults)) (PP (IN with) (NP (NN hypertension))))) (, ,) (VP (VBZ does) (S (VP (VBG initiating) (S (NP (NP (JJ antihypertensive) (JJ pharmacologic) (NN therapy)) (PP (IN at) (NP (JJ specific) (NN BP) (NNS thresholds)))) (VP (VBP improve) (NP (NN health) (NNS outcomes))))))) (. ?)))
(ROOT (S (PP (IN In) (NP (NP (NNS adults)) (PP (IN with) (NP (NN hypertension))))) (, ,) (VP (VBZ does) (NP (NP (NN treatment)) (PP (IN with) (NP (JJ antihypertensive) (JJ pharmacologic) (NN therapy)))) (PP (TO to) (NP (NP (DT a) (VBN specified) (NP (NNP BP) (NN goal) (NN lead))) (PP (TO to) (NP (NP (NNS improvements)) (PP (IN in) (NP (NN health) (NNS outcomes)))))))) (. ?)))
(ROOT (SQ (PP (IN In) (NP (NP (NNS adults)) (PP (IN with) (NP (NN hypertension))))) (, ,) (VBP do) (NP (NP (JJ various) (JJ antihypertensive) (NNS drugs)) (CC or) (NP (NN drug) (NNS classes))) (VP (VBP differ) (PP (IN in) (NP (NP (JJ comparative) (NNS benefits)) (CC and) (NP (NNS harms)))) (PP (IN on) (NP (JJ specific) (NN health) (NNS outcomes)))) (. ?)))
(ROOT (S (NP (DT The) (NN evidence) (NN review)) (VP (VP (VBD focused) (PP (IN on) (NP (NP (NNS adults)) (VP (VBN aged) (NP (NP (CD 18) (NNS years)) (CC or) (ADJP (JJR older) (PP (IN with) (NP (NN hypertension))))))))) (CC and) (VP (VBD included) (NP (NP (NNS studies)) (PP (IN with) (NP (NP (DT the) (VBG following) (NP (JJ prespecified) (NNS subgroups))) (: :) (NP (NP (NP (NN diabetes)) (, ,) (NP (JJ coronary) (NN artery) (NN disease)) (, ,) (NP (JJ peripheral) (NN artery) (NN disease))) (, ,) (NP (NN heart) (NN failure)) (, ,) (NP (JJ previous) (NN stroke)) (, ,) (NP (NP (JJ chronic) (NN kidney) (NN disease)) (PRN (-LRB- -LRB-) (NP (NN CKD)) (-RRB- -RRB-))) (, ,) (NP (NN proteinuria)) (, ,) (NP (JJR older) (NNS adults)) (, ,) (NP (NNS men)) (CC and) (NP (NNS women)) (, ,) (NP (JJ racial) (CC and) (JJ ethnic) (NNS groups)) (, ,) (CC and) (NP (NNS smokers)))))))) (. .)))
(ROOT (S (NP (NP (NNS Studies)) (PP (IN with) (NP (NP (NN sample) (NNS sizes)) (QP (JJR smaller) (IN than) (CD 100))))) (VP (VBD were) (VP (VBN excluded) (, ,) (SBAR (IN as) (S (VP (VBD were) (NP (NP (NNS studies)) (PP (IN with) (NP (NP (DT a) (JJ follow-up) (NN period)) (PP (IN of) (NP (QP (JJR less) (IN than) (CD 1)) (NN year)))))) (, ,) (SBAR (IN because) (S (NP (NP (JJ small) (NNS studies)) (PP (IN of) (NP (JJ brief) (NN duration)))) (VP (VBP are) (ADJP (JJ unlikely) (S (VP (TO to) (VP (VB yield) (NP (NP (RB enough) (JJ health-related) (NN outcome) (NN information)) (SBAR (S (VP (TO to) (VP (VB permit) (NP (NP (NN interpretation)) (PP (IN of) (NP (NN treatment) (NNS effects))))))))))))))))))))) (. .)))
(ROOT (S (NP (NNS Studies)) (VP (VBD were) (VP (VBN included) (PP (IN in) (NP (DT the) (NN evidence) (NN review) (SBAR (RB only) (IN if) (S (NP (PRP they)) (VP (VBD reported) (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (DT the) (VBN studied) (NNS interventions))) (PP (IN on) (NP (NP (DT any)) (PP (IN of) (NP (DT these) (JJ important) (NN health) (NNS outcomes))))))))))))) (: :)))
(ROOT (NP (NP (JJ Overall) (NN mortality)) (, ,) (NP (NP (JJ cardiovascular) (NN disease)) (PRN (-LRB- -LRB-) (NP (NN CVD)) (-RRB- -RRB-))) (: --) (NP (JJ related) (NN mortality) (, ,) (JJ CKD-related) (NN mortality))))
(ROOT (NP (NP (JJ Myocardial) (NN infarction)) (, ,) (NP (NN heart) (NN failure)) (, ,) (NP (NP (NN hospitalization)) (PP (IN for) (NP (NN heart) (NN failure)))) (, ,) (NP (NN stroke))))
(ROOT (NP (NP (NP (JJ Coronary) (NN revascularization)) (PRN (-LRB- -LRB-) (VP (VBZ includes) (NP (NP (JJ coronary) (NN artery) (NN bypass) (NN surgery)) (, ,) (NP (JJ coronary) (NN angioplasty)) (CC and) (NP (JJ coronary) (NN stent) (NN placement)))) (-RRB- -RRB-))) (, ,) (NP (NP (JJ other) (NN revascularization)) (PRN (-LRB- -LRB-) (VP (VBZ includes) (NP (NP (NN carotid)) (, ,) (NP (JJ renal)) (, ,) (CC and) (NP (JJR lower) (NN extremity) (NN revascularization)))) (-RRB- -RRB-)))))
(ROOT (NP (NP (NP (NP (JJ End-stage) (JJ renal) (NN disease)) (PRN (-LRB- -LRB-) (NP (NN ESRD)) (-RRB- -RRB-))) (PRN (-LRB- -LRB-) (NP (NP (ADVP (FW ie)) (, ,) (NN kidney) (NN failure)) (VP (VBG resulting) (PP (IN in) (NP (NP (NN dialysis)) (CC or) (NP (NN transplantation)))))) (-RRB- -RRB-))) (, ,) (VP (VBG doubling) (PP (IN of) (NP (NN creatinine) (NN level)))) (, ,) (NP (NP (NN halving)) (PP (IN of) (NP (NP (JJ glomerular) (NN filtration) (NN rate)) (PRN (-LRB- -LRB-) (NP (NN GFR)) (-RRB- -RRB-))))) (. .)))
(ROOT (S (NP (DT The) (NN panel)) (VP (VBD limited) (NP (PRP$ its) (NN evidence) (NN review)) (PP (TO to) (NP (NNS RCTs))) (SBAR (IN because) (S (S (NP (PRP they)) (VP (VBP are) (ADJP (ADJP (RBR less) (JJ subject) (PP (TO to) (NP (NN bias)))) (PP (IN than) (NP (JJ other) (NN study) (NNS designs)))))) (CC and) (S (VP (VBP represent) (NP (NP (DT the) (JJ gold) (NN standard)) (UCP (UCP (IN for) (S (VP (VBG determining) (NP (NN efficacy)))) (CC and)) (NP (NN effectiveness))))))))) (. .)))
(ROOT (S (NP (NP (DT The) (NNS studies)) (PP (IN in) (NP (DT the) (NN evidence) (NN review)))) (VP (VBD were) (PP (IN from) (NP (NP (JJ original) (NNS publications)) (PP (IN of) (NP (JJ eligible) (NNS RCTs)))))) (. .)))
(ROOT (S (S (NP (DT These) (NNS studies)) (VP (VBD were) (VP (VBN used) (S (VP (TO to) (VP (VB create) (NP (NP (NN evidence) (NNS tables) (CC and) (NN summary) (NNS tables)) (SBAR (WHNP (WDT that)) (S (VP (VBD were) (VP (VBN used) (PP (IN by) (NP (DT the) (NN panel))) (PP (IN for) (NP (PRP$ their) (NNS deliberations)))))))))))))) (PRN (-LRB- -LRB-) (VP (VB see) (NP (NN Supplement))) (-RRB- -RRB-)) (. .)))
(ROOT (FRAG (SBAR (IN Because) (S (NP (NP (DT the) (NN panel)) (VP (VBD conducted) (NP (PRP$ its) (JJ own) (JJ systematic) (NN review)) (S (VP (VBG using) (NP (NP (NP (JJ original) (NNS studies)) (, ,) (NP (JJ systematic) (NNS reviews)) (CC and) (NP (NP (NNS meta-analyses)) (PP (IN of) (NP (NNS RCTs))))) (VP (VBN conducted) (CC and) (VP (VBN published) (PP (IN by) (NP (JJ other) (NNS groups)))))))))) (VP (VBD were) (RB not) (VP (VBN included) (PP (IN in) (NP (DT the) (JJ formal) (NN evidence) (NN review))))))) (. .)))
(ROOT (S (NP (NP (JJ Initial) (NN search) (NNS dates)) (PP (IN for) (NP (DT the) (NN literature) (NN review)))) (VP (VBD were) (NP (NNP January) (CD 1) (, ,) (CD 1966)) (, ,) (PP (IN through) (NP (NNP December) (CD 31) (, ,) (CD 2009)))) (. .)))
(ROOT (S (NP (NP (DT The) (NN search) (NN strategy)) (CC and) (NP (NP (NNP PRISMA) (NN diagram)) (PP (IN for) (NP (DT each) (NN question))))) (VP (VBZ is) (PP (IN in) (NP (DT the) (NN online) (NN Supplement)))) (. .)))
(ROOT (S (S (VP (TO To) (VP (VB ensure) (SBAR (IN that) (S (NP (DT no) (JJ major) (JJ relevant) (NNS studies)) (VP (VBN published) (PP (IN after) (NP (NNP December) (CD 31) (, ,) (CD 2009))))))))) (, ,) (VP (VBD were) (VP (VP (VBN excluded) (PP (IN from) (NP (NN consideration)))) (, ,) (SBAR (S (NP (NP (NP (CD 2) (JJ independent) (NNS searches)) (PP (IN of) (NP (NNP PubMed) (CC and) (NNP CINAHL)))) (PP (IN between) (NP (NP (NNP December) (CD 2009)) (CC and) (NP (NNP August) (CD 2013))))) (VP (VBD were) (VP (VBN conducted) (PP (IN with) (NP (NP (DT the) (JJ same) (NN MeSH) (NNS terms)) (PP (IN as) (NP (DT the) (JJ original) (NN search))))))))))) (. .)))
(ROOT (S (NP (CD Three) (NN panel) (NNS members)) (VP (VBN reviewed) (NP (DT the) (NNS results))) (. .)))
(ROOT (S (NP (DT The) (NN panel)) (VP (VBD limited) (NP (NP (DT the) (NN inclusion) (NNS criteria)) (PP (IN of) (NP (NP (DT this) (JJ second) (NN search)) (PP (TO to) (NP (DT the) (VBG following))))))) (. .)))
(ROOT (S (LST (-LRB- -LRB-) (LS 1) (-RRB- -RRB-)) (NP (DT The) (NN study)) (VBD was) (NP (DT a) (JJ major) (NN study)) (IN in) (S (NP (NP (NN hypertension)) (PRN (-LRB- -LRB-) (NP (FW eg) (, ,) (NN ACCORD-BP) (, ,) (NN SPS3)) (: ;))) (ADVP (RB however)) (, ,) (NP (NN SPS3)) (VP (VBD did) (RB not) (VP (VB meet) (NP (JJ strict) (NN inclusion) (NNS criteria))) (SBAR (IN because) (S (NP (PRP it)) (VP (VBD included) (NP (JJ nonhypertensive) (NNS participants))))))) (. .)))
(ROOT (PRN (S (NP (NN SPS3)) (VP (MD would) (RB not) (VP (VB have) (VP (VBN changed) (NP (PRP$ our) (NNS conclusions/recommendations)) (SBAR (IN because) (S (S (NP (DT the) (JJ only) (JJ significant) (NN finding)) (VP (VBG supporting) (NP (NP (DT a) (JJR lower) (NN goal)) (PP (IN for) (NP (NN BP)))))) (VP (VBD occurred) (PP (IN in) (NP (DT an) (JJ infrequent) (JJ secondary) (NN outcome)))))))))) (-RRB- -RRB-) (. .)))
(ROOT (S (LST (-LRB- -LRB-) (LS 2) (-RRB- -RRB-)) (NP (DT The) (NN study)) (VP (VBD had) (NP (QP (IN at) (JJS least) (CD 2000)) (NNS participants))) (. .)))
(ROOT (S (LST (-LRB- -LRB-) (LS 3) (-RRB- -RRB-)) (NP (DT The) (NN study)) (VP (VBD was) (VP (VBN multicentered))) (. .)))
(ROOT (S (LST (-LRB- -LRB-) (LS 4) (-RRB- -RRB-)) (NP (DT The) (NN study)) (VP (VBD met) (NP (PDT all) (DT the) (JJ other) (NN inclusion/exclusion) (NNS criteria))) (. .)))
(ROOT (S (NP (NP (DT The) (ADJP (RB relatively) (JJ high)) (NN threshold)) (PP (IN of) (NP (CD 2000) (NNS participants)))) (VP (VBD was) (VP (VBN used) (PP (IN because) (IN of) (NP (NP (DT the) (ADJP (RB markedly) (JJR lower)) (NN event) (NNS rates)) (VP (VBN observed) (PP (IN in) (NP (NP (JJ recent) (NNS RCTs)) (PP (JJ such) (IN as) (NP (NN ACCORD))))))))) (, ,) (S (VP (VBG suggesting) (SBAR (IN that) (S (NP (JJR larger) (NN study) (NNS populations)) (VP (VBP are) (VP (VBN needed)) (S (VP (TO to) (VP (VB obtain) (NP (JJ interpretable) (NNS results))))))))))) (. .)))
(ROOT (S (ADVP (RB Additionally)) (, ,) (NP (DT all) (NN panel) (NNS members)) (VP (VBD were) (VP (VBN asked) (S (VP (TO to) (VP (VB identify) (NP (NP (ADJP (RB newly) (VBN published)) (NNS studies)) (PP (IN for) (NP (NN consideration))))))) (SBAR (IN if) (S (NP (PRP they)) (VP (VBD met) (NP (DT the) (JJ above) (NNS criteria))))))) (. .)))
(ROOT (S (NP (DT No) (JJ additional) (JJ clinical) (NNS trials)) (VP (VBD met) (NP (DT the) (ADJP (RB previously) (VBN described)) (NN inclusion) (NNS criteria))) (. .)))
(ROOT (S (NP (NP (NNS Studies)) (VP (VBN selected))) (VP (VP (VBD were) (VP (VBN rated) (PP (IN for) (NP (NN quality))) (S (VP (VBG using) (NP (NP (NP (NNP NHLBI) (POS 's)) (JJ standardized) (NN quality) (NN rating) (NN tool)) (PRN (-LRB- -LRB-) (VP (VB see) (NP (NN Supplement))) (-RRB- -RRB-))))))) (CC and) (VP (VBD were) (VP (ADVP (RB only)) (VBN included) (SBAR (IN if) (S (VP (VBN rated) (PP (IN as) (ADJP (ADJP (JJ good)) (CC or) (ADJP (JJ fair)))))))))) (. .)))
(ROOT (S (NP (DT An) (JJ external) (NN methodology) (NN team)) (VP (VBD performed) (NP (DT the) (NN literature) (NN review)) (, ,) (VP (VBN summarized) (NP (NP (NNS data)) (PP (IN from) (NP (NP (VBN selected) (NNS papers)) (PP (IN into) (NP (NN evidence) (NNS tables))))))) (, ,) (CC and) (VP (VBD provided) (NP (NP (DT a) (NN summary)) (PP (IN of) (NP (DT the) (NN evidence)))))) (. .)))
(ROOT (S (PP (IN From) (NP (DT this) (NN evidence) (NN review))) (, ,) (NP (DT the) (NN panel)) (VP (VP (VBD crafted) (NP (NN evidence) (NNS statements))) (CC and) (VP (VBD voted) (PP (IN on) (NP (NP (NP (NN agreement)) (CC or) (NP (NN disagreement))) (PP (IN with) (NP (DT each) (NN statement))))))) (. .)))
(ROOT (FRAG (PP (IN For) (NP (NP (VBN approved) (NN evidence) (NNS statements)) (, ,) (NP (NP (DT the) (NN panel)) (VP (ADVP (RB then)) (VBD voted) (PP (IN on) (NP (NP (DT the) (NN quality)) (PP (IN of) (NP (NP (DT the) (NN evidence)) (PRN (-LRB- -LRB-) (NNP Table) (LST (LS 2)) (-RRB- -RRB-)))))))))) (. .)))
(ROOT (S (SBAR (RB Once) (S (NP (NP (DT all) (NN evidence) (NNS statements)) (PP (IN for) (NP (DT each) (JJ critical) (NN question)))) (VP (VBD were) (VP (VBN identified))))) (, ,) (NP (DT the) (NN panel)) (VP (VP (VBN reviewed) (NP (NP (DT the) (NN evidence) (NNS statements)) (SBAR (S (VP (TO to) (VP (VB craft) (NP (DT the) (JJ clinical) (NNS recommendations)))))))) (, ,) (S (VP (VP (VBG voting) (PP (IN on) (NP (DT each) (NN recommendation)))) (CC and) (PP (IN on) (NP (NP (DT the) (NN strength)) (PP (IN of) (NP (DT the) (NN recommendation) (PRN (-LRB- -LRB-) (NNP Table) (LST (LS 3)) (-RRB- -RRB-))))))))) (. .)))
(ROOT (SINV (PP (IN For) (NP (DT both) (NN evidence) (NNS statements) (CC and) (NNS recommendations))) (, ,) (NP (NP (DT a) (NN record)) (PP (IN of) (S (NP (DT the) (NN vote) (NN count)) (-LRB- -LRB-) (PP (IN for) (PRN (, ,) (IN against) (PRN (, ,) (CC or) (NP (NN recusal)) (-RRB- -RRB-)))) (VP (VBD was) (VP (VBN made) (PP (IN without) (NP (NN attribution)))))))) (. .)))
(ROOT (S (NP (DT The) (NN panel)) (VP (VP (VBD attempted) (S (VP (TO to) (VP (VB achieve) (NP (ADJP (CD 100) (NN %)) (NN consensus)) (SBAR (WHADVP (WRB whenever)) (FRAG (ADJP (JJ possible)))))))) (, ,) (CC but) (S (NP (DT a) (NNS two-thirds) (NN majority)) (VP (VBD was) (VP (VBN considered) (S (ADJP (JJ acceptable))) (, ,) (SBAR (IN with) (S (NP (NP (DT the) (NN exception)) (PP (IN of) (NP (NNS recommendations)))) (VP (VBN based) (PP (IN on) (NP (NP (JJ expert) (NN opinion)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBD required) (NP (DT a) (ADJP (CD 75) (NN %)) (NN majority) (NN agreement) (S (VP (TO to) (VP (VB approve))))))))))))))))) (. .)))
(ROOT (S (NP (DT The) (JJ following) (NNS recommendations)) (VP (VBP are) (VP (VBN based) (PP (IN on) (NP (NP (DT the) (JJ systematic) (NN evidence) (NN review)) (VP (VBN described) (PP (IN above) (PRN (-LRB- -LRB-) (NP (NNP Box)) (-RRB- -RRB-)))))))) (. .)))
(ROOT (NP (NNS Recommendations) (NP (NP (CD 1)) (PP (IN through) (NP (NP (CD 5) (NN address) (NNS questions) (NP (NP (CD 1)) (CC and) (NP (CD 2)))) (PP (VBG concerning) (NP (NP (NNS thresholds) (CC and) (NNS goals)) (PP (IN for) (NP (NN BP) (NN treatment)))))))) (. .)))
(ROOT (NP (NP (NNS Recommendations) (CD 6) (, ,) (NP (CD 7)) (, ,) (CC and) (NP (NP (CD 8) (NN address) (NN question) (CD 3)) (VP (VBG concerning) (NP (NP (NN selection)) (PP (IN of) (NP (JJ antihypertensive) (NNS drugs))))))) (. .)))
(ROOT (S (NP (NN Recommendation) (CD 9)) (VP (VBZ is) (NP (NP (NP (DT a) (NN summary)) (PP (IN of) (NP (NNS strategies)))) (VP (VBN based) (PP (IN on) (NP (NP (JJ expert) (NN opinion)) (PP (IN for) (S (VP (VBG starting) (CC and) (VP (VBG adding) (NP (JJ antihypertensive) (NNS drugs))))))))))) (. .)))
(ROOT (S (NP (NP (DT The) (NN evidence) (NNS statements)) (VP (VBG supporting) (NP (DT the) (NNS recommendations)))) (VP (VBP are) (PP (IN in) (NP (DT the) (NN online) (NN Supplement)))) (. .)))
(ROOT (NP (NP (NN Recommendation) (CD 1)) (: :) (S (PP (IN In) (NP (NP (DT the) (JJ general) (NN population) (JJ aged) (NN ≥)) (NP (CD 60) (NNS years)))) (, ,) (VP (VBP initiate) (NP (JJ pharmacologic) (NN treatment)) (PP (TO to) (NP (NP (NP (JJR lower) (NN blood) (NN pressure) (PRN (-LRB- -LRB-) (NP (NN BP)) (-RRB- -RRB-))) (PP (IN at) (NP (NP (JJ systolic) (NN blood) (NN pressure) (-LRB- -LRB-) (NN SBP) (-RRB- -RRB-) (NN ≥)) (NP (NP (CD 150) (NN mm) (NN Hg)) (CC or) (NP (NP (JJ diastolic) (NN blood) (NN pressure)) (PRN (-LRB- -LRB-) (NP (NN DBP)) (-RRB- -RRB-))))))) (NP (NP (CD ≥) (CD 90) (NN mm) (NN Hg)) (CC and) (VP (VB treat) (PP (TO to) (NP (NP (DT a) (NN goal) (NN SBP)) (VP (JJR <) (S (NP (NP (CD 150) (NN mm) (NN Hg)) (CC and) (NP (NN goal) (NN DBP))) (NP (QP (JJR <) (CD 90)) (NN mm) (NN Hg)))))))))))) (. .)))
(ROOT (PRN (-LRB- -LRB-) (FRAG (NP (JJ Strong) (NN Recommendation)) (: --) (NP (NNP Grade) (NNP A) (-RRB- -RRB-)))))
(ROOT (NP (NP (NNP Corollary) (NNP Recommendation)) (: :) (S (PP (IN In) (NP (NP (DT the) (JJ general) (NN population) (JJ aged) (NN ≥)) (NP (CD 60) (NNS years)))) (, ,) (SBAR (IN if) (S (NP (NP (JJ pharmacologic) (NN treatment)) (PP (IN for) (NP (JJ high) (NN BP)))) (VP (VBZ results) (PP (IN in) (NP (NP (NP (JJR lower) (VBN achieved) (NN SBP)) (PRN (-LRB- -LRB-) (NP (FW eg) (, ,) (NP (QP (JJR <) (CD 140)) (NN mm) (NN Hg))) (-RRB- -RRB-))) (CC and) (NP (NN treatment))))))) (VP (VBZ is) (ADJP (ADJP (RB well) (VBN tolerated)) (CC and) (PP (IN without) (NP (NP (JJ adverse) (NNS effects)) (PP (IN on) (NP (NP (NN health) (CC or) (NN quality)) (PP (IN of) (NP (NN life))))))))) (, ,) (S (NP (NN treatment)) (VP (VBZ does) (RB not) (VP (VB need) (S (VP (TO to) (VP (VB be) (VP (VBN adjusted))))))))) (. .)))
(ROOT (PRN (-LRB- -LRB-) (FRAG (NP (NN Expert) (NN Opinion)) (: --) (NP (NNP Grade) (NNP E) (-RRB- -RRB-)))))
(ROOT (NP (NP (NN Recommendation) (CD 2)) (: :) (S (PP (IN In) (NP (DT the) (JJ general) (NN population))) (NP (QP (JJR <) (CD 60)) (NNS years)) (, ,) (VP (VBP initiate) (NP (JJ pharmacologic) (NN treatment)) (S (VP (TO to) (S (NP (NP (JJR lower) (NN BP)) (PP (IN at) (NP (NNP DBP) (CD ≥)))) (NP (NP (CD 90) (NN mm) (NN Hg)) (CC and) (VP (VB treat) (PP (TO to) (NP (NP (DT a) (NN goal) (NN DBP)) (NP (QP (JJR <) (CD 90)) (NN mm) (NN Hg))))))))))) (. .)))
(ROOT (PRN (-LRB- -LRB-) (PP (IN For) (NP (NP (NNS ages)) (NP (CD 30-59) (NNS years)))) (, ,) (NP (NP (JJ Strong) (NN Recommendation)) (: --) (NNP Grade) (NNP A) (: ;)) (FRAG (PP (IN For) (NP (NP (NNS ages)) (NP (CD 18-29) (NNS years)))) (, ,) (NP (NNP Expert) (NNP Opinion)) (: --) (NP (NNP Grade) (NNP E) (-RRB- -RRB-)))))
(ROOT (NP (NP (NN Recommendation) (CD 3)) (: :) (S (PP (IN In) (NP (DT the) (JJ general) (NN population))) (NP (QP (JJR <) (CD 60)) (NNS years)) (, ,) (VP (VP (VBP initiate) (NP (JJ pharmacologic) (NN treatment)) (PP (TO to) (NP (NP (JJR lower) (NN BP)) (PP (IN at) (NP (NP (NNP SBP) (CD ≥)) (NP (CD 140) (NN mm) (NN Hg))))))) (CC and) (VP (VB treat) (PP (TO to) (NP (NP (DT a) (NN goal) (NN SBP)) (NP (JJR <) (CD 140) (NN mm) (NN Hg))))))) (. .)))
(ROOT (PRN (-LRB- -LRB-) (FRAG (NP (NN Expert) (NN Opinion)) (: --) (NP (NNP Grade) (NNP E) (-RRB- -RRB-)))))
(ROOT (NP (NP (NN Recommendation) (CD 4)) (: :) (S (PP (IN In) (NP (DT the) (NN population) (JJ aged) (NN ≥))) (NP (NP (CD 18) (NNS years)) (PP (IN with) (NP (NP (JJ chronic) (NN kidney) (NN disease)) (PRN (-LRB- -LRB-) (NP (NN CKD)) (-RRB- -RRB-))))) (, ,) (VP (VP (VB initiate) (NP (JJ pharmacologic) (NN treatment)) (PP (TO to) (NP (NP (JJR lower) (NN BP)) (PP (IN at) (NP (NP (NNP SBP) (CD ≥)) (NP (CD 140) (NN mm) (NN Hg)) (CC or) (NP (NN DBP) (CD ≥) (CD 90) (NN mm) (NN Hg))))))) (CC and) (VP (VB treat) (PP (TO to) (NP (NN goal) (NN SBP))) (NP (NP (NP (QP (JJR <) (CD 140)) (NN mm) (NN Hg)) (CC and) (NP (NN goal) (NN DBP))) (NP (QP (JJR <) (CD 90)) (NN mm) (NN Hg)))))) (. .)))
(ROOT (PRN (-LRB- -LRB-) (FRAG (NP (NN Expert) (NN Opinion)) (: --) (NP (NNP Grade) (NNP E) (-RRB- -RRB-)))))
(ROOT (NP (NP (NN Recommendation) (CD 5)) (: :) (S (PP (IN In) (NP (DT the) (NN population) (JJ aged) (NN ≥))) (NP (NP (CD 18) (NNS years)) (PP (IN with) (NP (NN diabetes)))) (, ,) (VP (VP (VBP initiate) (NP (JJ pharmacologic) (NN treatment)) (PP (TO to) (NP (NP (JJR lower) (NN BP)) (PP (IN at) (NP (NP (NNP SBP) (CD ≥)) (NP (CD 140) (NN mm) (NN Hg)) (CC or) (NP (NN DBP) (CD ≥) (CD 90) (NN mm) (NN Hg))))))) (CC and) (VP (VB treat) (PP (TO to) (NP (NP (DT a) (NN goal) (NN SBP)) (NP (NP (QP (JJR <) (CD 140)) (NN mm) (NN Hg) (CC and) (NN goal) (NN DBP)) (NP (QP (JJR <) (CD 90)) (NN mm) (NN Hg)))))))) (. .)))
(ROOT (PRN (-LRB- -LRB-) (FRAG (NP (NN Expert) (NN Opinion)) (: --) (NP (NNP Grade) (NNP E) (-RRB- -RRB-)))))
(ROOT (NP (NP (NN Recommendation) (CD 6)) (: :) (S (PP (IN In) (NP (DT the) (JJ general) (JJ nonblack) (NN population))) (, ,) (PP (VBG including) (NP (NP (NP (DT those)) (PP (IN with) (NP (NN diabetes)))) (, ,) (NP (JJ initial) (JJ antihypertensive) (NN treatment)))) (VP (MD should) (VP (VB include) (NP (DT a) (JJ thiazide-type) (JJ diuretic) (, ,) (NP (NP (NP (NN calcium) (NN channel) (NN blocker)) (PRN (-LRB- -LRB-) (NP (NN CCB)) (-RRB- -RRB-))) (, ,) (NP (NP (JJ angiotensin-converting) (NN enzyme) (NN inhibitor)) (PRN (-LRB- -LRB-) (NP (NN ACEI)) (-RRB- -RRB-))) (, ,) (CC or) (NP (NP (NN angiotensin) (NN receptor) (NN blocker)) (PRN (-LRB- -LRB-) (NP (NN ARB)) (-RRB- -RRB-)))))))) (. .)))
(ROOT (PRN (-LRB- -LRB-) (FRAG (NP (JJ Moderate) (NN Recommendation)) (: --) (NP (NNP Grade) (NNP B) (-RRB- -RRB-)))))
(ROOT (NP (NP (NN Recommendation) (CD 7)) (: :) (S (PP (IN In) (NP (DT the) (JJ general) (JJ black) (NN population))) (, ,) (PP (VBG including) (NP (NP (NP (DT those)) (PP (IN with) (NP (NN diabetes)))) (, ,) (NP (JJ initial) (JJ antihypertensive) (NN treatment)))) (VP (MD should) (VP (VB include) (NP (DT a) (JJ thiazide-type) (JJ diuretic) (CC or) (NN CCB))))) (. .)))
(ROOT (FRAG (-LRB- -LRB-) (FRAG (PP (IN For) (NP (JJ general) (JJ black) (NN population))) (: :) (NP (NP (JJ Moderate) (NN Recommendation)) (: --) (NNP Grade) (NNP B) (: ;)) (PP (IN for) (NP (NP (JJ black) (NNS patients)) (PP (IN with) (NP (NN diabetes))))) (: :) (VP (VB Weak) (NP (NP (NN Recommendation)) (: --) (NP (NNP Grade) (NNP C)))) (-RRB- -RRB-))))
(ROOT (NP (NP (NN Recommendation) (CD 8)) (: :) (S (PP (IN In) (NP (DT the) (NN population) (JJ aged) (NN ≥))) (NP (NP (CD 18) (NNS years)) (PP (IN with) (NP (NP (NN CKD)) (, ,) (NP (ADJP (JJ initial) (PRN (-LRB- -LRB-) (CC or) (NP (ADJP (NP (JJ add-on)))) (-RRB- -RRB-))) (JJ antihypertensive) (NN treatment))))) (VP (MD should) (VP (VB include) (NP (NP (DT an) (NN ACEI) (CC or) (NN ARB)) (SBAR (S (VP (TO to) (VP (VB improve) (NP (NN kidney) (NNS outcomes)))))))))) (. .)))
(ROOT (S (NP (DT This)) (VP (VBZ applies) (PP (TO to) (NP (NP (DT all) (NN CKD) (NNS patients)) (PP (IN with) (NP (NP (NN hypertension)) (ADVP (RB regardless) (PP (IN of) (NP (NN race) (CC or) (NN diabetes) (NN status))))))))) (. .)))
(ROOT (PRN (-LRB- -LRB-) (FRAG (NP (JJ Moderate) (NN Recommendation)) (: --) (NP (NNP Grade) (NNP B) (-RRB- -RRB-)))))
(ROOT (NP (NP (NN Recommendation) (CD 9)) (: :) (S (NP (NP (DT The) (JJ main) (NN objective)) (PP (IN of) (NP (NN hypertension) (NN treatment)))) (VP (VBZ is) (S (VP (TO to) (VP (VB attain) (CC and) (VB maintain) (NP (NN goal) (NN BP))))))) (. .)))
(ROOT (S (SBAR (IN If) (S (NP (NN goal) (NN BP)) (VP (VBZ is) (RB not) (VP (VBN reached) (PP (IN within) (NP (NP (DT a) (NN month)) (PP (IN of) (NP (NN treatment))))))))) (, ,) (VP (VBP increase) (NP (NP (NP (DT the) (NN dose)) (PP (IN of) (NP (DT the) (JJ initial) (NN drug)))) (CC or) (VP (VB add) (NP (DT a) (JJ second) (NN drug)) (PP (IN from) (NP (NP (CD one)) (PP (IN of) (NP (DT the) (NNS classes))) (PP (IN in) (NP (NP (NN recommendation) (CD 6)) (PRN (-LRB- -LRB-) (NP (NP (JJ thiazide-type) (JJ diuretic) (, ,) (NNP CCB)) (, ,) (NP (NP (NNP ACEI)) (, ,) (CC or) (NP (NN ARB)))) (-RRB- -RRB-))))))))) (. .)))
(ROOT (S (NP (DT The) (NN clinician)) (VP (VP (MD should) (VP (VB continue) (S (VP (TO to) (VP (VB assess) (NP (NN BP))))))) (CC and) (VP (VBP adjust) (NP (DT the) (NN treatment) (NN regimen)) (SBAR (IN until) (S (NP (NN goal) (NN BP)) (VP (VBZ is) (VP (VBN reached))))))) (. .)))
(ROOT (FRAG (SBAR (IN If) (S (NP (NN goal) (NN BP)) (VP (MD can) (RB not) (VP (VB be) (VP (VP (VBN reached) (PP (IN with) (NP (CD 2) (NNS drugs)))) (, ,) (VP (VB add) (CC and) (VP (VB titrate) (NP (NP (DT a) (JJ third) (NN drug)) (PP (IN from) (NP (NP (DT the) (NN list)) (VP (VBN provided)))))))))))) (. .)))
(ROOT (S (VP (VB Do) (RB not) (VP (VB use) (NP (NP (DT an) (NN ACEI)) (CC and) (NP (DT an) (NN ARB))) (ADVP (RB together)) (PP (IN in) (NP (DT the) (JJ same) (NN patient))))) (. .)))
(ROOT (FRAG (SBAR (IN If) (S (S (NP (NN goal) (NN BP)) (VP (MD can) (RB not) (VP (VB be) (VP (VBN reached) (S (VP (VBG using) (NP (NP (RB only) (DT the) (NNS drugs)) (PP (IN in) (NP (NN recommendation) (CD 6)))) (PP (IN because) (IN of) (NP (NP (DT a) (NN contraindication)) (CC or) (NP (DT the) (NN need) (S (VP (TO to) (VP (VB use) (NP (QP (JJR more) (IN than) (CD 3)) (NNS drugs)) (S (VP (TO to) (VP (VB reach) (NP (NP (NN goal) (NN BP)) (, ,) (NP (NP (JJ antihypertensive) (NNS drugs)) (PP (IN from) (NP (JJ other) (NNS classes)))))))))))))))))))) (VP (MD can) (VP (VB be) (VP (VBN used)))))) (. .)))
(ROOT (S (NP (NP (NN Referral)) (PP (TO to) (NP (DT a) (NN hypertension) (NN specialist)))) (VP (MD may) (VP (VB be) (VP (VBN indicated) (PP (IN for) (NP (NP (NNS patients)) (SBAR (WHPP (IN in) (WHNP (WP whom))) (S (NP (NN goal) (NN BP)) (VP (MD can) (RB not) (VP (VB be) (VP (VBN attained) (S (VP (VBG using) (NP (NP (DT the) (JJ above) (NN strategy)) (CC or) (PP (IN for) (NP (NP (DT the) (NN management)) (PP (IN of) (NP (NP (JJ complicated) (NNS patients)) (SBAR (WHPP (IN for) (WHNP (WP whom))) (S (NP (JJ additional) (JJ clinical) (NN consultation)) (VP (VBZ is) (VP (VBN needed)))))))))))))))))))))) (. .)))
(ROOT (PRN (-LRB- -LRB-) (FRAG (NP (NN Expert) (NN Opinion)) (: --) (NP (NNP Grade) (NNP E) (-RRB- -RRB-)))))
(ROOT (NP (NN Recommendation) (CD 1)))
(ROOT (S (PP (IN In) (NP (DT the) (JJ general) (NN population))) (NP (JJ aged) (NP (CD 60) (NNS years)) (CC or) (NP (JJR older))) (, ,) (VP (VP (VB initiate) (NP (JJ pharmacologic) (NN treatment)) (PP (TO to) (NP (NP (JJR lower) (NN BP)) (PP (IN at) (NP (NP (NP (JJ systolic) (NN blood) (NN pressure)) (PRN (-LRB- -LRB-) (NP (NN SBP)) (-RRB- -RRB-))) (PP (IN of) (NP (NP (NP (CD 150) (NN mm) (NN Hg)) (CC or) (NP (ADJP (JJR higher) (CC or) (JJ diastolic)) (NN blood) (NN pressure) (PRN (-LRB- -LRB-) (NP (NN DBP)) (-RRB- -RRB-)))) (PP (IN of) (NP (NP (CD 90) (NN mm) (NN Hg)) (CC or) (NP (JJR higher))))))))))) (CC and) (VP (VB treat) (PP (TO to) (NP (NP (DT a) (NN goal) (NN SBP)) (ADJP (JJR lower) (PP (IN than) (NP (NP (NP (CD 150) (NN mm) (NN Hg)) (CC and) (NP (NN goal) (NN DBP))) (NP (QP (JJR lower) (IN than) (CD 90)) (NN mm) (NN Hg))))))))) (. .)))
(ROOT (NP (NP (JJ Strong) (NN Recommendation)) (: --) (NP (NNP Grade) (NNP A))))
(ROOT (NP (NNP Corollary) (NNP Recommendation)))
(ROOT (S (PP (IN In) (NP (DT the) (JJ general) (NN population))) (S (S (VP (JJ aged) (NP (NP (CD 60) (NNS years)) (CC or) (NP (JJR older) (, ,) (SBAR (IN if) (S (NP (NP (JJ pharmacologic) (NN treatment)) (PP (IN for) (NP (JJ high) (NN BP)))) (VP (VBZ results) (PP (IN in) (NP (NP (JJR lower) (VBN achieved) (NN SBP)) (-LRB- -LRB-) (PP (IN for) (NP (NN example))) (, ,) (NP (QP (JJR <) (CD 140)) (NN mm) (NN Hg))))))))))) (-RRB- -RRB-) (CC and) (S (NP (NN treatment)) (VP (VBZ is) (RB not) (VP (VBN associated) (PP (IN with) (NP (NP (UCP (NP (JJ adverse) (NNS effects)) (PP (IN on) (NP (NN health))) (CC or)) (NN quality)) (PP (IN of) (NP (NN life))))))))) (, ,) (NP (NN treatment)) (VP (VBZ does) (RB not) (VP (VB need) (S (VP (TO to) (VP (VB be) (VP (VBN adjusted))))))) (. .)))
(ROOT (NP (NP (NN Expert) (NN Opinion)) (: --) (NP (NNP Grade) (NNP E))))
(ROOT (S (NP (NN Recommendation) (CD 1)) (VP (VBZ is) (VP (VBN based) (PP (IN on) (NP (NN evidence) (NNS statements) (CD 1))) (PP (IN through) (NP (NP (NP (CD 3)) (PP (IN from) (NP (NP (NN question) (CD 2)) (SBAR (WHPP (IN in) (WHNP (WDT which))) (S (NP (EX there)) (VP (VBZ is) (NP (JJ moderate)))))))) (: -) (PP (TO to) (NP (NP (JJ high-quality) (NN evidence)) (PP (IN from) (NP (NP (NNS RCTs)) (SBAR (WHNP (WDT that)) (S (PP (IN in) (NP (DT the) (JJ general) (NN population))) (NP (JJ aged) (NP (CD 60) (NNS years)) (CC or) (JJR older)) (, ,) (S (VP (VBG treating) (NP (JJ high) (NN BP)) (PP (TO to) (NP (NP (DT a) (NN goal)) (PP (IN of) (NP (QP (JJR lower) (IN than) (CD 150/90)) (NN mm) (NN Hg))))))) (VP (VBZ reduces) (NP (NP (NN stroke)) (, ,) (NP (NN heart) (NN failure)) (, ,) (CC and) (NP (NP (JJ coronary) (NN heart) (NN disease)) (PRN (-LRB- -LRB-) (NP (NN CHD)) (-RRB- -RRB-))))))))))))))) (. .)))
(ROOT (S (S (NP (EX There)) (VP (VBZ is) (ADVP (RB also)) (NP (NP (NP (NN evidence)) (PRN (-LRB- -LRB-) (PP (IN albeit) (NP (JJ low) (NN quality))) (-RRB- -RRB-))) (PP (IN from) (NP (NN evidence) (NN statement) (CD 6)))))) (, ,) (VP (NN question) (NP (CD 2) (SBAR (WDT that) (S (S (VP (VBG setting) (NP (NP (DT a) (NN goal) (NN SBP)) (PP (IN of) (NP (QP (JJR lower) (IN than) (CD 140)) (NN mm) (NN Hg)))) (PP (IN in) (NP (DT this) (NN age) (NN group))))) (VP (VBZ provides) (NP (NP (DT no) (JJ additional) (NN benefit)) (VP (VBN compared) (PP (IN with) (NP (NP (DT a) (JJR higher) (NN goal) (NN SBP)) (PP (IN of) (NP (NP (QP (CD 140) (TO to) (CD 160)) (NN mm) (NN Hg)) (CC or) (NP (QP (CD 140) (TO to) (CD 149)) (NN mm) (NN Hg))))))))))))) (. .)))
(ROOT (S (S (VP (TO To) (VP (VB answer) (NP (NP (NN question) (CD 2)) (PP (IN about) (NP (NP (NN goal) (NN BP)) (, ,) (SBAR (S (NP (DT the) (NN panel)) (VP (VBN reviewed) (NP (NP (DT all) (NNS RCTs)) (SBAR (WHNP (WDT that)) (S (VP (VBD met) (NP (DT the) (NN eligibility) (NNS criteria))))))))))))))) (CC and) (S (NP (NP (IN that)) (NP (CC either) (NP (NP (NP (VBN compared) (NN treatment)) (PP (IN with) (NP (DT a) (JJ particular) (NN goal)))) (UCP (CC vs) (NP (DT no) (NN treatment) (CC or) (NN placebo)) (CC or)) (VBN compared) (NN treatment)) (PP (IN with) (NP (CD one) (NN BP) (NN goal))) (PP (IN with) (NP (NN treatment))))) (PP (TO to) (NP (DT another) (NNP BP) (NN goal)))) (. .)))
(ROOT (S (NP (NP (DT The) (NNS trials)) (SBAR (WHPP (IN on) (WHNP (WDT which))) (S (NP (NP (DT these) (NN evidence) (NNS statements)) (CC and) (NP (DT this) (NN recommendation))) (VP (VBP are) (VP (VBN based)))))) (VP (VBP include) (NP (NNP HYVET) (, ,) (NNP Syst-Eur) (, ,) (NNP SHEP) (, ,) (NNP JATOS) (, ,) (NNP VALISH) (, ,) (CC and) (NN CARDIO-SIS))) (. .)))
(ROOT (S (NP (NP (NNS Strengths)) (, ,) (NP (NNS limitations)) (, ,) (CC and) (NP (NP (JJ other) (NNS considerations)) (VP (VBN related) (PP (TO to) (NP (DT this) (NN evidence) (NN review)))))) (VP (VBP are) (VP (VP (VBN presented) (PP (IN in) (NP (DT the) (NN evidence) (NN statement) (NNS narratives)))) (CC and) (S (ADVP (RB clearly)) (VP (VBP support) (NP (NP (DT the) (NN benefit)) (PP (IN of) (S (VP (VBG treating) (PP (TO to) (NP (NP (DT a) (NN BP)) (ADJP (JJR lower) (PP (IN than) (NP (CD 150) (NN mm) (NN Hg)))))))))))))) (. .)))
(ROOT (S (NP (NP (DT The) (NN corollary)) (PP (TO to) (NP (NN recommendation) (CD 1)))) (VP (VBZ reflects) (SBAR (IN that) (S (NP (EX there)) (VP (VBP are) (NP (NP (JJ many) (JJ treated) (JJ hypertensive) (NNS patients)) (VP (JJ aged) (NP (NP (CD 60) (NNS years)) (CC or) (NP (JJR older) (SBAR (WHPP (IN in) (WHNP (WP whom))) (S (NP (NNP SBP)) (VP (VBZ is) (NP (NP (QP (RB currently) (JJR lower) (IN than) (CD 140)) (NN mm) (NN Hg)) (, ,) (PP (VBN based) (PP (IN on) (NP (NP (NN implementation)) (PP (IN of) (NP (JJ previous) (NN guideline) (NNS recommendations)))))))))))))))))) (. .)))
(ROOT (S (NP (NP (DT The) (NN panel) (POS 's)) (NN opinion)) (VP (VBZ is) (SBAR (IN that) (S (PP (IN in) (NP (DT these) (NNS patients))) (, ,) (NP (PRP it)) (VP (VBZ is) (RB not) (ADJP (JJ necessary)) (S (VP (TO to) (VP (VB adjust) (NP (NN medication)) (S (VP (TO to) (VP (VB allow) (S (NP (NNP BP)) (VP (TO to) (VP (VB increase)))))))))))))) (. .)))
(ROOT (S (PP (IN In) (NP (NP (CD 2)) (PP (IN of) (NP (NP (DT the) (NNS trials)) (SBAR (WHNP (WDT that)) (S (VP (VBP provide) (S (NP (NN evidence)) (VP (VBG supporting) (NP (NP (DT an) (NN SBP) (NN goal)) (ADJP (JJR lower) (PP (IN than) (NP (CD 150) (NN mm) (NN Hg)))))))))))))) (, ,) (NP (DT the) (JJ average) (JJ treated) (NN SBP)) (VP (VBD was) (NP (NP (CD 143)) (PP (TO to) (NP (CD 144) (NN mm) (NN Hg))))) (. .)))
(ROOT (S (NP (NP (JJ Many) (NNS participants)) (PP (IN in) (NP (DT those) (NNS studies)))) (VP (VBD achieved) (NP (NP (DT an) (NN SBP)) (NP (NP (QP (JJR lower) (IN than) (CD 140)) (NN mm) (NN Hg)) (PP (IN with) (NP (NP (NN treatment)) (SBAR (WHNP (WDT that)) (S (VP (VBD was) (ADVP (RB generally)) (ADVP (RB well)) (VP (VBN tolerated)))))))))) (. .)))
(ROOT (S (S (NP (CD Two) (JJ other) (NN trials9) (CD ,10)) (VP (VBP suggest) (SBAR (S (NP (EX there)) (VP (VBD was) (NP (NP (DT no) (NN benefit)) (PP (IN for) (NP (NP (DT an) (NN SBP) (NN goal)) (ADJP (JJR lower) (PP (IN than) (NP (CD 140) (NN mm) (NN Hg)))))))))))) (, ,) (CC but) (S (S (NP (NP (DT the) (NN confidence) (NNS intervals)) (PP (IN around) (NP (DT the) (NN effect) (NNS sizes)))) (VP (VBD were) (ADJP (JJ wide)))) (CC and) (VP (VBD did) (RB not) (VP (VB exclude) (NP (NP (DT the) (NN possibility)) (PP (IN of) (NP (DT a) (ADJP (RB clinically) (JJ important)) (NN benefit))))))) (. .)))
(ROOT (S (ADVP (RB Therefore)) (, ,) (NP (DT the) (NN panel)) (VP (VBD included) (NP (NP (DT a) (JJ corollary) (NN recommendation)) (VP (VBN based) (PP (IN on) (NP (NP (JJ expert) (NN opinion)) (SBAR (WDT that) (S (NP (NP (NN treatment)) (PP (IN for) (NP (NN hypertension)))) (VP (VBZ does) (RB not) (VP (VB need) (S (VP (TO to) (VP (VB be) (VP (VBN adjusted) (SBAR (IN if) (S (NP (NN treatment)) (VP (VBZ results) (UCP (IN in) (UCP (NP (NNP SBP)) (NP (QP (JJR lower) (IN than) (CD 140)) (NN mm) (NN Hg)) (CC and)) (S (VP (VBZ is) (RB not) (VP (VBN associated) (PP (IN with) (S (UCP (NP (JJ adverse) (NNS effects)) (PP (IN on) (NP (NN health))) (CC or)) (NP (NP (NN quality)) (PP (IN of) (NP (NN life)))))))))))))))))))))))))) (. .)))
(ROOT (S (SBAR (IN While) (S (NP (DT all) (NN panel) (NNS members)) (VP (VBD agreed) (SBAR (IN that) (S (NP (NP (DT the) (NN evidence)) (VP (VBG supporting) (NP (NN recommendation) (CD 1)))) (VP (VBZ is) (ADJP (RB very) (JJ strong)))))))) (, ,) (NP (DT the) (NN panel)) (VP (VBD was) (ADJP (JJ unable) (S (VP (TO to) (VP (VB reach) (NP (NP (NN unanimity)) (PP (IN on) (NP (NP (DT the) (NN recommendation)) (PP (IN of) (NP (NP (DT a) (NN goal) (NN SBP)) (PP (IN of) (NP (QP (JJR lower) (IN than) (CD 150)) (NN mm) (NN Hg))))))))))))) (. .)))
(ROOT (S (NP (DT Some) (NNS members)) (VP (VBD recommended) (S (VP (VBG continuing) (NP (NP (DT the) (NN JNC) (CD 7) (NN SBP) (NN goal)) (PP (IN of) (NP (NP (QP (JJR lower) (IN than) (CD 140)) (NN mm) (NN Hg)) (PP (IN for) (NP (NP (NNS individuals)) (ADJP (JJR older) (PP (IN than) (NP (NP (CD 60) (NNS years)) (VP (VBN based) (PP (IN on) (NP (JJ expert) (NN opinion))))))))))))))) (. .)))
(ROOT (S (NP (DT These) (NNS members)) (VP (VBD concluded) (SBAR (IN that) (S (NP (DT the) (NN evidence)) (VP (VBD was) (ADJP (JJ insufficient) (S (VP (TO to) (VP (VB raise) (NP (NP (DT the) (NN SBP) (NN target)) (PP (IN from) (NP (ADJP (JJR lower) (PP (IN than) (NP (CD 140))) (PP (TO to) (NP (NP (QP (JJR lower) (IN than) (CD 150)) (NN mm) (NN Hg)) (PP (IN in) (NP (NP (JJ high-risk) (NNS groups)) (, ,) (PP (JJ such) (IN as) (NP (JJ black) (NNS persons)))))))) (, ,) (NP (NP (NP (DT those)) (PP (IN with) (NP (NP (NN CVD)) (PP (VBG including) (NP (NN stroke)))))) (, ,) (CC and) (NP (NP (DT those)) (PP (IN with) (NP (JJ multiple) (NN risk) (NNS factors)))))))))))))))) (. .)))
(ROOT (S (NP (DT The) (NN panel)) (VP (VBD agreed) (SBAR (IN that) (S (NP (JJR more) (NN research)) (VP (VBZ is) (VP (VBN needed) (S (VP (TO to) (VP (VB identify) (NP (NP (NP (JJ optimal) (NNS goals)) (PP (IN of) (NP (NN SBP)))) (PP (IN for) (NP (NP (NNS patients)) (PP (IN with) (NP (JJ high) (NN BP)))))))))))))) (. .)))
(ROOT (NP (NN Recommendation) (CD 2)))
(ROOT (S (PP (IN In) (NP (NP (DT the) (JJ general) (NN population)) (ADJP (JJR younger) (PP (IN than) (NP (CD 60) (NNS years)))))) (, ,) (VP (VP (VBP initiate) (NP (JJ pharmacologic) (NN treatment)) (PP (TO to) (NP (NP (JJR lower) (NN BP)) (PP (IN at) (NP (NP (NNP DBP)) (PP (IN of) (NP (NP (CD 90) (NN mm) (NN Hg)) (CC or) (NP (JJR higher))))))))) (CC and) (VP (VB treat) (PP (TO to) (NP (NP (DT a) (NN goal) (NN DBP)) (PP (IN of) (NP (QP (JJR lower) (IN than) (CD 90)) (NN mm) (NN Hg))))))) (. .)))
(ROOT (FRAG (PP (IN For) (NP (NNS ages) (CD 30))) (FRAG (PP (IN through) (NP (CD 59) (NNS years))) (, ,) (NP (JJ Strong) (NN Recommendation)) (: --) (NP (NNP Grade) (NNP A)))))
(ROOT (X (PP (IN For) (NP (NP (NNS ages) (CD 18)) (PP (IN through) (NP (CD 29) (NNS years))))) (, ,) (NP (NP (NNP Expert) (NNP Opinion)) (: --) (NP (NNP Grade) (NNP E)))))
(ROOT (S (NP (NN Recommendation) (CD 2)) (VP (VBZ is) (VP (VBN based) (PP (IN on) (NP (NP (JJ high-quality) (NN evidence)) (PP (IN from) (NP (NP (NP (CD 5) (NN DBP) (NNS trials)) (PRN (-LRB- -LRB-) (NP (NP (NN HDFP)) (, ,) (NP (NNP Hypertension-Stroke) (NNP Cooperative)) (, ,) (NP (NNP MRC)) (, ,) (NP (NNP ANBP)) (, ,) (CC and) (NP (NNP VA) (NNP Cooperative))) (-RRB- -RRB-))) (SBAR (WHNP (WDT that)) (S (VP (VBP demonstrate) (NP (NP (NNS improvements)) (PP (IN in) (NP (NN health) (NNS outcomes))) (PP (IN among) (NP (NP (NNS adults)) (NP (JJ aged) (CD 30) (PP (IN through) (NP (CD 69) (NNS years))))))) (PP (IN with) (NP (JJ elevated) (NN BP)))))))))))) (. .)))
(ROOT (S (NP (NP (NN Initiation)) (PP (IN of) (NP (NP (JJ antihypertensive) (NN treatment)) (PP (IN at) (NP (NP (DT a) (NN DBP) (NN threshold)) (PP (IN of) (NP (NP (CD 90) (NN mm) (NN Hg)) (CC or) (NP (JJR higher) (CC and) (NP (NN treatment))))))))) (PP (TO to) (NP (NP (DT a) (NNP DBP) (NN goal)) (PP (IN of) (NP (QP (JJR lower) (IN than) (CD 90)) (NN mm) (NN Hg)))))) (VP (VBZ reduces) (NP (NP (JJ cerebrovascular) (NNS events)) (, ,) (NP (NN heart) (NN failure)) (, ,) (CC and) (NP (NP (JJ overall) (NN mortality)) (PRN (-LRB- -LRB-) (NP (NP (NP (NN question) (CD 1)) (, ,) (NP (NN evidence) (NNS statements) (CD 10)) (, ,) (NP (CD 11)) (, ,) (NP (CD 13))) (: ;) (NP (NN question) (CD 2)) (, ,) (NP (NN evidence) (NN statement) (CD 10))) (-RRB- -RRB-))))) (. .)))
(ROOT (S (PP (IN In) (NP (NP (JJ further) (NN support)) (PP (IN for) (NP (NP (DT a) (NNP DBP) (NN goal)) (PP (IN of) (NP (NP (QP (JJR lower) (IN than) (CD 90)) (NN mm) (NN Hg)) (, ,) (NP (DT the) (NN panel)))))))) (VP (VBD found) (NP (NN evidence) (SBAR (IN that) (S (NP (EX there)) (VP (VBZ is) (NP (NP (DT no) (NN benefit)) (PP (IN in) (S (VP (VBG treating) (NP (NNS patients)) (PP (TO to) (NP (NP (DT a) (NN goal)) (PP (IN of) (NP (NP (CC either) (NP (CD 80) (NN mm) (NN Hg)) (CC or) (NP (ADJP (JJR lower) (CC or) (CD 85)) (NN mm) (NN Hg))) (CC or) (ADJP (JJR lower) (PP (VBN compared) (PP (IN with) (NP (NP (CD 90) (NN mm) (NN Hg)) (CC or) (NP (JJR lower) (PP (VBN based) (PP (IN on) (NP (NP (DT the) (JJ HOT) (NN trial)) (, ,) (SBAR (WHPP (IN in) (WHNP (WDT which))) (S (NP (NNS patients)) (VP (VBD were) (VP (VBN randomized) (PP (TO to) (NP (DT these) (CD 3) (NNS goals))) (PP (IN without) (ADVP (RB statistically))) (NP (NP (JJ significant) (NNS differences)) (PP (IN between) (NP (NP (NN treatment) (NNS groups)) (PP (IN in) (NP (NP (DT the) (ADJP (ADJP (JJ primary)) (CC or) (ADJP (JJ secondary))) (NNS outcomes)) (PRN (-LRB- -LRB-) (NP (NP (NN question) (CD 2)) (, ,) (NP (NN evidence) (NN statement) (CD 14))) (-RRB- -RRB-)))))))))))))))))))))))))))))))) (. .)))
(ROOT (S (PP (IN In) (NP (NP (NNS adults)) (ADJP (JJR younger) (PP (IN than) (NP (CD 30) (NNS years)))))) (, ,) (NP (EX there)) (VP (VBP are) (NP (NP (DT no) (JJ good) (: -) (CC or) (JJ fair-quality) (NNS RCTs)) (SBAR (WHNP (WDT that)) (S (VP (VBD assessed) (NP (NP (DT the) (NNS benefits)) (PP (IN of) (S (VP (VBG treating) (NP (JJ elevated) (NN DBP)) (PP (IN on) (NP (NP (NN health) (NNS outcomes)) (PRN (-LRB- -LRB-) (NP (NP (NN question) (CD 1)) (, ,) (NP (NN evidence) (NN statement) (CD 14))) (-RRB- -RRB-))))))))))))) (. .)))
(ROOT (S (PP (IN In) (NP (NP (DT the) (NN absence)) (PP (IN of) (NP (JJ such) (NN evidence))))) (, ,) (NP (PRP it)) (VP (VBZ is) (NP (NP (DT the) (NN panel) (POS 's)) (NN opinion) (SBAR (IN that) (S (PP (IN in) (NP (NP (NNS adults)) (ADJP (JJR younger) (PP (IN than) (NP (CD 30) (NNS years)))))) (, ,) (NP (NP (DT the) (NN DBP) (NN threshold)) (CC and) (NP (NN goal))) (VP (MD should) (VP (VB be) (NP (NP (DT the) (JJ same)) (PP (IN as) (PP (IN in) (NP (NP (NNS adults)) (VP (CD 30) (PP (IN through) (NP (NP (CD 59) (NNS years)) (PP (IN of) (NP (NN age)))))))))))))))) (. .)))
(ROOT (NP (NN Recommendation) (CD 3)))
(ROOT (S (PP (IN In) (NP (NP (DT the) (JJ general) (NN population)) (ADJP (JJR younger) (PP (IN than) (NP (CD 60) (NNS years)))))) (, ,) (VP (VBP initiate) (NP (JJ pharmacologic) (NN treatment)) (PP (TO to) (NP (JJR lower) (NN BP))) (UCP (PP (IN at) (NP (NP (NP (NN SBP)) (PP (IN of) (NP (CD 140) (NN mm) (NN Hg)))) (CC or) (ADJP (JJR higher)))) (CC and) (VP (VB treat) (PP (TO to) (NP (NP (DT a) (NN goal) (NN SBP)) (PP (IN of) (NP (QP (JJR lower) (IN than) (CD 140)) (NN mm) (NN Hg)))))))) (. .)))
(ROOT (NP (NP (NN Expert) (NN Opinion)) (: --) (NP (NNP Grade) (NNP E))))
(ROOT (S (NP (NN Recommendation) (CD 3)) (VP (VBZ is) (VP (VBN based) (PP (IN on) (NP (JJ expert) (NN opinion))))) (. .)))
(ROOT (S (SBAR (IN While) (S (NP (EX there)) (VP (VBZ is) (NP (NP (JJ high-quality) (NN evidence)) (SBAR (S (VP (TO to) (VP (VP (VB support) (NP (DT a) (JJ specific) (NN SBP) (NN threshold))) (CC and) (VP (NN goal) (SBAR (IN for) (S (NP (NNS persons)) (VP (JJ aged) (NP (NP (CD 60) (NNS years) (QP (CC or) (JJR older))) (PRN (-LRB- -LRB-) (VP (VB See) (NP (NN recommendation) (CD 1))) (-RRB- -RRB-))))))))))))))) (, ,) (NP (DT the) (NN panel)) (VP (VBD found) (NP (NP (JJ insufficient) (NN evidence)) (PP (IN from) (UCP (JJ good) (: -) (CC or) (NP (NP (JJ fair-quality) (NNS RCTs)) (SBAR (S (VP (TO to) (VP (VB support) (NP (NP (DT a) (JJ specific) (NN SBP) (NN threshold)) (CC or) (NP (NN goal))) (PP (IN for) (NP (NP (NNS persons)) (ADJP (JJR younger) (PP (IN than) (NP (CD 60) (NNS years))))))))))))))) (. .)))
(ROOT (FRAG (PP (IN In) (NP (NP (DT the) (NN absence)) (PP (IN of) (NP (NP (JJ such) (NN evidence)) (, ,) (S (NP (DT the) (NN panel)) (VP (VP (VBZ recommends) (NP (NP (DT an) (NN SBP) (NN treatment) (NN threshold)) (PP (IN of) (NP (CD 140) (NN mm) (NN Hg))))) (CC or) (NP (NP (JJR higher) (CC and) (DT an) (NN SBP) (NN treatment) (NN goal)) (PP (IN of) (NP (QP (JJR lower) (IN than) (CD 140)) (NN mm) (NN Hg))) (PP (VBN based) (PP (IN on) (NP (JJ several) (NNS factors))))))))))) (. .)))
(ROOT (UCP (ADVP (RB First)) (, ,) (PP (IN in) (NP (NP (DT the) (NN absence)) (PP (IN of) (NP (NP (DT any) (NNS RCTs)) (SBAR (WHNP (IN that)) (S (PP (VBN compared) (NP (NP (DT the) (JJ current) (NNP SBP) (NN standard)) (PP (IN of) (NP (CD 140) (NN mm) (NN Hg))) (SBAR (IN with) (S (ADVP (DT another) (JJR higher) (CC or) (JJR lower) (NN standard)) (PP (IN in) (NP (DT this) (NN age) (NN group))))))) (, ,) (NP (EX there)) (VP (VBD was) (NP (NP (DT no) (JJ compelling) (NN reason)) (SBAR (S (VP (TO to) (VP (VB change) (NP (JJ current) (NNS recommendations)))))))))))))) (. .)))
(ROOT (S (ADVP (RB Second)) (, ,) (PP (IN in) (NP (NP (DT the) (NN DBP) (NNS trials)) (SBAR (WHNP (WDT that)) (S (VP (VBD demonstrated) (NP (NP (DT the) (NN benefit)) (PP (IN of) (S (VP (VBG treating) (NP (NNP DBP)) (PP (TO to) (NP (QP (JJR lower) (IN than) (CD 90)) (NN mm) (NN Hg)))))))))))) (, ,) (NP (NP (JJ many)) (PP (IN of) (NP (NP (DT the) (NN study) (NNS participants)) (SBAR (WHNP (WP who)) (S (VP (VBD achieved) (NP (NP (NNP DBP)) (PP (IN of) (NP (QP (JJR lower) (IN than) (CD 90)) (NN mm) (NN Hg)))))))))) (VP (VBD were) (ADVP (RB also)) (ADJP (JJ likely) (S (VP (TO to) (VP (VB have) (VP (VBN achieved) (NP (NP (NNS SBPs)) (PP (IN of) (NP (NP (QP (JJR lower) (IN than) (CD 140)) (NN mm) (NN Hg)) (PP (IN with) (NP (NN treatment)))))))))))) (. .)))
(ROOT (S (NP (PRP It)) (VP (VBZ is) (RB not) (ADJP (JJ possible)) (S (VP (TO to) (VP (VB determine) (SBAR (IN whether) (S (NP (NP (DT the) (NN outcome) (NNS benefits)) (PP (IN in) (NP (DT these) (NNS trials)))) (VP (VBD were) (ADJP (JJ due) (PP (TO to) (S (VP (VBG lowering) (NP (NP (NNP DBP)) (, ,) (NP (NNP SBP)) (, ,) (CC or) (NP (DT both)))))))))))))) (. .)))
(ROOT (S (ADVP (NNP Third)) (, ,) (VP (VP (VBN given) (NP (NP (DT the) (VBN recommended) (NN SBP) (NN goal)) (PP (IN of) (NP (QP (JJR lower) (IN than) (CD 140)) (NN mm) (NN Hg)))) (PP (IN in) (NP (NP (NNS adults)) (PP (IN with) (NP (NP (NN diabetes)) (CC or) (NP (NP (NN CKD)) (PRN (-LRB- -LRB-) (NP (NNS recommendations) (NP (NP (CD 4)) (CC and) (NP (CD 5)))) (-RRB- -RRB-)))))))) (, ,) (SBAR (S (NP (NP (DT a) (JJ similar) (NN SBP) (NN goal)) (PP (IN for) (NP (NP (DT the) (JJ general) (NN population)) (ADJP (JJR younger) (PP (IN than) (NP (CD 60) (NNS years))))))) (VP (MD may) (VP (VB facilitate) (NP (NN guideline) (NN implementation))))))) (. .)))
(ROOT (NP (NN Recommendation) (CD 4)))
(ROOT (S (PP (IN In) (NP (DT the) (NN population))) (NP (JJ aged) (NP (CD 18) (NNS years)) (CC or) (ADJP (JJR older) (PP (IN with) (NP (NNP CKD))))) (, ,) (VP (VBP initiate) (NP (JJ pharmacologic) (NN treatment)) (PP (TO to) (NP (JJR lower) (NN BP))) (PP (IN at) (NP (NP (NP (NN SBP)) (PP (IN of) (NP (CD 140) (NN mm) (NN Hg)))) (CC or) (ADJP (ADJP (JJR higher)) (CC or) (NP (NP (NP (NN DBP)) (PP (IN of) (NP (NP (CD 90) (NN mm) (NN Hg)) (CC or) (NP (JJR higher))))) (CC and) (VP (VB treat) (PP (TO to) (NP (NP (NN goal) (NN SBP)) (PP (IN of) (NP (NP (QP (JJR lower) (IN than) (CD 140)) (NN mm) (NN Hg)) (CC and) (NP (NN goal) (NN DBP)))))) (NP (QP (JJR lower) (IN than) (CD 90)) (NN mm) (NN Hg)))))))) (. .)))
(ROOT (NP (NP (NN Expert) (NN Opinion)) (: --) (NP (NNP Grade) (NNP E))))
(ROOT (S (PP (VBN Based) (PP (IN on) (NP (NP (DT the) (NN inclusion) (NNS criteria)) (VP (VBN used) (PP (IN in) (NP (NP (DT the) (NNS RCTs)) (VP (VBN reviewed) (PP (IN by) (NP (DT the) (NN panel)))))))))) (, ,) (NP (DT this) (NN recommendation)) (VP (VBZ applies) (PP (TO to) (NP (NP (NNS individuals)) (ADJP (JJR younger) (PP (IN than) (NP (CD 70) (NNS years)))))) (PP (IN with) (NP (NP (DT an) (VBN estimated) (NN GFR)) (CC or) (NP (NP (VBN measured) (NN GFR)) (NP (QP (JJR less) (IN than) (CD 60)) (NN mL/min/1)))))) (. .)))
(ROOT (NP (NP (NP (NN m2)) (CC and) (PP (IN in) (NP (NP (NNS people)) (PP (IN of) (NP (DT any) (NN age))) (SBAR (IN with) (S (NP (NN albuminuria)) (VP (VBN defined) (PP (IN as) (NP (NP (QP (JJR greater) (IN than) (CD 30)) (NN mg)) (PP (IN of) (NP (NP (NN albumin/g)) (PP (IN of) (NP (NN creatinine))) (PP (IN at) (NP (NP (DT any) (NN level)) (PP (IN of) (NP (NN GFR))))))))))))))) (. .)))
(ROOT (S (NP (NN Recommendation) (CD 4)) (VP (VBZ is) (VP (VBN based) (PP (IN on) (NP (NP (NN evidence) (NNS statements) (CD 15-17)) (PP (IN from) (NP (NN question) (CD 2))))))) (. .)))
(ROOT (S (PP (IN In) (NP (NP (NP (NNS adults)) (ADJP (JJR younger) (PP (IN than) (NP (CD 70) (NNS years))))) (PP (IN with) (NP (NN CKD))))) (, ,) (NP (DT the) (NN evidence)) (VP (VBZ is) (ADJP (JJ insufficient) (S (VP (TO to) (VP (VB determine) (SBAR (IN if) (S (NP (EX there)) (VP (VBZ is) (NP (NP (DT a) (NN benefit)) (PP (IN in) (NP (NP (NP (NN mortality)) (, ,) (CC or) (NP (ADJP (JJ cardiovascular))) (CC or) (NP (JJ cerebrovascular) (NN health) (NNS outcomes))) (PP (IN with) (NP (NP (JJ antihypertensive) (NN drug) (NN therapy)) (PP (TO to) (NP (NP (DT a) (JJR lower) (NN BP) (NN goal)) (PRN (-LRB- -LRB-) (FRAG (PP (IN for) (NP (NN example))) (, ,) (NP (JJR <) (CD 130/80) (NN mm) (NN Hg))) (-RRB- -RRB-))))))))) (PP (VBN compared) (PP (IN with) (NP (NP (DT a) (NN goal)) (PP (IN of) (NP (NP (QP (JJR lower) (IN than) (CD 140/90)) (NN mm) (NN Hg)) (PRN (-LRB- -LRB-) (NP (NP (NN question) (CD 2)) (, ,) (NP (NN evidence) (NN statement) (CD 15))) (-RRB- -RRB-))))))))))))))) (. .)))
(ROOT (S (NP (EX There)) (VP (VBZ is) (NP (NP (NP (NN evidence)) (PP (IN of) (NP (JJ moderate) (NN quality)))) (VP (VBG demonstrating) (NP (NP (DT no) (NN benefit)) (PP (IN in) (S (VP (VBG slowing) (NP (NP (DT the) (NN progression)) (PP (IN of) (NP (NN kidney) (NN disease)))) (PP (IN from) (NP (NP (NN treatment)) (PP (IN with) (NP (NP (JJ antihypertensive) (NN drug) (NN therapy)) (PP (TO to) (NP (NP (DT a) (JJR lower) (NN BP) (NN goal)) (PRN (-LRB- -LRB-) (FRAG (PP (IN for) (NP (NN example))) (, ,) (NP (JJR <) (CD 130/80) (NN mm) (NN Hg))) (-RRB- -RRB-)))))))))))) (PP (VBN compared) (PP (IN with) (NP (NP (DT a) (NN goal)) (PP (IN of) (NP (NP (QP (JJR lower) (IN than) (CD 140/90)) (NN mm) (NN Hg)) (PRN (-LRB- -LRB-) (NP (NP (NN question) (CD 2)) (, ,) (NP (NN evidence) (NN statement) (CD 16))) (-RRB- -RRB-)))))))))) (. .)))
(ROOT (S (S (NP (NP (CD Three) (NNS trials)) (SBAR (WHNP (WDT that)) (S (VP (VBD met) (NP (NP (PRP$ our) (NNS criteria)) (PP (IN for) (NP (NN review)))))))) (VP (VBD addressed) (NP (NP (DT the) (NN effect)) (PP (IN of) (NP (NP (JJ antihypertensive) (NN drug) (NN therapy)) (PP (IN on) (NP (NN change))) (PP (IN in) (NP (NP (NN GFR)) (CC or) (NP (NN time))))))) (PP (TO to) (NP (NP (NN development)) (PP (IN of) (NP (NN ESRD))))))) (, ,) (CC but) (S (NP (QP (RB only) (CD one)) (NN trial)) (VP (VBD addressed) (NP (JJ cardiovascular) (NN disease) (NN end) (NNS points)))) (. .)))
(ROOT (S (NP (NN Blood) (NN pressure) (NNS goals)) (VP (VBD differed) (PP (IN across) (NP (DT the) (NNS trials))) (, ,) (PP (PP (IN with) (NP (NP (CD 2) (NP (NP (NNS trials)) (PRN (-LRB- -LRB-) (NP (NP (NN AASK)) (CC and) (NP (NN MDRD))) (-RRB- -RRB-)))) (VP (VBG using) (NP (NP (JJ mean) (JJ arterial) (NN pressure)) (CC and) (NP (NP (JJ different) (NNS targets)) (PP (IN by) (NP (NN age)))))))) (NP (NP (, ,) (CC and) (CD 1) (NN trial) (-LRB- -LRB-) (NN REIN-2) (-RRB- -RRB-)) (VP (VBG using) (NP (RB only) (NNP DBP) (NNS goals)))))) (. .)))
(ROOT (S (NP (NP (NN None)) (PP (IN of) (NP (DT the) (NNS trials)))) (VP (VBD showed) (NP (IN that) (NN treatment)) (PP (TO to) (NP (NP (DT a) (JJR lower) (NN BP) (NN goal)) (S (-LRB- -LRB-) (PP (IN for) (NP (NN example))) (PRN (, ,) (NP (QP (JJR <) (CD 130/80)) (NN mm) (NN Hg)) (-RRB- -RRB-)) (ADVP (RB significantly)) (VP (VBD lowered) (NP (NP (NN kidney)) (CC or) (NP (JJ cardiovascular) (NN disease) (NN end) (NNS points))) (PP (VBN compared) (PP (IN with) (NP (NP (DT a) (NN goal)) (PP (IN of) (NP (QP (JJR lower) (IN than) (CD 140/90)) (NN mm) (NN Hg))))))))))) (. .)))
(ROOT (S (PP (IN For) (NP (NP (NP (NNS patients)) (PP (IN with) (NP (NN proteinuria)))) (PRN (-LRB- -LRB-) (NP (JJR >) (CD 3) (NN g/24) (NNS hours)) (-RRB- -RRB-)))) (, ,) (S (NP (NP (NN post) (FW hoc) (NN analysis)) (PP (IN from) (NP (NP (RB only) (CD 1) (NN study)) (PRN (-LRB- -LRB-) (NP (NN MDRD)) (-RRB- -RRB-))))) (VP (VBD indicated) (NP (NP (NN benefit)) (PP (IN from) (NP (NN treatment)))) (PP (TO to) (NP (NP (DT a) (JJR lower) (NN BP) (NN goal)) (PRN (-LRB- -LRB-) (NP (JJR <) (CD 130/80) (NN mm) (NN Hg)) (-RRB- -RRB-)))))) (, ,) (CC and) (S (NP (NP (DT this) (JJ related)) (PP (TO to) (NP (NN kidney) (NNS outcomes)))) (ADVP (RB only))) (. .)))
(ROOT (S (SBAR (IN Although) (S (S (NP (NN post)) (VP (FW hoc) (NP (NP (JJ observational) (NNS analyses)) (PP (IN of) (NP (NNS data))) (PP (IN from) (NP (DT this) (NN trial)))))) (CC and) (S (NP (NNS others)) (VP (VBD suggested) (NP (NP (NN benefit)) (PP (IN from) (NP (DT the) (JJR lower) (NN goal))) (PP (IN at) (NP (NP (JJR lower) (NNS levels)) (PP (IN of) (NP (NN proteinuria)))))))))) (, ,) (NP (DT this) (NN result)) (VP (VBD was) (RB not) (VP (VBN seen) (PP (IN in) (NP (NP (DT the) (JJ primary) (NNS analyses)) (CC or) (PP (IN in) (NP (NP (NN AASK)) (CC or) (NP (NP (NN REIN-2)) (PRN (-LRB- -LRB-) (NP (NP (NN question) (CD 2)) (, ,) (NP (NN evidence) (NN statement) (CD 17))) (-RRB- -RRB-))))))))) (. .)))
(ROOT (FRAG (PP (VBN Based) (PP (IN on) (NP (NP (JJ available) (NN evidence)) (SBAR (S (NP (DT the) (NN panel)) (VP (MD can) (RB not) (VP (VB make) (NP (NP (DT a) (NN recommendation)) (PP (IN for) (NP (NP (DT a) (NN BP) (NN goal)) (PP (IN for) (NP (NP (NNS people)) (NP (NP (JJ aged) (NP (CD 70) (NNS years)) (CC or) (ADJP (JJR older) (PP (IN with) (NP (NN GFR))))) (NP (QP (RBR less) (IN than) (CD 60)) (NN mL/min/1) (CD .73) (NN m2))))))))))))))) (. .)))
(ROOT (S (NP (NP (DT The) (ADJP (RB commonly) (VBN used)) (VBG estimating) (NNS equations)) (PP (IN for) (NP (NN GFR)))) (VP (VBD were) (RB not) (VP (VBN developed) (PP (IN in) (NP (NP (NNS populations)) (PP (IN with) (NP (NP (JJ significant) (NNS numbers)) (PP (IN of) (NP (NP (NNS people)) (ADJP (JJR older) (PP (IN than) (NP (CD 70) (NNS years))))))))))) (CC and) (VP (VBP have) (RB not) (VP (VBN been) (VP (VBN validated) (PP (IN in) (NP (JJR older) (NNS adults))))))) (. .)))
(ROOT (S (NP (NP (DT No) (NN outcome) (NNS trials)) (VP (VBN reviewed) (PP (IN by) (NP (DT the) (NN panel))))) (VP (VBD included) (NP (NP (JJ large) (NNS numbers)) (PP (IN of) (NP (NP (NNS adults)) (ADJP (ADJP (JJR older)) (PP (IN than) (NP (CD 70) (NNS years)))))) (PP (IN with) (NP (NN CKD))))) (. .)))
(ROOT (S (ADVP (RB Further)) (, ,) (NP (NP (DT the) (JJ diagnostic) (NNS criteria)) (PP (IN for) (NP (NNP CKD)))) (VP (VBP do) (RB not) (VP (VB consider) (NP (NP (JJ age-related) (NN decline)) (PP (IN in) (NP (NN kidney) (NN function)))) (SBAR (IN as) (S (VP (VBN reflected) (PP (IN in) (NP (VBN estimated) (NN GFR)))))))) (. .)))
(ROOT (S (ADVP (RB Thus)) (, ,) (SBAR (WHADVP (WRB when)) (S (VP (VBG weighing) (NP (NP (DT the) (NNS risks) (CC and) (NNS benefits)) (PP (IN of) (NP (DT a) (JJR lower) (NN BP) (NN goal)))) (PP (IN for) (NP (NP (NNS people)) (NP (JJ aged) (NP (CD 70) (NNS years)) (CC or) (ADJP (JJR older) (PP (IN with) (NP (VBN estimated) (NNP GFR) (QP (JJR less) (IN than) (CD 60)) (NN mL/min/1) (CD .73) (NN m2)))))))))) (, ,) (NP (JJ antihypertensive) (NN treatment)) (VP (MD should) (VP (VB be) (VP (VBN individualized))) (, ,) (S (VP (VBG taking) (PP (IN into) (NP (NP (NN consideration) (NNS factors)) (PP (JJ such) (IN as) (NP (NP (NN frailty)) (, ,) (NP (NNS comorbidities)) (, ,) (CC and) (NP (NN albuminuria))))))))) (. .)))
(ROOT (NP (NN Recommendation) (CD 5)))
(ROOT (S (PP (IN In) (NP (DT the) (NN population))) (NP (JJ aged) (NP (CD 18) (NNS years)) (CC or) (ADJP (JJR older) (PP (IN with) (NP (NN diabetes))))) (, ,) (VP (VBP initiate) (NP (JJ pharmacologic) (NN treatment)) (PP (TO to) (NP (JJR lower) (NN BP))) (PP (IN at) (NP (NP (NP (NN SBP)) (PP (IN of) (NP (CD 140) (NN mm) (NN Hg)))) (CC or) (ADJP (ADJP (JJR higher)) (CC or) (NP (NP (NP (NN DBP)) (PP (IN of) (NP (NP (CD 90) (NN mm) (NN Hg)) (CC or) (NP (JJR higher))))) (CC and) (VP (VB treat) (PP (TO to) (NP (NP (DT a) (NN goal) (NN SBP)) (PP (IN of) (NP (NP (QP (JJR lower) (IN than) (CD 140)) (NN mm) (NN Hg)) (CC and) (NP (NN goal) (NN DBP)))))) (NP (QP (JJR lower) (IN than) (CD 90)) (NN mm) (NN Hg)))))))) (. .)))
(ROOT (NP (NP (NN Expert) (NN Opinion)) (: --) (NP (NNP Grade) (NNP E))))
(ROOT (S (NP (NN Recommendation) (CD 5)) (VP (VBZ is) (VP (VBN based) (PP (IN on) (NP (NP (NN evidence) (NNS statements) (CD 18-21)) (PP (IN from) (NP (NN question) (CD 2) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBP address) (NP (NP (NNP BP) (NNS goals)) (PP (IN in) (NP (NP (NNS adults)) (PP (IN with) (NP (DT both) (NP (NN diabetes)) (CC and) (NP (NN hypertension)))))))))))))))) (. .)))
(ROOT (S (NP (EX There)) (VP (VBZ is) (SBAR (S (NP (JJ moderate-quality) (NN evidence)) (PP (IN from) (NP (NP (NP (CD 3) (NNS trials)) (PRN (-LRB- -LRB-) (NP (NP (NNS SHEP)) (, ,) (NP (NNP Syst-Eur)) (, ,) (CC and) (NP (NN UKPDS))) (-RRB- -RRB-))) (NP (WDT that) (NN treatment)))) (PP (TO to) (NP (NP (DT an) (NN SBP) (NN goal)) (PP (IN of) (NP (QP (JJR lower) (IN than) (CD 150)) (NN mm) (NN Hg))))) (VP (VP (VBZ improves) (NP (ADJP (JJ cardiovascular) (CC and) (JJ cerebrovascular)) (NN health) (NNS outcomes))) (CC and) (VP (VBZ lowers) (NP (NN mortality)) (S (-LRB- -LRB-) (VP (VB see) (NP (NP (NN question) (CD 2)) (, ,) (NP (NN evidence) (NN statement) (CD 18))) (-RRB- -RRB-) (PP (IN in) (NP (NP (NNS adults)) (PP (IN with) (NP (NP (NN diabetes)) (CC and) (NP (NP (NN hypertension)) (CD .23)))))) (: -) (SBAR (S (NP (CD 25) (DT No) (NNS RCTs)) (VP (VBD addressed) (SBAR (IN whether) (S (NP (NP (NN treatment)) (PP (TO to) (NP (NP (DT an) (NN SBP) (NN goal)) (PP (IN of) (NP (QP (JJR lower) (IN than) (CD 140)) (NN mm) (NN Hg)))))) (VP (VBN compared) (S (IN with) (NP (DT a) (JJR higher) (NN goal)) (-LRB- -LRB-) (PP (IN for) (NP (NN example))) (PRN (, ,) (NP (JJR <) (CD 150) (NN mm) (NN Hg)) (-RRB- -RRB-)) (VP (VBZ improves) (NP (NN health) (NNS outcomes)) (PP (IN in) (NP (NP (NNS adults)) (PP (IN with) (NP (NP (NN diabetes)) (CC and) (NP (NN hypertension))))))))))))))))))))) (. .)))
(ROOT (FRAG (PP (IN In) (NP (NP (DT the) (NN absence)) (PP (IN of) (NP (NP (JJ such) (NN evidence)) (, ,) (S (NP (DT the) (NN panel)) (VP (VBZ recommends) (NP (NP (DT an) (NN SBP) (NN goal)) (PP (IN of) (NP (NP (QP (JJR lower) (IN than) (CD 140)) (NN mm) (NN Hg)) (CC and) (NP (NP (DT a) (NNP DBP) (NN goal)) (NP (QP (JJR lower) (IN than) (CD 90)) (NN mm) (NN Hg)))))) (PP (IN in) (NP (DT this) (NN population))) (PP (VBN based) (PP (IN on) (NP (NP (JJ expert) (NN opinion)) (, ,) (ADJP (JJ consistent) (PP (IN with) (NP (NP (DT the) (NNP BP) (NNS goals)) (PP (IN in) (NP (NN recommendation) (CD 3))) (PP (IN for) (NP (NP (DT the) (JJ general) (NN population)) (ADJP (JJR younger) (PP (IN than) (NP (NP (CD 60) (NNS years)) (PP (IN with) (NP (NN hypertension)))))))))))))))))))) (. .)))
(ROOT (S (UCP (NP (NP (NN Use)) (PP (IN of) (NP (NP (DT a) (JJ consistent) (NNP BP) (NN goal)) (PP (IN in) (NP (DT the) (JJ general) (NN population)))))) (ADJP (JJR younger) (PP (IN than) (NP (CD 60) (NNS years)))) (CC and)) (PP (IN in) (NP (NP (NNS adults)) (PP (IN with) (NP (NP (NN diabetes)) (PP (IN of) (NP (DT any) (NN age))))))) (VP (MD may) (VP (VB facilitate) (NP (NN guideline) (NN implementation)))) (. .)))
(ROOT (S (NP (NP (DT This) (NN recommendation)) (PP (IN for) (NP (NP (DT an) (NN SBP) (NN goal)) (PP (IN of) (NP (NP (QP (JJR lower) (IN than) (CD 140)) (NN mm) (NN Hg)) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (NN diabetes)))))))))) (VP (VBZ is) (ADVP (RB also)) (VP (VBN supported) (PP (IN by) (NP (NP (DT the) (NN ACCORD-BP) (NN trial)) (, ,) (SBAR (WHPP (IN in) (WHNP (WDT which))) (S (NP (DT the) (NN control) (NN group)) (VP (VP (VBD used) (NP (DT this) (NN goal))) (CC and) (VP (VBD had) (NP (JJ similar) (NNS outcomes)) (PP (VBN compared) (PP (IN with) (NP (DT a) (JJR lower) (NN goal)))))))))))) (. .)))
(ROOT (S (S (NP (DT The) (NN panel)) (VP (VBZ recognizes) (SBAR (IN that) (S (NP (DT the) (NN ADVANCE) (NN trial)) (VP (VBD tested) (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (NN treatment))) (PP (TO to) (NP (NP (JJR lower) (NN BP)) (PP (IN on) (NP (NP (JJ major) (ADJP (JJ macrovascular) (CC and) (JJ microvascular)) (NNS events)) (PP (IN in) (NP (NP (NNS adults)) (PP (IN with) (NP (NN diabetes))) (SBAR (WHNP (WP who)) (S (VP (VBD were) (PP (IN at) (NP (NP (VBN increased) (NN risk)) (PP (IN of) (NP (NNP CVD)))))))))))))))))))) (, ,) (CC but) (S (NP (DT the) (NN study)) (VP (VBD did) (RB not) (VP (VB meet) (NP (NP (DT the) (NN panel) (POS 's)) (NN inclusion) (NNS criteria))))) (SBAR (IN because) (S (NP (NNS participants)) (VP (VBD were) (NP (NP (JJ eligible) (JJ irrespective)) (PP (IN of) (NP (NN baseline) (NN BP))))))) (, ,) (CC and) (S (NP (EX there)) (VP (VBD were) (NP (DT no) (VBN randomized) (NP (NN BP) (NN treatment) (NNS thresholds) (CC or) (NNS goals))))) (. .)))
(ROOT (S (NP (DT The) (NN panel)) (ADVP (RB also)) (VP (VBZ recognizes) (SBAR (IN that) (S (NP (NP (DT an) (NN SBP) (NN goal)) (PP (IN of) (NP (QP (JJR lower) (IN than) (CD 130)) (NN mm) (NN Hg)))) (VP (VBZ is) (VP (ADVP (RB commonly)) (VBN recommended) (PP (IN for) (NP (NP (NNS adults)) (PP (IN with) (NP (NP (NN diabetes)) (CC and) (NP (NN hypertension))))))))))) (. .)))
(ROOT (S (ADVP (RB However)) (, ,) (NP (DT this) (JJR lower) (NN SBP) (NN goal)) (VP (VP (VBZ is) (RB not) (VP (VBN supported) (PP (IN by) (NP (NP (DT any) (NN RCT)) (SBAR (WHNP (WDT that)) (S (VP (VBD randomized) (NP (NP (NNS participants)) (PP (IN into) (NP (NP (QP (CD 2) (CC or) (JJR more)) (NNS groups)) (SBAR (WHPP (IN in) (WHNP (WDT which))) (S (NP (NN treatment)) (VP (VBD was) (VP (VBN initiated) (PP (PP (IN at) (NP (NP (DT a) (JJR lower) (NN SBP) (NN threshold)) (PP (IN than) (NP (CD 140) (NN mm) (NN Hg))))) (CC or) (PP (IN into) (NP (NP (NN treatment) (NNS groups)) (SBAR (WHPP (IN in) (WHNP (WDT which))) (S (NP (DT the) (NN SBP) (NN goal)) (VP (VBD was) (NP (QP (JJR lower) (IN than) (CD 140)) (NN mm) (NN Hg)))))))))))))))))))))) (CC and) (SBAR (IN that) (S (VP (VBN assessed) (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (NP (DT a) (JJR lower) (NN SBP) (NN threshold)) (CC or) (NP (NN goal)))) (PP (IN on) (NP (JJ important) (NN health) (NNS outcomes)))))))) (. .)))
(ROOT (FRAG (NP (NP (DT The) (JJ only) (NN RCT)) (SBAR (SBAR (WHNP (IN that)) (S (VP (VBN compared) (NP (NP (DT an) (NN SBP) (NN treatment) (NN goal)) (PP (IN of) (NP (NP (QP (JJR lower) (IN than) (CD 140)) (NN mm) (NN Hg)) (PP (IN with) (NP (DT a) (JJR lower) (NN SBP) (NN goal))))))))) (CC and) (VP (VBN assessed) (NP (DT the) (NNS effects)) (SBAR (IN on) (S (NP (JJ important) (NN health) (NNS outcomes)) (VP (VBZ is) (NP (NP (NN ACCORD-BP)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBD compared) (NP (NP (DT an) (NN SBP) (NN treatment) (NN goal)) (PP (IN of) (NP (NP (QP (JJR lower) (IN than) (CD 120)) (NN mm) (NN Hg)) (PP (IN with) (NP (NP (DT a) (NN goal)) (NP (QP (JJR lower) (IN than) (CD 140)) (NN mm) (NN Hg))))))))))))))))) (. .)))
(ROOT (S (NP (EX There)) (VP (VBD was) (NP (DT no) (NN difference)) (PP (IN in) (NP (NP (DT the) (JJ primary) (NN outcome)) (, ,) (NP (NP (DT a) (NN composite)) (PP (IN of) (NP (JJ cardiovascular) (NN death)))) (, ,) (NP (JJ nonfatal) (JJ myocardial) (NN infarction)) (, ,) (CC and) (NP (JJ nonfatal) (NN stroke))))) (. .)))
(ROOT (S (NP (EX There)) (VP (VBD were) (ADVP (RB also)) (NP (NP (DT no) (NNS differences)) (PP (IN in) (NP (NP (DT any)) (PP (IN of) (NP (DT the) (JJ secondary) (NNS outcomes))))) (PP (IN except) (PP (IN for) (NP (NP (DT a) (NN reduction)) (PP (IN in) (NP (NN stroke)))))))) (. .)))
(ROOT (S (ADVP (RB However)) (, ,) (S (S (NP (NP (DT the) (NN incidence)) (PP (IN of) (NP (NN stroke))) (PP (IN in) (NP (NP (DT the) (NN group)) (VP (VBN treated) (PP (TO to) (NP (QP (JJR lower) (IN than) (CD 140)) (NN mm) (NN Hg))))))) (VP (VBD was) (ADJP (ADJP (RB much) (JJR lower)) (SBAR (IN than) (S (VP (VBN expected))))))) (, ,) (IN so) (S (NP (NP (DT the) (JJ absolute) (NN difference)) (PP (IN in) (NP (ADJP (ADJP (JJ fatal)) (CC and) (ADJP (JJ nonfatal))) (NN stroke))) (PP (IN between) (NP (DT the) (CD 2) (NNS groups)))) (VP (VBD was) (NP (NP (QP (RB only) (CD 0.21)) (NN %)) (PP (IN per) (NP (NN year))))))) (. .)))
(ROOT (S (NP (DT The) (NN panel)) (VP (VBD concluded) (SBAR (IN that) (S (NP (NP (DT the) (NNS results)) (PP (IN from) (NP (NN ACCORD-BP)))) (VP (VBD did) (RB not) (VP (VB provide) (NP (NP (JJ sufficient) (NN evidence)) (SBAR (S (VP (TO to) (VP (VB recommend) (NP (NP (DT an) (NN SBP) (NN goal)) (PP (IN of) (ADJP (JJR lower) (PP (IN than) (NP (NP (CD 120) (NN mm) (NN Hg)) (PP (IN in) (NP (NP (NNS adults)) (PP (IN with) (NP (NP (NN diabetes)) (CC and) (NP (NN hypertension))))))))))))))))))))) (. .)))
(ROOT (S (NP (DT The) (NN panel)) (ADVP (RB similarly)) (VP (VBZ recommends) (NP (NP (DT the) (JJ same) (NN goal) (NN DBP)) (PP (IN in) (NP (NP (NNS adults)) (PP (IN with) (NP (NP (NN diabetes)) (CC and) (NP (NN hypertension))))))) (PP (IN as) (FRAG (PP (IN in) (NP (DT the) (JJ general) (NN population))))) (PRN (-LRB- -LRB-) (NP (QP (JJR <) (CD 90)) (NN mm) (NN Hg)) (-RRB- -RRB-))) (. .)))
(ROOT (FRAG (SBAR (IN Despite) (S (NP (NP (DT some) (JJ existing) (NNS recommendations)) (SBAR (WHNP (WDT that)) (S (NP (NP (NNS adults)) (PP (IN with) (NP (NP (NN diabetes)) (CC and) (NP (NN hypertension))))) (VP (MD should) (VP (VB be) (VP (VBN treated) (PP (TO to) (NP (NP (DT a) (NNP DBP) (NN goal)) (PP (IN of) (NP (NP (QP (JJR lower) (IN than) (CD 80)) (NN mm) (NN Hg)) (, ,) (NP (DT the) (NN panel)))))))))))) (VP (VBD did) (RB not) (VP (VB find) (NP (NP (JJ sufficient) (NN evidence)) (SBAR (S (VP (TO to) (VP (VB support) (NP (PDT such) (DT a) (NN recommendation))))))))))) (. .)))
(ROOT (S (PP (IN For) (NP (NN example))) (, ,) (NP (EX there)) (VP (VBP are) (FRAG (DT no) (JJ good) (: -) (PP (CC or) (NP (NP (JJ fair-quality) (NNS RCTs)) (PP (IN with) (NP (NP (NN mortality)) (PP (IN as) (NP (NP (DT a) (ADJP (ADJP (JJ primary)) (CC or) (ADJP (JJ secondary))) (JJ prespecified) (NN outcome)) (SBAR (WHNP (IN that)) (S (VP (VBN compared) (NP (NP (DT a) (NNP DBP) (NN goal)) (PP (IN of) (S (NP (QP (JJR lower) (IN than) (CD 90)) (NN mm) (NN Hg)) (IN with) (NP (DT a) (JJR lower) (NN goal)) (-LRB- -LRB-) (NP (NP (NN evidence) (NN statement) (CD 21) (-RRB- -RRB-))))))))))))))))) (. .)))
(ROOT (S (PP (IN In) (NP (DT the) (JJ HOT) (NN trial))) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBZ is) (ADVP (RB frequently)) (VP (VBN cited) (S (VP (TO to) (VP (VB support) (NP (DT a) (JJR lower) (NN DBP) (NN goal))))))))) (, ,) (NP (NNS investigators)) (VP (VBD compared) (NP (NP (DT a) (NNP DBP) (NN goal)) (PP (IN of) (NP (NP (CD 90) (NN mm) (NN Hg)) (CC or) (NP (NP (JJR lower) (CC vs) (DT a) (NN goal)) (PP (IN of) (NP (NP (CD 80) (NN mm) (NN Hg)) (CC or) (ADJP (JJR lower))))))))) (. .)))
(ROOT (S (S (NP (DT The) (JJR lower) (NN goal)) (VP (VBD was) (VP (VBN associated) (PP (IN with) (NP (NP (DT a) (NN reduction)) (PP (IN in) (NP (NP (DT a) (JJ composite) (NNP CVD) (NN outcome)) (PRN (-LRB- -LRB-) (NP (NP (NN question) (CD 2)) (, ,) (NP (NN evidence) (NN statement) (CD 20))) (-RRB- -RRB-))))))))) (, ,) (CC but) (S (NP (DT this)) (VP (VBD was) (NP (NP (DT a) (NN post) (FW hoc) (NN analysis)) (PP (IN of) (NP (NP (NP (DT a) (JJ small) (NN subgroup)) (PRN (-LRB- -LRB-) (NP (CD 8) (NN %)) (-RRB- -RRB-))) (PP (IN of) (NP (NP (DT the) (NN study) (NN population)) (SBAR (WHNP (WDT that)) (S (VP (VBD was) (RB not) (VP (VBN prespecified)))))))))))) (. .)))
(ROOT (S (PP (IN As) (NP (DT a) (NN result))) (, ,) (NP (DT the) (NN evidence)) (VP (VBD was) (VP (VBN graded) (S (VP (ADVP (RB as) (JJ low)) (NN quality))))) (. .)))
(ROOT (S (NP (NP (DT Another) (ADJP (RB commonly) (VBN cited)) (NN study)) (SBAR (S (VP (TO to) (VP (VB support) (NP (DT a) (JJR lower) (NN DBP) (NN goal))))))) (VP (VBZ is) (NP (NP (NN UKPDS) (CD ,25)) (SBAR (WHNP (WDT which)) (S (VP (VBD had) (NP (NP (DT a) (NNP BP) (NN goal)) (PP (IN of) (NP (NP (QP (JJR lower) (IN than) (CD 150/85)) (NN mm) (NN Hg)) (PP (IN in) (NP (DT the) (JJ more-intensively) (JJ treated) (NN group)))))) (PP (VBN compared) (PP (IN with) (NP (NP (DT a) (NN goal)) (PP (IN of) (NP (NP (QP (JJR lower) (IN than) (CD 180/105)) (NN mm) (NN Hg)) (PP (IN in) (NP (DT the) (JJ less-intensively) (JJ treated) (NN group))))))))))))) (. .)))
(ROOT (S (S (NP (NN UKPDS)) (VP (VBD did) (VP (VB show) (NP (IN that) (NN treatment)) (PP (IN in) (NP (DT the) (JJR lower) (NN goal) (NN BP) (NN group)))))) (VP (VBD was) (VP (VBN associated) (PP (IN with) (NP (NP (NP (DT a) (ADJP (RB significantly) (JJR lower)) (NN rate)) (PP (IN of) (NP (NN stroke)))) (, ,) (NP (NN heart) (NN failure)) (, ,) (NP (JJ diabetes-related) (NN end) (NNS points)) (, ,) (CC and) (NP (NP (NNS deaths)) (ADJP (VBN related) (PP (TO to) (NP (NN diabetes))))))))) (. .)))
(ROOT (S (ADVP (RB However)) (, ,) (NP (NP (DT the) (NN comparison)) (PP (IN in) (NP (NN UKPDS)))) (VP (VBD was) (NP (NP (DT a) (NNP DBP) (NN goal)) (PP (IN of) (NP (NP (QP (JJR lower) (IN than) (CD 85)) (NN mm) (NN Hg)) (PP (CC vs) (NP (NP (JJR lower) (NN than105) (NN mm) (NN Hg)) (: ;) (ADVP (RB therefore)) (S (, ,) (NP (PRP it)) (VP (VBZ is) (RB not) (ADJP (JJ possible)) (S (VP (TO to) (VP (VB determine) (SBAR (IN whether) (S (NP (NP (NN treatment)) (PP (TO to) (NP (NP (DT a) (NNP DBP) (NN goal)) (PP (IN of) (NP (QP (JJR lower) (IN than) (CD 85)) (NN mm) (NN Hg)))))) (VP (VBZ improves) (NP (NNS outcomes)) (PP (VBN compared) (PP (IN with) (NP (NP (NN treatment)) (PP (TO to) (NP (NP (DT a) (NNP DBP) (NN goal)) (PP (IN of) (NP (QP (JJR lower) (IN than) (CD 90)) (NN mm) (NN Hg)))))))))))))))))))))) (. .)))
(ROOT (S (PP (IN In) (NP (NN addition))) (, ,) (S (NP (NN UKPDS)) (VP (VBD was) (NP (NP (DT a) (JJ mixed) (NN systolic)) (CC and) (NP (NP (JJ diastolic) (NN BP) (NN goal) (NN study)) (PRN (-LRB- -LRB-) (NP (NP (JJ combined) (NN SBP)) (CC and) (NP (NN DBP) (NNS goals))) (-RRB- -RRB-)))))) (, ,) (IN so) (S (NP (PRP it)) (VP (MD can) (RB not) (VP (VB be) (VP (VBN determined) (SBAR (IN if) (S (NP (DT the) (NNS benefits)) (VP (VBD were) (ADJP (JJ due) (PP (TO to) (S (VP (VBG lowering) (NP (NP (NNP SBP)) (, ,) (NP (NNP DBP)) (, ,) (CC or) (NP (DT both)))))))))))))) (. .)))
(ROOT (NP (NN Recommendation) (CD 6)))
(ROOT (S (PP (IN In) (NP (DT the) (JJ general) (JJ nonblack) (NN population))) (, ,) (PP (VBG including) (NP (NP (NP (DT those)) (PP (IN with) (NP (NN diabetes)))) (, ,) (NP (JJ initial) (JJ antihypertensive) (NN treatment)))) (VP (MD should) (VP (VB include) (NP (DT a) (JJ thiazide-type) (JJ diuretic) (, ,) (NP (NP (NP (NN calcium) (NN channel) (NN blocker)) (PRN (-LRB- -LRB-) (NP (NN CCB)) (-RRB- -RRB-))) (, ,) (NP (NP (JJ angiotensin-converting) (NN enzyme) (NN inhibitor)) (PRN (-LRB- -LRB-) (NP (NN ACEI)) (-RRB- -RRB-))) (, ,) (CC or) (NP (NP (NN angiotensin) (NN receptor) (NN blocker)) (PRN (-LRB- -LRB-) (NP (NN ARB)) (-RRB- -RRB-))))))) (. .)))
(ROOT (NP (NP (JJ Moderate) (NN Recommendation)) (: --) (NP (NNP Grade) (NNP B))))
(ROOT (S (S (UCP (PP (IN For) (NP (DT this) (NN recommendation))) (, ,) (QP (RB only) (NNS RCTs)) (UCP (WHNP (IN that)) (PP (VBN compared) (NP (NP (CD one) (NN class)) (PP (IN of) (NP (JJ antihypertensive) (NN medication))) (PP (TO to) (NP (DT another))))) (CC and)) (S (VP (VBN assessed) (NP (DT the) (NNS effects)) (PP (IN on) (NP (NN health) (NNS outcomes)))))) (VP (VBD were) (VP (VBN reviewed)))) (: ;) (S (NP (JJ placebo-controlled) (NNS RCTs)) (VP (VBD were) (RB not) (VP (VBN included)))) (. .)))
(ROOT (S (ADVP (RB However)) (, ,) (NP (DT the) (NN evidence) (NN review)) (VP (VBD was) (SBAR (S (VBN informed) (PP (IN by) (NP (NP (JJ major) (JJ placebo-controlled) (NN hypertension) (NNS trials)) (, ,) (PP (VBG including) (NP (NP (CD 3) (ADJP (RB federally) (VBN funded)) (NNS trials)) (PRN (-LRB- -LRB-) (NP (NP (NNP VA) (NNP Cooperative) (NNP Trial)) (, ,) (NP (NN HDFP)) (, ,) (CC and) (NP (NN SHEP))) (-RRB- -RRB-)))))) (, ,) (NP (WDT that)) (VP (VBD were) (ADJP (JJ pivotal)) (PP (IN in) (S (VP (VBG demonstrating) (SBAR (IN that) (S (NP (NP (NN treatment)) (PP (IN of) (NP (NP (NN hypertension)) (PP (IN with) (NP (JJ antihypertensive) (NNS medications)))))) (VP (VBZ reduces) (NP (NP (ADJP (ADJP (JJ cardiovascular)) (CC or) (ADJP (JJ cerebrovascular))) (NNS events)) (CC and/or) (NP (NN mortality))))))))))))) (. .)))
(ROOT (NP (NP (NP (DT These) (NNS trials)) (SBAR (S (NP (DT all) (VBN used) (NP (JJ thiazide-type) (NNS diuretics))) (VP (VBN compared) (PP (IN with) (NP (NP (NP (NN placebo)) (CC or) (NP (JJ usual) (NN care))) (PP (IN as) (NP (NP (DT the) (NN basis)) (PP (IN of) (NP (NN therapy))))))))))) (. .)))
(ROOT (NP (NP (JJ Additional) (NN evidence) (SBAR (IN that) (S (S (NP (NNP BP)) (VP (VBG lowering) (VP (VBZ reduces) (NP (NN risk))))) (VP (VBZ comes) (PP (IN from) (NP (NP (NNS trials)) (PP (IN of) (NP (NP (NP (NP (NP (NN β-blocker)) (CC vs) (NP (NN placebo16))) (CD ,27)) (CC and) (NP (NNP CCB))) (CC vs) (NP (NN placebo)))))))))) (. .)))
(ROOT (S (NP (NP (DT Each)) (PP (IN of) (NP (NP (DT the) (CD 4) (NN drug) (NNS classes)) (VP (VBN recommended) (PP (IN by) (NP (NP (DT the) (NN panel)) (PP (IN in) (NP (NN recommendation) (CD 6))))))))) (VP (VBD yielded) (NP (NP (JJ comparable) (NNS effects)) (PP (IN on) (NP (NP (JJ overall) (NN mortality)) (CC and) (NP (JJ cardiovascular)) (, ,) (NP (JJ cerebrovascular)) (, ,) (CC and) (NP (NN kidney) (NNS outcomes)))) (, ,) (PP (IN with) (NP (CD one) (NN exception))))) (: :) (NP (NN heart) (NN failure)) (. .)))
(ROOT (S (NP (NP (JJ Initial) (NN treatment)) (PP (IN with) (NP (DT a) (JJ thiazide-type) (NN diuretic)))) (VP (VP (VBD was) (ADJP (ADJP (RBR more) (JJ effective)) (PP (IN than) (NP (DT a) (NN CCB) (CC or) (NN ACEI) (PRN (-LRB- -LRB-) (NP (NP (NN question) (CD 3)) (, ,) (NP (NN evidence) (NNS statements) (CD 14)) (CC and) (NP (CD 15))) (-RRB- -RRB-)))))) (, ,) (CC and) (SBAR (S (NP (DT an) (NN ACEI)) (VP (VBD was) (ADJP (ADJP (RBR more) (JJ effective)) (PP (IN than) (NP (NP (NP (DT a) (NN CCB)) (PRN (-LRB- -LRB-) (NP (NP (NN question) (CD 3)) (, ,) (NP (NN evidence) (NN statement) (CD 1))) (-RRB- -RRB-))) (PP (IN in) (S (VP (VBG improving) (NP (NN heart) (NN failure) (NNS outcomes)))))))))))) (. .)))
(ROOT (FRAG (SBAR (IN While) (S (NP (NP (DT the) (NN panel)) (VP (VBD recognized) (SBAR (IN that) (S (NP (JJ improved) (NN heart) (NN failure) (NNS outcomes)) (VP (VBD was) (NP (NP (DT an) (JJ important) (NN finding)) (SBAR (WHNP (IN that)) (S (VP (MD should) (VP (VB be) (VP (VBN considered) (SBAR (WHADVP (WRB when)) (S (VP (VBG selecting) (NP (NP (DT a) (NN drug)) (PP (IN for) (NP (NP (JJ initial) (NN therapy)) (PP (IN for) (NP (NP (NN hypertension)) (, ,) (NP (DT the) (NN panel))))))))))))))))))))) (VP (VBD did) (RB not) (VP (VB conclude) (SBAR (IN that) (S (NP (PRP it)) (VP (VBD was) (ADJP (JJ compelling) (RB enough) (PP (IN within) (NP (NP (DT the) (NN context)) (PP (IN of) (NP (NP (DT the) (JJ overall) (NN body)) (PP (IN of) (NP (NN evidence))) (S (VP (TO to) (VP (VB preclude) (NP (NP (DT the) (NN use)) (PP (IN of) (NP (DT the) (JJ other) (NN drug) (NNS classes))) (PP (IN for) (NP (JJ initial) (NN therapy))))))))))))))))))) (. .)))
(ROOT (S (NP (DT The) (NN panel)) (ADVP (RB also)) (VP (VBD acknowledged) (SBAR (IN that) (S (NP (DT the) (NN evidence)) (VP (VBD supported) (NP (NP (NN BP) (NN control)) (, ,) (CONJP (RB rather) (IN than)) (NP (NP (DT a) (JJ specific) (NN agent)) (VP (VBN used) (S (VP (TO to) (VP (VB achieve) (NP (DT that) (NN control)) (, ,) (PP (IN as) (NP (NP (DT the) (ADJP (RBS most) (JJ relevant)) (NN consideration)) (PP (IN for) (NP (DT this) (NN recommendation))))))))))))))) (. .)))
(ROOT (S (NP (DT The) (NN panel)) (VP (VBD did) (RB not) (VP (VB recommend) (NP (NNS β-blockers)) (PP (IN for) (NP (NP (DT the) (JJ initial) (NN treatment)) (PP (IN of) (NP (NN hypertension))))) (SBAR (IN because) (S (PP (IN in) (NP (NP (CD one) (NN study) (NN use)) (PP (IN of) (NP (NNS β-blockers))))) (VP (VBD resulted) (PP (IN in) (NP (NP (NP (NP (DT a) (JJR higher) (NN rate)) (PP (IN of) (NP (NP (DT the) (JJ primary) (JJ composite) (NN outcome)) (PP (IN of) (NP (JJ cardiovascular) (NN death)))))) (, ,) (NP (JJ myocardial) (NN infarction)) (, ,) (CC or) (NP (NN stroke))) (VP (VBN compared) (S (VP (TO to) (VP (VB use) (PP (IN of) (NP (NP (DT an) (NN ARB)) (, ,) (NP (NP (DT a) (NN finding)) (SBAR (WHNP (WDT that)) (S (VP (VBD was) (VP (VBN driven) (ADVP (RB largely)) (PP (IN by) (NP (NP (DT an) (NN increase)) (PP (IN in) (NP (NP (NN stroke)) (PRN (-LRB- -LRB-) (NP (NP (NN question) (CD 3)) (, ,) (NP (NN evidence) (NN statement) (CD 22))) (-RRB- -RRB-)))))))))))))))))))))))) (. .)))
(ROOT (S (PP (IN In) (NP (NP (DT the) (JJ other) (NNS studies)) (SBAR (WHNP (IN that)) (S (VP (VBN compared) (NP (NP (DT a) (NN β-blocker)) (PP (TO to) (NP (DT the) (CD 4) (VBN recommended) (NN drug) (NNS classes))))))))) (, ,) (NP (NP (DT the) (NN β-blocker)) (VP (VBN performed) (ADVP (RB similarly)) (PP (TO to) (NP (NP (NP (DT the) (JJ other) (NNS drugs)) (PRN (-LRB- -LRB-) (NP (NP (NN question) (CD 3)) (, ,) (NP (NN evidence) (NN statement) (CD 8))) (-RRB- -RRB-))) (CC or) (NP (DT the) (NN evidence)))))) (VP (VBD was) (ADJP (JJ insufficient) (S (VP (TO to) (VP (VB make) (NP (NP (DT a) (NN determination)) (PRN (-LRB- -LRB-) (NP (NP (NN question) (CD 3)) (, ,) (NP (NN evidence) (NNS statements) (CD 7)) (, ,) (NP (CD 12)) (, ,) (NP (CD 21)) (, ,) (NP (CD 23)) (, ,) (CC and) (NP (CD 24))) (-RRB- -RRB-)))))))) (. .)))
(ROOT (S (NP (NNS α-Blockers)) (VP (VBD were) (RB not) (VP (VBN recommended) (PP (IN as) (NP (JJ first-line) (NN therapy))) (SBAR (IN because) (S (PP (IN in) (NP (NP (NP (CD one) (NN study)) (NP (JJ initial) (NN treatment))) (PP (IN with) (NP (DT an) (NN α-blocker))))) (VP (VBD resulted) (PRN (PP (IN in) (NP (NP (JJR worse) (NN cerebrovascular)) (, ,) (NP (NN heart) (NN failure)) (, ,) (CC and) (NP (VBN combined) (JJ cardiovascular) (NNS outcomes)))) (PP (IN than) (NP (NP (JJ initial) (NN treatment)) (PP (IN with) (NP (DT a) (JJ diuretic) (PRN (-LRB- -LRB-) (NP (NP (NN question) (CD 3)) (, ,) (NP (NN evidence) (NN statement) (CD 13))) (-RRB- -RRB-)))))))))))) (. .)))
(ROOT (S (S (NP (EX There)) (VP (VBD were) (NP (NP (DT no) (NNS RCTs)) (PP (IN of) (NP (ADJP (JJ good) (CC or) (JJ fair)) (NN quality))) (VP (VBG comparing) (NP (DT the) (VBG following) (NP (NN drug) (NNS classes))) (PP (TO to) (NP (DT the) (CD 4) (VBD recommended) (NNS classes))))))) (: :) (S (NP (JJ dual) (NN α1)) (: -) (CC +) (NP (NP (JJ β-blocking) (NNS agents)) (PRN (-LRB- -LRB-) (NP (FW eg) (, ,) (NN carvedilol)) (-RRB- -RRB-))) (, ,) (VP (VBG vasodilating) (NP (NP (NP (NNS β-blockers)) (PRN (-LRB- -LRB-) (NP (FW eg) (, ,) (NN nebivolol)) (-RRB- -RRB-))) (, ,) (NP (NP (JJ central) (JJ α2-adrenergic) (NNS agonists)) (PRN (-LRB- -LRB-) (NP (FW eg) (, ,) (NN clonidine)) (-RRB- -RRB-))) (, ,) (NP (NP (JJ direct) (NNS vasodilators)) (PRN (-LRB- -LRB-) (FW eg) (, ,) (NP (NN hydralazine)) (-RRB- -RRB-))) (, ,) (NP (NP (NN aldosterone) (NN receptor) (NNS antagonists)) (PRN (-LRB- -LRB-) (NP (FW eg) (, ,) (NN spironolactone)) (-RRB- -RRB-))) (, ,) (NP (NP (JJ adrenergic) (JJ neuronal) (VBG depleting) (NNS agents)) (PRN (-LRB- -LRB-) (NP (NN reserpine)) (-RRB- -RRB-))) (, ,) (CC and) (NP (NP (NP (NN loop) (NNS diuretics)) (PRN (-LRB- -LRB-) (NP (FW eg) (, ,) (NN furosemide)) (-RRB- -RRB-))) (PRN (-LRB- -LRB-) (NP (NP (NN question) (CD 3)) (, ,) (NP (NN evidence) (NN statement) (CD 30))) (-RRB- -RRB-)))))) (. .)))
(ROOT (S (ADVP (RB Therefore)) (, ,) (NP (DT these) (NN drug) (NNS classes)) (VP (VBP are) (RB not) (VP (VBN recommended) (PP (IN as) (NP (JJ first-line) (NN therapy))))) (. .)))
(ROOT (S (PP (IN In) (NP (NN addition))) (, ,) (NP (DT no) (JJ eligible) (NNS RCTs)) (VP (VBD were) (VP (VBN identified) (SBAR (WHNP (WDT that)) (S (VP (VBD compared) (NP (NP (NP (NP (DT a) (JJ diuretic)) (CC vs) (NP (DT an) (NN ARB))) (, ,) (CC or) (NP (DT an) (NN ACEI))) (CC vs) (NP (DT an) (NN ARB)))))))) (. .)))
(ROOT (S (NP (NNP ONTARGET)) (VP (VBD was) (RB not) (VP (JJ eligible) (SBAR (IN because) (S (NP (NN hypertension)) (VP (VBD was) (RB not) (VP (VBN required) (PP (IN for) (NP (NP (NN inclusion)) (PP (IN in) (NP (DT the) (NN study))))))))))) (. .)))
(ROOT (S (ADVP (JJ Similar) (PP (TO to) (NP (NP (DT those)) (PP (IN for) (NP (DT the) (JJ general) (NN population)))))) (, ,) (NP (DT this) (NN recommendation)) (VP (VBZ applies) (PP (TO to) (NP (NP (DT those)) (PP (IN with) (NP (NN diabetes))))) (SBAR (IN because) (S (NP (NP (NNS trials)) (PP (VBG including) (NP (NP (NNS participants)) (PP (IN with) (NP (NN diabetes)))))) (VP (VBD showed) (NP (NP (DT no) (NNS differences)) (PP (IN in) (NP (NP (JJ major) (ADJP (ADJP (JJ cardiovascular)) (CC or) (ADJP (JJ cerebrovascular))) (NNS outcomes)) (PP (IN from) (NP (NP (DT those)) (PP (IN in) (NP (NP (DT the) (JJ general) (NN population)) (PRN (-LRB- -LRB-) (NP (NP (NN question) (CD 3)) (, ,) (NP (NN evidence) (NNS statements) (CD 36-48))) (-RRB- -RRB-))))))))))))) (. .)))
(ROOT (S (NP (DT The) (VBG following) (NP (JJ important) (NNS points))) (VP (MD should) (VP (VB be) (VP (VBN noted)))) (. .)))
(ROOT (S (ADVP (RB First)) (, ,) (NP (JJ many) (NNS people)) (VP (MD will) (VP (VB require) (NP (NP (NN treatment)) (SBAR (IN with) (S (NP (QP (JJR more) (IN than) (CD one)) (JJ antihypertensive) (NN drug)) (VP (TO to) (VP (VB achieve) (NP (NN BP) (NN control))))))))) (. .)))
(ROOT (S (SBAR (IN While) (S (NP (DT this) (NN recommendation)) (VP (VBZ applies) (ADVP (RB only)) (PP (TO to) (NP (NP (DT the) (NN choice)) (PP (IN of) (NP (NP (DT the) (JJ initial) (JJ antihypertensive) (NN drug)) (, ,) (NP (DT the) (NN panel))))))))) (VP (VBZ suggests) (SBAR (IN that) (S (NP (NP (DT any)) (PP (IN of) (NP (DT these) (CD 4) (NNS classes)))) (VP (MD would) (VP (VB be) (NP (NP (JJ good) (NNS choices)) (PP (IN as) (NP (NP (JJ add-on) (NNS agents)) (PRN (-LRB- -LRB-) (NP (NN recommendation) (CD 9)) (-RRB- -RRB-)))))))))) (. .)))
(ROOT (S (S (ADVP (RB Second)) (, ,) (NP (DT this) (NN recommendation)) (VP (VBZ is) (ADJP (JJ specific) (PP (IN for) (NP (NP (JJ thiazide-type) (NNS diuretics)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBP include) (NP (NP (JJ thiazide) (NNS diuretics)) (, ,) (NP (NN chlorthalidone)) (, ,) (CC and) (NP (NN indapamide))))))))))) (: ;) (S (NP (PRP it)) (VP (VBZ does) (RB not) (VP (VB include) (NP (NP (NN loop)) (CC or) (NP (JJ potassium-sparing) (NNS diuretics)))))) (. .)))
(ROOT (S (ADVP (NNP Third)) (, ,) (NP (PRP it)) (VP (VBZ is) (ADJP (JJ important)) (SBAR (IN that) (S (NP (NNS medications)) (VP (VB be) (VP (VBN dosed) (ADVP (RB adequately)) (S (VP (TO to) (VP (VB achieve) (NP (NP (NP (NNS results)) (ADJP (JJ similar) (PP (TO to) (NP (NP (DT those)) (VP (VBN seen) (PP (IN in) (NP (DT the) (NNS RCTs)))))))) (PRN (-LRB- -LRB-) (NNP Table) (LST (LS 4)) (-RRB- -RRB-))))))))))) (. .)))
(ROOT (S (ADVP (JJ Fourth)) (, ,) (NP (NP (NNS RCTs)) (SBAR (WHNP (WDT that)) (S (VP (VBD were) (VP (VBN limited) (PP (TO to) (NP (NP (JJ specific) (JJ nonhypertensive) (NNS populations)) (, ,) (PP (JJ such) (IN as) (NP (NP (DT those)) (PP (IN with) (NP (NP (JJ coronary) (NN artery) (NN disease)) (CC or) (NP (NN heart) (NN failure)) (, ,)))))))))))) (VP (VBD were) (RB not) (VP (VBN reviewed) (PP (IN for) (NP (DT this) (NN recommendation))))) (. .)))
(ROOT (S (ADVP (RB Therefore)) (, ,) (NP (NN recommendation) (CD 6)) (VP (MD should) (VP (VB be) (VP (VBN applied) (PP (IN with) (NP (NN caution))) (PP (TO to) (NP (DT these) (NNS populations)))))) (. .)))
(ROOT (S (NP (NP (NNS Recommendations)) (PP (IN for) (NP (NP (DT those)) (PP (IN with) (NP (NN CKD)))))) (VP (VBP are) (VP (VBN addressed) (PP (IN in) (NP (NN recommendation) (CD 8))))) (. .)))
(ROOT (NP (NN Recommendation) (CD 7)))
(ROOT (S (PP (IN In) (NP (DT the) (JJ general) (JJ black) (NN population))) (, ,) (PP (VBG including) (NP (NP (NP (DT those)) (PP (IN with) (NP (NN diabetes)))) (, ,) (NP (JJ initial) (JJ antihypertensive) (NN treatment)))) (VP (MD should) (VP (VB include) (NP (DT a) (JJ thiazide-type) (JJ diuretic) (CC or) (NN CCB)))) (. .)))
(ROOT (UCP (PP (IN For) (NP (JJ general) (JJ black) (NN population))) (: :) (NP (NP (JJ Moderate) (NN Recommendation)) (: --) (NP (NNP Grade) (NNP B)))))
(ROOT (S (PP (IN For) (NP (NP (JJ black) (NNS patients)) (PP (IN with) (NP (NN diabetes))))) (: :) (VP (VB Weak) (NP (NP (NN Recommendation)) (: --) (NP (NNP Grade) (NNP C))))))
(ROOT (S (NP (NN Recommendation) (CD 7)) (VP (VBZ is) (VP (VBN based) (PP (IN on) (NP (NP (NN evidence) (NNS statements)) (PP (IN from) (NP (NN question) (CD 3))))))) (. .)))
(ROOT (S (PP (IN In) (NP (NP (NNS cases)) (SBAR (WHPP (IN for) (WHNP (WDT which))) (S (NP (NP (NN evidence)) (PP (IN for) (NP (DT the) (JJ black) (NN population)))) (VP (VBD was) (ADJP (DT the) (JJ same) (PP (IN as) (PP (IN for) (NP (DT the) (JJ general) (NN population)))))))))) (, ,) (NP (NP (DT the) (NN evidence) (NNS statements)) (PP (IN for) (NP (DT the) (JJ general) (NN population)))) (VP (VB apply) (PP (TO to) (NP (DT the) (JJ black) (NN population)))) (. .)))
(ROOT (S (ADVP (RB However)) (, ,) (NP (EX there)) (VP (VBP are) (NP (NP (DT some) (NNS cases)) (SBAR (WHPP (IN for) (WHNP (WDT which))) (S (NP (NP (DT the) (NNS results)) (PP (IN for) (NP (JJ black) (NNS persons)))) (VP (VBD were) (ADJP (JJ different) (PP (IN from) (NP (NP (DT the) (NNS results)) (PP (IN for) (NP (NP (DT the) (JJ general) (NN population)) (PRN (-LRB- -LRB-) (NP (NP (NN question) (CD 3)) (, ,) (NP (NN evidence) (NNS statements) (CD 2)) (, ,) (NP (CD 10)) (, ,) (CC and) (NP (CD 17))) (-RRB- -RRB-)))))))))))) (. .)))
(ROOT (S (PP (IN In) (NP (DT those) (NNS cases))) (, ,) (NP (JJ separate) (NN evidence) (NNS statements)) (VP (VBD were) (VP (VBN developed))) (. .)))
(ROOT (S (NP (DT This) (NN recommendation)) (VP (VBZ stems) (PP (IN from) (NP (NP (DT a) (JJ prespecified) (NN subgroup) (NN analysis)) (PP (IN of) (NP (NP (NNS data)) (PP (IN from) (NP (NP (NP (DT a) (JJ single) (JJ large) (NN trial)) (PRN (-LRB- -LRB-) (NP (NN ALLHAT)) (-RRB- -RRB-))) (SBAR (WHNP (WDT that)) (S (VP (VBD was) (VP (VBN rated) (S (ADJP (JJ good)))))))))))))) (. .)))
(ROOT (S (PP (IN In) (NP (DT that) (NN study))) (, ,) (S (NP (DT a) (JJ thiazide-type) (NN diuretic)) (VP (VBD was) (VP (VBN shown) (S (VP (TO to) (VP (VB be) (ADJP (RBR more) (JJ effective) (PP (IN in) (S (VP (VBG improving) (ADJP (JJ cerebrovascular)))))))))))) (, ,) (NP (NP (NN heart) (NN failure)) (, ,) (CC and) (NP (NP (VBN combined) (JJ cardiovascular) (NNS outcomes)) (VP (VBN compared) (PP (TO to) (NP (NP (DT an) (NN ACEI)) (PP (IN in) (NP (NP (DT the) (JJ black) (NN patient) (NN subgroup)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBD included) (NP (NP (JJ large) (NNS numbers)) (PP (IN of) (NP (NP (ADJP (JJ diabetic))) (CC and) (NP (NP (JJ nondiabetic) (NNS participants)) (PRN (-LRB- -LRB-) (NP (NP (NN question) (CD 3)) (, ,) (NP (NN evidence) (NNS statements) (CD 10)) (, ,) (NP (CD 15)) (CC and) (NP (CD 17))) (-RRB- -RRB-)))))))))))))))) (. .)))
(ROOT (S (ADVP (RB Therefore)) (, ,) (NP (DT the) (NN recommendation)) (VP (VBZ is) (S (VP (TO to) (VP (VB choose) (NP (NP (JJ thiazide-type) (NNS diuretics)) (PP (IN over) (NP (NP (NNP ACEI)) (PP (IN for) (NP (JJ black) (NNS patients)))))))))) (. .)))
(ROOT (S (SBAR (IN Although) (S (NP (DT a) (NN CCB)) (VP (VBD was) (ADJP (ADJP (RBR less) (JJ effective)) (PP (IN than) (NP (NP (DT a) (JJ diuretic)) (PP (IN in) (S (VP (VBG preventing) (NP (NN heart) (NN failure)) (PP (IN in) (NP (NP (DT the) (JJ black) (NN subgroup)) (PP (IN of) (NP (NP (DT this) (NN trial)) (PRN (-LRB- -LRB-) (NP (NP (NN question) (CD 3)) (, ,) (NP (NN evidence) (NN statement) (CD 14))) (-RRB- -RRB-))))))))))))))) (, ,) (NP (EX there)) (VP (VBD were) (NP (NP (DT no) (NNS differences)) (PP (IN in) (NP (NP (JJ other) (NNS outcomes)) (PRN (-LRB- -LRB-) (NP (JJ cerebrovascular) (, ,) (NN CHD) (, ,) (VP (VP (VBN combined) (ADJP (JJ cardiovascular))) (, ,) (CC and) (NP (NP (NN kidney) (NNS outcomes)) (, ,) (CC or) (NP (JJ overall) (NN mortality))))) (-RRB- -RRB-)))) (PP (IN between) (NP (NP (DT a) (NN CCB)) (CC and) (NP (DT a) (JJ diuretic) (PRN (-LRB- -LRB-) (NP (NP (NN question) (CD 3)) (, ,) (NP (NN evidence) (NNS statements) (CD 6)) (, ,) (CD 8) (, ,) (CD 11) (, ,) (NP (CD 18)) (, ,) (CC and) (NP (CD 19))) (-RRB- -RRB-))))))) (. .)))
(ROOT (S (ADVP (RB Therefore)) (, ,) (NP (DT both) (JJ thiazide-type) (NNS diuretics) (CC and) (NNS CCBs)) (VP (VBP are) (VP (VBN recommended) (PP (IN as) (NP (NP (JJ first-line) (NN therapy)) (PP (IN for) (NP (NP (NN hypertension)) (PP (IN in) (NP (JJ black) (NNS patients))))))))) (. .)))
(ROOT (S (NP (DT The) (NN panel)) (VP (VBD recommended) (NP (DT a) (NN CCB)) (PP (IN over) (NP (NP (DT an) (NN ACEI)) (PP (IN as) (NP (NP (JJ first-line) (NN therapy)) (PP (IN in) (NP (JJ black) (NNS patients))))))) (SBAR (IN because) (S (NP (EX there)) (VP (VBD was) (NP (NP (NP (DT a) (ADJP (CD 51) (NN %)) (JJR higher) (NN rate)) (PRN (-LRB- -LRB-) (NP (NP (NP (JJ relative) (NN risk)) (, ,) (NP (CD 1.51))) (: ;) (NP (NP (ADJP (CD 95) (NN %)) (NN CI)) (, ,) (NP (QP (CD 1.22-1) (CD .86))))) (-RRB- -RRB-))) (PP (IN of) (NP (NN stroke)))) (PP (IN in) (NP (JJ black) (NNS persons))) (PP (IN in) (NP (NN ALLHAT))) (PP (IN with) (NP (NP (DT the) (NN use)) (PP (IN of) (NP (DT an) (NN ACEI))) (SBAR (IN as) (S (NP (JJ initial) (NN therapy)) (VP (VBN compared) (PP (IN with) (NP (NP (NN use)) (PP (IN of) (NP (NP (DT a) (NN CCB)) (PRN (-LRB- -LRB-) (NP (NP (NN question) (CD 3)) (, ,) (NP (NN evidence) (NN statement) (CD 2))) (-RRB- -RRB-))))))))))))))) (. .)))
(ROOT (S (S (NP (DT The) (NNP ACEI)) (VP (VBD was) (ADVP (RB also)) (VP (ADJP (RBR less) (JJ effective)) (PP (IN in) (S (VP (VBG reducing) (NP (NP (NNP BP)) (PP (IN in) (NP (JJ black) (NNS individuals))))))) (PP (VBN compared) (PP (IN with) (NP (NP (DT the) (NN CCB) (-LRB- -LRB-) (NN question) (CD 3)) (, ,) (NP (NN evidence) (NN statement) (CD 2)))))))) (-RRB- -RRB-) (. .)))
(ROOT (S (NP (EX There)) (VP (VBD were) (NP (NP (DT no) (NN outcome) (NNS studies)) (VP (VBG meeting) (NP (NP (PRP$ our) (NN eligibility) (NNS criteria)) (SBAR (WHNP (IN that)) (S (NP (NP (VBN compared) (NNS diuretics) (CC or) (NNS CCBs)) (CC vs) (NP (NNS β-blockers)) (, ,) (NP (NNS ARBs)) (, ,) (CC or) (NP (NP (JJ other) (JJ renin-angiotensin) (NN system) (NNS inhibitors)) (PP (IN in) (NP (JJ black) (NNS patients))))))))))) (. .)))
(ROOT (S (NP (NP (DT The) (NN recommendation)) (PP (IN for) (NP (NP (JJ black) (NNS patients)) (PP (IN with) (NP (NN diabetes)))))) (VP (VBZ is) (ADJP (ADJP (JJR weaker)) (PP (IN than) (NP (NP (DT the) (NN recommendation)) (PP (IN for) (NP (DT the) (JJ general) (JJ black) (NN population)))))) (SBAR (IN because) (S (NP (NP (NNS outcomes)) (PP (IN for) (NP (NP (DT the) (NN comparison)) (PP (IN between) (NP (NP (JJ initial) (NN use)) (PP (IN of) (NP (DT a) (NN CCB))))))) (PP (VBN compared) (PP (TO to) (NP (NP (JJ initial) (NN use)) (PP (IN of) (NP (NP (DT an) (NN ACEI)) (PP (IN in) (NP (JJ black) (NNS persons))))) (PP (IN with) (NP (NNS diabetes))))))) (VP (VBD were) (RB not) (VP (VBN reported) (PP (IN in) (NP (NP (DT any)) (PP (IN of) (NP (NP (DT the) (NNS studies)) (ADJP (NN eligible) (PP (IN for) (NP (PRP$ our) (NN evidence) (NN review))))))))))))) (. .)))
(ROOT (FRAG (ADVP (RB Therefore)) (, ,) (NP (DT this) (NN evidence)) (VBD was) (VBN extrapolated) (PP (IN from) (NP (NP (NNS findings)) (PP (IN in) (NP (NP (DT the) (JJ black) (NNS participants)) (PP (IN in) (NP (NNP ALLHAT))))))) (, ,) (SBAR (WHNP (NP (CD 46) (NN %)) (WHPP (IN of) (WHNP (WP whom)))) (S (VP (VBD had) (NP (NNS diabetes))))) (. .)))
(ROOT (FRAG (S (NP (JJ Additional) (NN support)) (VP (VBZ comes) (PP (IN from) (NP (NP (DT a) (NN post) (FW hoc) (NN analysis)) (PP (IN of) (NP (NP (JJ black) (NNS participants)) (PP (IN in) (NP (NP (NNP ALLHAT)) (SBAR (WHNP (WDT that)) (S (VP (VBD met) (NP (NP (DT the) (NNS criteria)) (PP (IN for) (NP (DT the) (JJ metabolic) (NN syndrome))))))))))))))) (, ,) (SBAR (WHNP (NP (CD 68) (NN %)) (WHPP (IN of) (WHNP (WP whom)))) (S (VP (VBD had) (NP (NNS diabetes))))) (. .)))
(ROOT (S (ADVP (RB However)) (, ,) (NP (DT this) (NN study)) (VP (VBD did) (RB not) (VP (VB meet) (NP (NP (DT the) (NNS criteria)) (PP (IN for) (NP (PRP$ our) (NN review))))) (SBAR (IN because) (S (NP (PRP it)) (VP (VBD was) (NP (ADJP (DT a) (NN post) (FW hoc)) (NN analysis)))))) (. .)))
(ROOT (S (NP (DT This) (NN recommendation)) (ADVP (RB also)) (VP (VBZ does) (RB not) (VP (VB address) (NP (JJ black) (NNS persons)) (PP (IN with) (NP (NP (NN CKD)) (, ,) (SBAR (WHNP (WP who)) (S (VP (VBP are) (VP (VBN addressed) (PP (IN in) (NP (NN recommendation) (CD 8))))))))))) (. .)))
(ROOT (NP (NN Recommendation) (CD 8)))
(ROOT (FRAG (PP (IN In) (NP (DT the) (NN population))) (NP (ADJP (JJ aged) (SBAR (S (NP (NP (CD 18) (NNS years)) (CC or) (NP (JJR older) (PP (IN with) (NP (NP (NP (NN CKD)) (CC and) (NP (NN hypertension))) (, ,) (NP (ADJP (JJ initial) (PRN (-LRB- -LRB-) (CC or) (NP (ADJP (NP (JJ add-on)))) (-RRB- -RRB-))) (JJ antihypertensive) (NN treatment)))))) (VP (MD should) (VP (VB include) (NP (NP (DT an) (NN ACEI) (CC or) (NN ARB)) (SBAR (S (VP (TO to) (VP (VB improve) (NP (NN kidney) (NNS outcomes))))))))))))) (. .)))
(ROOT (S (NP (DT This)) (VP (VBZ applies) (PP (TO to) (NP (NP (DT all) (NN CKD) (NNS patients)) (PP (IN with) (NP (NP (NN hypertension)) (ADVP (RB regardless) (PP (IN of) (NP (NN race) (CC or) (NN diabetes) (NN status))))))))) (. .)))
(ROOT (NP (NP (JJ Moderate) (NN Recommendation)) (: --) (NP (NNP Grade) (NNP B))))
(ROOT (S (NP (DT The) (NN evidence)) (VP (VBZ is) (ADJP (ADJP (JJ moderate) (PRN (-LRB- -LRB-) (NP (NP (NN question) (CD 3)) (, ,) (NP (NN evidence) (NNS statements) (NP (CD 31-32)))) (-RRB- -RRB-))) (SBAR (WDT that) (S (NP (NP (NN treatment)) (PP (IN with) (NP (DT an) (NN ACEI) (CC or) (NN ARB)))) (VP (VBZ improves) (NP (NN kidney) (NNS outcomes)) (PP (IN for) (NP (NP (NNS patients)) (PP (IN with) (NP (NN CKD)))))))))) (. .)))
(ROOT (S (NP (DT This) (NN recommendation)) (VP (VBZ applies) (PP (TO to) (NP (NP (NP (NN CKD) (NNS patients)) (PP (PP (IN with)) (CC and) (PP (IN without)))) (NP (NN proteinuria) (, ,)))) (SBAR (IN as) (S (NP (NP (NNS studies)) (VP (VBG using) (NP (NP (NNS ACEIs)) (CC or) (NP (NNS ARBs))))) (VP (VBD showed) (NP (NP (NN evidence)) (PP (IN of) (NP (NP (VBN improved) (NN kidney) (NNS outcomes)) (PP (IN in) (NP (DT both) (NNS groups)))))))))) (. .)))
(ROOT (S (NP (DT This) (NN recommendation)) (VP (VBZ is) (VP (VBN based) (PP (ADVP (RB primarily)) (IN on) (NP (NN kidney) (NNS outcomes))))) (SBAR (IN because) (S (NP (EX there)) (VP (VBZ is) (NP (NP (JJR less) (NN evidence)) (VP (VBG favoring) (NP (NP (NP (NN ACEI)) (CC or) (NP (NN ARB))) (PP (IN for) (NP (NP (JJ cardiovascular) (NNS outcomes)) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (NN CKD))))))))))))) (. .)))
(ROOT (S (NP (DT Neither) (NP (NNS ACEIs)) (CC nor) (NP (NNS ARBs))) (VP (VBD improved) (NP (NP (JJ cardiovascular) (NNS outcomes)) (PP (IN for) (NP (NN CKD) (NNS patients)))) (PP (VBN compared) (PP (IN with) (NP (DT a) (NN β-blocker) (CC or) (VP (NN CCB) (PRN (-LRB- -LRB-) (NP (NP (NN question) (CD 3)) (, ,) (NP (NN evidence) (NNS statements) (CD 33-34))) (-RRB- -RRB-))))))) (. .)))
(ROOT (S (NP (NP (CD One) (NN trial)) (PRN (-LRB- -LRB-) (NP (NN IDNT)) (-RRB- -RRB-))) (VP (VBD did) (VP (VB show) (NP (NN improvement)) (PP (IN in) (NP (NN heart) (NN failure) (NNS outcomes))) (PP (IN with) (NP (NP (DT an) (NN ARB)) (VP (VBN compared) (PP (IN with) (NP (NP (DT a) (NNP CCB)) (, ,) (CC but) (NP (DT this) (NN trial))))))))) (VBD was) (VP (JJ restricted) (PP (TO to) (NP (NP (DT a) (NN population)) (PP (IN with) (NP (NP (JJ diabetic) (NN nephropathy)) (CC and) (NP (NP (NN proteinuria)) (PRN (-LRB- -LRB-) (NP (NP (NN question) (CD 3)) (, ,) (NP (NN evidence) (NN statement) (CD 5))) (-RRB- -RRB-)))))))) (. .)))
(ROOT (S (NP (EX There)) (VP (VBP are) (NP (DT no) (NNS RCTs)) (PP (IN in) (NP (NP (DT the) (NN evidence) (NN review)) (SBAR (WHNP (WDT that)) (S (ADVP (RB directly)) (VP (VBN compared) (NP (NN ACEI)) (PP (TO to) (NP (NP (NN ARB)) (PP (IN for) (NP (DT any) (JJ cardiovascular) (NN outcome))))))))))) (. .)))
(ROOT (S (ADVP (RB However)) (, ,) (NP (DT both)) (VP (VP (VBP are) (NP (JJ renin-angiotensin) (NN system) (NNS inhibitors))) (CC and) (VP (VBP have) (VP (VBN been) (VP (VBN shown) (S (VP (TO to) (VP (VB have) (NP (NP (JJ similar) (NNS effects)) (PP (IN on) (NP (NP (NN kidney) (NNS outcomes)) (PRN (-LRB- -LRB-) (NP (NP (NN question) (CD 3)) (, ,) (NP (NN evidence) (NNS statements) (CD 31-32))) (-RRB- -RRB-)))))))))))) (. .)))
(ROOT (S (NP (NN Recommendation) (CD 8)) (VP (VBZ is) (ADVP (RB specifically)) (VP (VBN directed) (PP (IN at) (NP (NP (DT those)) (PP (IN with) (NP (NP (NP (NN CKD)) (CC and) (NP (NN hypertension))) (CC and) (NP (NNS addresses))))))) (NP (NP (NP (DT the) (JJ potential) (NN benefit)) (PP (IN of) (NP (JJ specific) (NNS drugs)))) (PP (IN on) (NP (NN kidney) (NNS outcomes))))) (. .)))
(ROOT (S (NP (DT The) (NNP AASK) (NN study)) (VP (VP (VBD showed) (NP (NP (NP (NP (DT the) (NN benefit)) (PP (IN of) (NP (DT an) (NN ACEI)))) (PP (IN on) (NP (NN kidney) (NNS outcomes)))) (PP (IN in) (NP (NP (JJ black) (NNS patients)) (PP (IN with) (NP (NN CKD))))))) (CC and) (VP (VBZ provides) (NP (JJ additional) (NN evidence) (SBAR (IN that) (S (VP (VBZ supports) (S (NP (NNP ACEI)) (VP (VB use) (PP (IN in) (NP (DT that) (NN population))))))))))) (. .)))
(ROOT (S (NP (NP (JJ Additional) (NNS trials)) (SBAR (WHNP (WDT that)) (S (VP (VBP support) (NP (NP (DT the) (NNS benefits)) (PP (IN of) (NP (NP (NN ACEI)) (CC or) (NP (NN ARB) (NN therapy))))))))) (VP (VBD did) (RB not) (VP (VB meet) (NP (PRP$ our) (NN inclusion) (NNS criteria))) (SBAR (IN because) (S (NP (PRP they)) (VP (VBD were) (RB not) (ADJP (JJ restricted) (PP (TO to) (NP (NP (NNS patients)) (PP (IN with) (NP (NN hypertension)))))))))) (. .)))
(ROOT (S (NP (JJ Direct) (NN renin) (NNS inhibitors)) (VP (VBP are) (RB not) (VP (VBN included) (PP (IN in) (NP (DT this) (NN recommendation))) (SBAR (IN because) (S (NP (EX there)) (VP (VBD were) (NP (NP (DT no) (NNS studies)) (VP (VBG demonstrating) (NP (PRP$ their) (NNS benefits)) (PP (IN on) (NP (ADJP (NN kidney) (CC or) (JJ cardiovascular)) (NNS outcomes)))))))))) (. .)))
(ROOT (S (NP (DT The) (NN panel)) (VP (VBD noted) (S (NP (NP (DT the) (JJ potential) (NN conflict)) (PP (IN between) (NP (DT this) (NN recommendation)))) (VP (TO to) (VP (VB use) (NP (DT an) (NN ACEI) (CC or) (NN ARB)) (PP (IN in) (NP (NP (DT those)) (PP (IN with) (NP (NP (NP (NN CKD)) (CC and) (NP (NN hypertension))) (CC and) (NP (DT the) (NN recommendation) (S (VP (TO to) (VP (VB use) (NP (DT a) (JJ diuretic) (CC or) (NP (NP (NN CCB)) (PRN (-LRB- -LRB-) (NP (NN recommendation) (CD 7)) (-RRB- -RRB-)))) (PP (IN in) (NP (JJ black) (NNS persons)))))))))))))) (: :) (FRAG (WHNP (WP what)) (SBAR (SBAR (IN if) (S (NP (DT the) (NN person)) (VP (VBZ is) (ADJP (JJ black))))) (CC and) (SQ (VP (VBZ has) (NP (NNP CKD))))))) (. ?)))
(ROOT (S (S (VP (TO To) (VP (VB answer) (NP (DT this))))) (, ,) (NP (DT the) (NN panel)) (VP (VBN relied) (PP (IN on) (NP (JJ expert) (NN opinion)))) (. .)))
(ROOT (S (PP (IN In) (NP (NP (JJ black) (NNS patients)) (PP (IN with) (NP (NP (NN CKD)) (CC and) (NP (NN proteinuria)))))) (, ,) (NP (DT an) (NN ACEI) (CC or) (NN ARB)) (VP (VBZ is) (VP (VBN recommended) (PP (IN as) (NP (JJ initial) (NN therapy))) (PP (IN because) (IN of) (NP (NP (DT the) (JJR higher) (NN likelihood)) (PP (IN of) (NP (NP (NN progression)) (PP (TO to) (NP (NN ESRD))))))))) (. .)))
(ROOT (S (PP (PP (IN In) (NP (NP (JJ black) (NNS patients)) (PP (IN with) (NP (NN CKD))))) (CC but) (PP (IN without) (NP (NN proteinuria)))) (, ,) (NP (NP (DT the) (NN choice)) (PP (IN for) (NP (JJ initial) (NN therapy)))) (VP (VP (VBZ is) (ADJP (RBR less) (JJ clear))) (CC and) (VP (VBZ includes) (NP (NP (DT a) (JJ thiazide-type) (JJ diuretic)) (, ,) (NP (NNP CCB)) (, ,) (NP (NNP ACEI)) (, ,) (CC or) (NP (NN ARB))))) (. .)))
(ROOT (S (SBAR (IN If) (S (NP (NP (DT an) (NN ACEI)) (CC or) (NP (NN ARB))) (VP (VBZ is) (RB not) (VP (VBN used) (PP (IN as) (NP (DT the) (JJ initial) (NN drug))))))) (, ,) (ADVP (RB then)) (NP (DT an) (NN ACEI) (CC or) (NN ARB)) (VP (MD can) (VP (VB be) (VP (VBN added) (PP (IN as) (NP (NP (DT a) (JJ second-line) (NN drug)) (SBAR (IN if) (FRAG (S (ADJP (JJ necessary)) (S (VP (TO to) (VP (VB achieve) (NP (NN goal) (NN BP))))))))))))) (. .)))
(ROOT (S (SBAR (IN Because) (S (NP (NP (DT the) (NN majority)) (PP (IN of) (NP (NP (NNS patients)) (PP (IN with) (NP (NP (NN CKD)) (CC and) (NP (NN hypertension))))))) (VP (MD will) (VP (VB require) (S (NP (QP (JJR more) (IN than) (CD 1)) (NN drug)) (VP (TO to) (VP (VB achieve) (NP (NN goal) (NN BP))))))))) (, ,) (NP (PRP it)) (VP (VBZ is) (VP (VBN anticipated) (SBAR (IN that) (S (NP (DT an) (NN ACEI) (CC or) (NN ARB)) (VP (MD will) (VP (VB be) (VP (VBN used) (PP (DT either) (IN as) (NP (NP (JJ initial) (NN therapy)) (CC or) (PP (IN as) (NP (NP (JJ second-line) (NN therapy)) (PP (IN in) (NP (NP (NN addition)) (PP (TO to) (NP (NP (DT a) (JJ diuretic) (CC or) (NN CCB)) (PP (IN in) (NP (NP (JJ black) (NNS patients)) (PP (IN with) (NP (NN CKD)))))))))))))))))))) (. .)))
(ROOT (S (S (NP (NN Recommendation) (CD 8)) (VP (VBZ applies) (PP (TO to) (S (NP (NNS adults)) (VP (VBN aged) (NP (NP (CD 18) (NNS years)) (CC or) (ADJP (JJR older) (PP (IN with) (NP (NN CKD)))))))))) (, ,) (CC but) (S (NP (EX there)) (VP (VBZ is) (NP (NP (DT no) (NN evidence)) (SBAR (S (VP (TO to) (VP (VB support) (NP (NP (JJ renin-angiotensin) (NN system) (NN inhibitor) (NN treatment)) (PP (IN in) (NP (NP (DT those)) (ADJP (ADJP (JJR older)) (PP (IN than) (NP (CD 75) (NNS years)))))))))))))) (. .)))
(ROOT (S (SBAR (IN Although) (S (NP (NP (NN treatment)) (PP (IN with) (NP (DT an) (NN ACEI) (CC or) (NN ARB)))) (VP (MD may) (VP (VB be) (ADJP (JJ beneficial)) (PP (IN in) (NP (NP (DT those)) (ADJP (ADJP (JJR older)) (PP (IN than) (NP (CD 75) (NNS years)))))))))) (, ,) (NP (NP (NN use)) (PP (IN of) (NP (DT a) (JJ thiazide-type) (JJ diuretic) (CC or) (NN CCB)))) (VP (VBZ is) (ADVP (RB also)) (NP (NP (DT an) (NN option)) (PP (IN for) (NP (NP (NNS individuals)) (PP (IN with) (NP (NP (NN CKD)) (PP (IN in) (NP (DT this) (NN age) (NN group))))))))) (. .)))
(ROOT (S (NP (NP (NN Use)) (PP (IN of) (NP (NP (DT an) (NN ACEI)) (CC or) (NP (DT an) (NN ARB))))) (VP (MD will) (ADVP (RB commonly)) (VP (VP (VB increase) (NP (NN serum) (NN creatinine))) (CC and) (VP (MD may) (VP (VB produce) (NP (NP (JJ other) (JJ metabolic) (NNS effects)) (PP (JJ such) (IN as) (NP (NN hyperkalemia)))) (, ,) (PP (ADVP (RB particularly)) (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (VBN decreased) (NN kidney) (NN function))))))))) (. .)))
(ROOT (S (S (SBAR (IN Although) (S (NP (NP (DT an) (NN increase)) (PP (IN in) (NP (NP (NN creatinine)) (CC or) (NP (NN potassium) (NN level))))) (VP (VBZ does) (RB not) (ADVP (RB always)) (VP (VB require) (S (VP (VBG adjusting) (NP (NN medication)))))))) (, ,) (NP (NP (NN use)) (PP (IN of) (NP (JJ renin-angiotensin) (NN system) (NNS inhibitors))) (PP (IN in) (NP (DT the) (NNP CKD) (NN population)))) (VP (VBZ requires) (NP (NP (NP (NN monitoring)) (PP (IN of) (NP (NN electrolyte)))) (CC and) (NP (NN serum) (NN creatinine) (NNS levels))))) (, ,) (CC and) (S (PP (IN in) (NP (DT some) (NNS cases))) (, ,) (VP (MD may) (VP (VB require) (NP (NP (NN reduction)) (PP (IN in) (NP (NP (NN dose)) (CC or) (NP (NN discontinuation)))) (PP (IN for) (NP (NN safety) (NNS reasons))))))) (. .)))
(ROOT (NP (NN Recommendation) (CD 9)))
(ROOT (S (NP (NP (DT The) (JJ main) (NN objective)) (PP (IN of) (NP (NN hypertension) (NN treatment)))) (VP (VBZ is) (S (VP (TO to) (VP (VB attain) (CC and) (VB maintain) (NP (NN goal) (NN BP)))))) (. .)))
(ROOT (S (SBAR (IN If) (S (NP (NN goal) (NN BP)) (VP (VBZ is) (RB not) (VP (VBN reached) (PP (IN within) (NP (NP (DT a) (NN month)) (PP (IN of) (NP (NN treatment))))))))) (, ,) (VP (VBP increase) (NP (NP (NP (DT the) (NN dose)) (PP (IN of) (NP (DT the) (JJ initial) (NN drug)))) (CC or) (VP (VB add) (NP (DT a) (JJ second) (NN drug)) (PP (IN from) (NP (NP (CD one)) (PP (IN of) (NP (DT the) (NNS classes))) (PP (IN in) (NP (NP (NN recommendation) (CD 6)) (PRN (-LRB- -LRB-) (NP (NP (JJ thiazide-type) (JJ diuretic) (, ,) (NNP CCB)) (, ,) (NP (NP (NNP ACEI)) (, ,) (CC or) (NP (NN ARB)))) (-RRB- -RRB-))))))))) (. .)))
(ROOT (S (NP (DT The) (NN clinician)) (VP (VP (MD should) (VP (VB continue) (S (VP (TO to) (VP (VB assess) (NP (NN BP))))))) (CC and) (VP (VBP adjust) (NP (DT the) (NN treatment) (NN regimen)) (SBAR (IN until) (S (NP (NN goal) (NN BP)) (VP (VBZ is) (VP (VBN reached))))))) (. .)))
(ROOT (FRAG (SBAR (IN If) (S (NP (NN goal) (NN BP)) (VP (MD can) (RB not) (VP (VB be) (VP (VP (VBN reached) (PP (IN with) (NP (CD 2) (NNS drugs)))) (, ,) (VP (VB add) (CC and) (VP (VB titrate) (NP (NP (DT a) (JJ third) (NN drug)) (PP (IN from) (NP (NP (DT the) (NN list)) (VP (VBN provided)))))))))))) (. .)))
(ROOT (S (VP (VB Do) (RB not) (VP (VB use) (NP (NP (DT an) (NN ACEI)) (CC and) (NP (DT an) (NN ARB))) (ADVP (RB together)) (PP (IN in) (NP (DT the) (JJ same) (NN patient))))) (. .)))
(ROOT (FRAG (SBAR (IN If) (S (S (NP (NN goal) (NN BP)) (VP (MD can) (RB not) (VP (VB be) (VP (VBN reached) (S (VP (VBG using) (NP (DT the) (NNS drugs)) (PP (IN in) (NP (NN recommendation) (CD 6))) (PP (IN because) (IN of) (NP (NP (DT a) (NN contraindication)) (CC or) (NP (DT the) (NN need) (S (VP (TO to) (VP (VB use) (NP (QP (JJR more) (IN than) (CD 3)) (NNS drugs)) (S (VP (TO to) (VP (VB reach) (NP (NP (NN goal) (NN BP)) (, ,) (NP (NP (JJ antihypertensive) (NNS drugs)) (PP (IN from) (NP (JJ other) (NNS classes)))))))))))))))))))) (VP (MD can) (VP (VB be) (VP (VBN used)))))) (. .)))
(ROOT (S (NP (NP (NN Referral)) (PP (TO to) (NP (DT a) (NN hypertension) (NN specialist)))) (VP (MD may) (VP (VB be) (VP (VBN indicated) (PP (IN for) (NP (NP (NNS patients)) (SBAR (WHPP (IN in) (WHNP (WP whom))) (S (NP (NN goal) (NN BP)) (VP (MD can) (RB not) (VP (VB be) (VP (VBN attained) (S (VP (VBG using) (NP (NP (DT the) (JJ above) (NN strategy)) (CC or) (PP (IN for) (NP (NP (DT the) (NN management)) (PP (IN of) (NP (NP (JJ complicated) (NNS patients)) (SBAR (WHPP (IN for) (WHNP (WP whom))) (S (NP (JJ additional) (JJ clinical) (NN consultation)) (VP (VBZ is) (VP (VBN needed)))))))))))))))))))))) (. .)))
(ROOT (NP (NP (NN Expert) (NN Opinion)) (: --) (NP (NNP Grade) (NNP E))))
(ROOT (S (NP (NN Recommendation) (CD 9)) (VP (VBD was) (VP (VBN developed) (PP (IN by) (NP (DT the) (NN panel))) (PP (IN in) (NP (NP (NN response)) (PP (TO to) (NP (NP (DT a) (VBN perceived) (NN need)) (SBAR (IN for) (S (NP (JJ further) (NN guidance)) (VP (TO to) (VP (VB assist) (PP (IN in) (NP (NP (NN implementation)) (PP (IN of) (NP (NNS recommendations) (CD 1))))) (PP (IN through) (NP (CD 8))))))))))))) (. .)))
(ROOT (S (NP (NN Recommendation) (CD 9)) (VP (VBZ is) (VP (VBN based) (PP (IN on) (NP (NP (NNS strategies)) (VP (VBN used) (PP (IN in) (NP (NP (NNS RCTs)) (SBAR (WHNP (WDT that)) (S (VP (VBD demonstrated) (NP (NP (JJ improved) (NN patient) (NNS outcomes)) (CC and) (NP (NP (DT the) (NN expertise)) (CC and) (NP (NP (JJ clinical) (NN experience)) (PP (IN of) (NP (NN panel) (NNS members)))))))))))))))) (. .)))
(ROOT (S (NP (DT This) (NN recommendation)) (VP (VBZ differs) (PP (IN from) (NP (DT the) (JJ other) (NNS recommendations))) (SBAR (IN because) (S (NP (PRP it)) (VP (VBD was) (RB not) (VP (VBN developed) (PP (IN in) (NN response) (TO to) (NP (DT the) (CD 3) (JJ critical) (NNS questions))) (S (VP (VBG using) (NP (NP (DT a) (JJ systematic) (NN review)) (PP (IN of) (NP (DT the) (NN literature))))))))))) (. .)))
(ROOT (S (NP (DT The) (NN Figure)) (VP (VBZ is) (NP (NP (DT an) (NN algorithm)) (VP (VBG summarizing) (NP (DT the) (NNS recommendations))))) (. .)))
(ROOT (S (ADVP (RB However)) (, ,) (NP (DT this) (NN algorithm)) (VP (VBZ has) (RB not) (VP (VBN been) (VP (VBN validated) (PP (IN with) (NP (NP (NN respect)) (PP (TO to) (S (VP (VBG achieving) (NP (VBN improved) (NN patient) (NNS outcomes)))))))))) (. .)))
(ROOT (SBARQ (WHADVP (WRB How)) (SQ (MD should) (NP (NNS clinicians)) (VP (VB titrate) (CC and) (VP (VB combine) (NP (NP (DT the) (NNS drugs)) (VP (VBN recommended) (PP (IN in) (NP (DT this) (NN report)))))))) (. ?)))
(ROOT (S (NP (EX There)) (VP (VBD were) (NP (NP (DT no) (NNS RCTs)) (CC and) (RB thus) (NP (NP (DT the) (NN panel)) (VP (VBN relied) (PP (IN on) (NP (JJ expert) (NN opinion))))))) (. .)))
(ROOT (S (NP (NP (CD Three) (NNS strategies)) (PRN (-LRB- -LRB-) (NP (NNP Table) (CD 5)) (-RRB- -RRB-))) (VP (VP (VBP have) (VP (VBN been) (VP (VBN used) (PP (IN in) (NP (NP (NNS RCTs)) (PP (IN of) (NP (JJ high) (NN BP) (NN treatment)))))))) (CC but) (VP (VBD were) (RB not) (PP (VBN compared) (PP (IN with) (NP (DT each) (JJ other)))))) (. .)))
(ROOT (S (PP (VBN Based) (PP (IN on) (NP (NP (DT the) (NN evidence)) (VP (VBN reviewed) (PP (IN for) (NP (NNS questions) (CD 1))) (PP (IN through) (NP (CD 3) (CC and) (PP (IN on) (NP (NP (DT the) (JJ expert) (NN opinion)) (PP (IN of) (NP (DT the) (NN panel) (NNS members))))))))))) (, ,) (NP (PRP it)) (VP (VBZ is) (RB not) (VP (VBN known) (SBAR (IN if) (S (NP (NP (CD one)) (PP (IN of) (NP (DT the) (NNS strategies)))) (VP (VBZ results) (PP (IN in) (NP (NP (VBN improved) (JJ cardiovascular) (NNS outcomes)) (, ,) (NP (JJ cerebrovascular) (NNS outcomes)) (, ,) (NP (NN kidney) (NNS outcomes)) (, ,) (CC or) (NP (NP (NN mortality)) (VP (VBN compared) (PP (IN with) (NP (DT an) (JJ alternative) (NN strategy)))))))))))) (. .)))
(ROOT (S (NP (EX There)) (VP (VBZ is) (RB not) (ADJP (JJ likely) (S (VP (TO to) (VP (VB be) (NP (NP (NN evidence)) (PP (IN from) (NP (NP (JJ well-designed) (NNS RCTs)) (SBAR (WHNP (WDT that)) (S (VP (VP (VBP compare) (NP (DT these) (NNS strategies))) (CC and) (VP (VB assess) (NP (PRP$ their) (NNS effects)) (PP (IN on) (NP (JJ important) (NN health) (NNS outcomes))))))))))))))) (. .)))
(ROOT (S (NP (EX There)) (VP (MD may) (VP (VB be) (NP (NN evidence) (SBAR (SBAR (IN that) (S (NP (JJ different) (NNS strategies)) (VP (VBP result) (PP (PP (IN in) (NP (NP (ADJP (RBR more) (JJ rapid)) (NN attainment)) (PP (IN of) (NP (NNP BP) (NN goal))))) (CC or) (PP (IN in) (NP (VBN improved) (NN adherence))))))) (, ,) (CC but) (S (NP (DT those)) (VP (VBP are) (VP (JJ intermediate) (NP (NP (NNS outcomes)) (SBAR (WHNP (WDT that)) (S (VP (VBD were) (RB not) (VP (VBN included) (PP (IN in) (NP (DT the) (NN evidence) (NN review))))))))))))))) (. .)))
(ROOT (S (ADVP (RB Therefore)) (, ,) (NP (DT each) (NN strategy)) (VP (VP (VBZ is) (NP (NP (DT an) (JJ acceptable) (JJ pharmacologic) (NN treatment) (NN strategy)) (SBAR (WHNP (WDT that)) (S (VP (MD can) (VP (VB be) (VP (VBN tailored) (VP (VBN based) (PP (IN on) (NP (JJ individual) (NNS circumstances) (, ,) (NN clinician) (CC and) (NN patient) (NNS preferences))))))))))) (, ,) (CC and) (NP (NN drug) (NN tolerability))) (. .)))
(ROOT (S (S (PP (IN With) (NP (DT each) (NN strategy))) (, ,) (NP (NNS clinicians)) (VP (MD should) (VP (ADVP (RB regularly)) (VB assess) (NP (NNP BP))))) (, ,) (VP (VP (VBP encourage) (NP (NP (JJ evidence-based) (NN lifestyle)) (CC and) (NP (NN adherence) (NNS interventions)))) (, ,) (CC and) (VP (VBP adjust) (NP (NN treatment)) (SBAR (IN until) (S (S (NP (NN goal) (NN BP)) (VP (VBZ is) (VP (VBN attained)))) (CC and) (VP (VBN maintained)))))) (. .)))
(ROOT (S (PP (IN In) (NP (JJS most) (NNS cases))) (, ,) (S (VP (VBG adjusting) (NP (NN treatment)))) (VP (VBZ means) (NP (NP (VBG intensifying) (NN therapy)) (PP (IN by) (S (VP (UCP (VBG increasing) (NP (DT the) (NN drug) (NN dose)) (CC or)) (PP (IN by) (S (VP (VBG adding) (NP (JJ additional) (NNS drugs)) (PP (TO to) (NP (DT the) (NN regimen))))))))))) (. .)))
(ROOT (S (S (VP (TO To) (VP (VB avoid) (NP (NP (JJ unnecessary) (NN complexity)) (PP (IN in) (NP (DT this) (NN report))))))) (, ,) (NP (NP (DT the) (NN hypertension) (NN management) (NN algorithm)) (PRN (-LRB- -LRB-) (NP (NN Figure)) (-RRB- -RRB-))) (VP (VBZ does) (RB not) (ADVP (RB explicitly)) (VP (VB define) (NP (DT all) (JJ potential) (NN drug) (NN treatment) (NNS strategies)))) (. .)))
(ROOT (S (ADVP (RB Finally)) (, ,) (NP (NN panel) (NNS members)) (VP (VBP point) (PRT (RP out)) (SBAR (IN that) (S (PP (IN in) (NP (JJ specific) (NNS situations))) (, ,) (NP (CD one) (JJ antihypertensive) (NN drug)) (VP (VP (MD may) (VP (VB be) (VP (VBN replaced) (PP (IN with) (NP (DT another))))) (SBAR (IN if) (S (NP (PRP it)) (VP (VBZ is) (VP (VBN perceived) (S (RB not) (VP (TO to) (VP (VB be) (ADJP (JJ effective)))))))))) (CC or) (SBAR (IN if) (S (NP (EX there)) (VP (VBP are) (NP (JJ adverse) (NNS effects))))))))) (. .)))
(ROOT (S (NP (NP (DT This) (JJ evidence-based) (NN guideline)) (PP (IN for) (NP (NP (DT the) (NN management)) (PP (IN of) (NP (JJ high) (NN BP))) (PP (IN in) (NP (NNS adults)))))) (VP (VP (VBZ is) (RB not) (NP (DT a) (JJ comprehensive) (NN guideline))) (CC and) (VP (VBZ is) (VP (VBN limited) (PP (IN in) (NP (NN scope))) (PP (IN because) (IN of) (NP (NP (NP (DT the) (JJ focused) (NN evidence) (NN review)) (SBAR (S (VP (TO to) (VP (VB address) (NP (DT the) (CD 3) (JJ specific) (NNS questions))))))) (PRN (-LRB- -LRB-) (NNP Table) (LST (LS 1)) (-RRB- -RRB-))))))) (. .)))
(ROOT (S (S (NP (NNS Clinicians)) (ADVP (RB often)) (VP (VBP provide) (NP (NN care)) (PP (IN for) (NP (NP (NNS patients)) (PP (IN with) (NP (NP (JJ numerous) (NNS comorbidities)) (CC or) (NP (NP (JJ other) (JJ important) (NNS issues)) (VP (VBN related) (PP (TO to) (NP (NN hypertension))))))))))) (, ,) (CC but) (S (NP (DT the) (NN decision)) (VP (VBD was) (VP (VBN made) (S (VP (TO to) (VP (VB focus) (PP (IN on) (NP (NP (CD 3) (NNS questions)) (VP (VBN considered) (S (VP (TO to) (VP (VB be) (ADJP (JJ relevant) (PP (TO to) (NP (JJS most) (NP (NNS physicians) (CC and) (NNS patients))))))))))))))))) (. .)))
(ROOT (S (S (NP (NP (NN Treatment) (NN adherence)) (CC and) (NP (NN medication) (NNS costs))) (VP (VBD were) (VP (VBN thought) (S (VP (TO to) (VP (VB be) (PP (IN beyond) (NP (NP (DT the) (NN scope)) (PP (IN of) (NP (DT this) (NN review))))))))))) (, ,) (CC but) (S (NP (DT the) (NN panel)) (VP (VBZ acknowledges) (NP (NP (DT the) (NN importance)) (PP (IN of) (NP (DT both) (NNS issues)))))) (. .)))
(ROOT (S (NP (DT The) (NN evidence) (NN review)) (VP (VBD did) (RB not) (VP (VB include) (SBAR (S (NP (NP (JJ observational) (NNS studies)) (, ,) (NP (JJ systematic) (NNS reviews)) (, ,) (CC or) (NP (NNS meta-analyses)) (, ,) (CC and) (NP (DT the) (NN panel))) (VP (VBD did) (RB not) (VP (VB conduct) (NP (NP (PRP$ its) (JJ own) (NN meta-analysis)) (VP (VBN based) (PP (IN on) (NP (JJ prespecified) (NN inclusion) (NNS criteria))))))))))) (. .)))
(ROOT (S (ADVP (RB Thus)) (, ,) (NP (NP (NN information)) (PP (IN from) (NP (NP (DT these) (NNS types)) (PP (IN of) (NP (NNS studies)))))) (VP (VBD was) (RB not) (VP (VBN incorporated) (PP (IN into) (NP (DT the) (NN evidence) (NNS statements) (CC or) (NNS recommendations))))) (. .)))
(ROOT (S (SBAR (IN Although) (S (NP (DT this)) (VP (MD may) (VP (VB be) (VP (VBN considered) (S (NP (DT a) (NN limitation)))))))) (, ,) (NP (DT the) (NN panel)) (VP (VBD decided) (S (VP (TO to) (VP (VB focus) (ADVP (RB only)) (PP (IN on) (NP (NNS RCTs)))))) (SBAR (IN because) (S (NP (PRP they)) (UCP (VBP represent) (NP (DT the) (JJS best) (JJ scientific) (NN evidence)) (CC and)) (SBAR (SBAR (IN because) (S (NP (EX there)) (VP (VBD were) (NP (NP (DT a) (JJ substantial) (NN number)) (PP (IN of) (NP (NP (NNS studies)) (SBAR (WHNP (WDT that)) (S (VP (VBD included) (NP (NP (JJ large) (NNS numbers)) (PP (IN of) (NP (NNS patients))))))))))))) (CC and) (VP (VBD met) (NP (PRP$ our) (NN inclusion) (NNS criteria))))))) (. .)))
(ROOT (NP (NP (NP (VBN Randomized) (JJ controlled) (NNS trials)) (SBAR (WHNP (WDT that)) (S (VP (VBD included) (SBAR (S (NP (NP (NNS participants)) (PP (IN with) (NP (JJ normal) (NN BP)))) (VP (VBD were) (VP (VBN excluded) (PP (IN from) (NP (PRP$ our) (JJ formal) (NN analysis))))))))))) (. .)))
(ROOT (S (S (PP (IN In) (NP (NP (NP (NNS cases)) (SBAR (WHPP (IN in) (WHNP (WDT which))) (S (NP (JJ high-quality) (NN evidence)) (VP (VBD was) (RB not) (ADJP (JJ available)))))) (CC or) (NP (DT the) (NN evidence)))) (VP (VBD was) (ADJP (ADJP (JJ weak)) (CC or) (ADJP (JJ absent))))) (, ,) (NP (DT the) (NN panel)) (VP (VBN relied) (PP (IN on) (NP (NP (JJ fair-quality) (NN evidence)) (, ,) (NP (NP (NP (NN panel) (NNS members) (POS ')) (NN knowledge)) (PP (IN of) (NP (NP (DT the) (VBN published) (NN literature)) (SBAR (IN beyond) (S (NP (DT the) (NNS RCTs)) (VP (VBN reviewed))))))) (, ,) (CC and) (NP (NP (JJ personal) (NN experience)) (SBAR (S (VP (TO to) (VP (VB make) (NP (NNS recommendations)))))))))) (. .)))
(ROOT (S (NP (NP (DT The) (NN duration)) (PP (IN of) (NP (DT the) (NN guideline) (NN development) (NN process))) (PP (VBG following) (NP (NP (NN completion)) (PP (IN of) (NP (DT the) (JJ systematic) (NN search)))))) (VP (MD may) (VP (VB have) (VP (VBN caused) (S (NP (DT the) (NN panel)) (VP (TO to) (VP (VB miss) (NP (NP (NNS studies)) (VP (VBN published) (PP (IN after) (NP (PRP$ our) (NN literature) (NN review))))))))))) (. .)))
(ROOT (S (ADVP (RB However)) (, ,) (S (NP (DT a) (NN bridge) (NN search)) (VP (VBD was) (VP (VBN performed) (PP (IN through) (NP (NNP August) (CD 2013)))))) (, ,) (CC and) (S (NP (DT the) (NN panel)) (VP (VBD found) (NP (NP (DT no) (JJ additional) (NNS studies)) (SBAR (WHNP (WDT that)) (S (VP (MD would) (VP (VB have) (VP (VBN changed) (NP (DT the) (NNS recommendations)))))))))) (. .)))
(ROOT (S (S (NP (NP (JJ Many)) (PP (IN of) (NP (DT the) (VBN reviewed) (NNS studies)))) (VP (VBD were) (VP (VBN conducted) (SBAR (WHADVP (WRB when)) (S (NP (NP (DT the) (JJ overall) (NN risk)) (PP (IN of) (NP (NP (JJ cardiovascular) (NN morbidity)) (CC and) (NP (NN mortality))))) (VP (VBD was) (ADJP (ADJP (RB substantially) (JJR higher)) (SBAR (IN than) (S (NP (PRP it)) (VP (VBZ is) (NP (NN today)))))))))))) (: ;) (S (ADVP (RB therefore)) (, ,) (NP (NN effect) (NNS sizes)) (VP (MD may) (VP (VB have) (VP (VBN been) (VP (VBN overestimated)))))) (. .)))
(ROOT (S (ADVP (RB Further)) (, ,) (NP (NP (NNS RCTs)) (SBAR (WHNP (WDT that)) (S (VP (VBD enrolled) (NP (ADJP (ADJP (JJ prehypertensive)) (CC or) (ADJP (JJ nonhypertensive))) (NNS individuals)))))) (VP (VBD were) (VP (VBN excluded))) (. .)))
(ROOT (S (ADVP (RB Thus)) (, ,) (NP (PRP$ our) (NNS recommendations)) (VP (VBP do) (RB not) (VP (VB apply) (PP (TO to) (NP (NP (DT those)) (PP (IN without) (NP (NN hypertension))))))) (. .)))
(ROOT (FRAG (S (SBAR (IN In) (S (NP (JJ many) (NNS studies)) (VP (VBD focused) (PP (IN on) (NP (NNP DBP)))))) (, ,) (NP (NNS participants)) (ADVP (RB also)) (VP (VBD had) (NP (JJ elevated) (NNP SBP)) (SBAR (IN so) (S (NP (PRP it)) (VP (VBD was) (RB not) (ADJP (JJ possible)) (S (VP (TO to) (VP (VB determine) (SBAR (IN whether) (S (NP (NP (DT the) (NN benefit)) (VP (VBN observed) (PP (IN in) (NP (DT those) (NNS trials))))) (VP (VBD arose) (PP (IN from) (S (VP (VBG lowering) (NP (NNP DBP)))))))))))))))) (, ,) (NP (NP (NNP SBP)) (, ,) (CC or) (NP (DT both))) (. .)))
(ROOT (S (PP (IN In) (NP (NN addition))) (, ,) (NP (DT the) (NN ability) (S (VP (TO to) (VP (VB compare) (NP (NP (NNS studies)) (PP (IN from) (NP (JJ different) (NN time) (NNS periods)))))))) (VP (VBD was) (VP (VBN limited) (PP (IN by) (NP (NP (NNS differences)) (PP (IN in) (NP (NP (JJ clinical) (NN trial) (NN design)) (CC and) (NP (JJ analytic) (NNS techniques)))))))) (. .)))
(ROOT (FRAG (X (SBAR (IN While) (S (NP (NNS physicians)) (VP (VBP use) (NP (NP (NN cost)) (, ,) (NP (NN adherence)))))) (PRN (, ,) (CC and) (ADVP (RB often)) (NP (NP (JJ observational) (NNS data)) (SBAR (S (VP (TO to) (VP (VB make) (NP (NP (NN treatment) (NNS decisions)) (, ,) (SBAR (S (NP (JJ medical) (NNS interventions)) (VP (MD should) (SBAR (WHADVP (WRB whenever)) (S (FRAG (ADJP (JJ possible))) (S (VP (VB be) (VP (VBN based) (PP (ADVP (RB first) (CC and) (RB foremost)) (IN on) (NP (NP (JJ good) (NN science)) (VP (VBG demonstrating) (NP (NNS benefits)) (PP (TO to) (NP (NNS patients)))))))))))))))))))))) (. .)))
(ROOT (S (VP (VBN Randomized) (SBAR (S (NP (JJ controlled) (NNS trials)) (VP (VP (VBP are) (NP (NP (DT the) (JJ gold) (NN standard)) (PP (IN for) (NP (DT this) (NN assessment))))) (CC and) (ADVP (RB thus)) (VP (VBD were) (NP (NP (DT the) (NN basis)) (PP (IN for) (S (VP (VBG providing) (NP (DT the) (NN evidence)) (PP (IN for) (NP (PRP$ our) (JJ clinical) (NNS recommendations)))))))))))) (. .)))
(ROOT (S (SBAR (IN Although) (S (NP (NP (JJ adverse) (NNS effects)) (CC and) (NP (NP (NNS harms)) (PP (IN of) (NP (NP (JJ antihypertensive) (NN treatment)) (VP (VBN documented) (PP (IN in) (NP (DT the) (NNS RCTs)))))))) (VP (VBD were) (VP (VBN considered) (SBAR (WHADVP (WRB when)) (S (NP (DT the) (NN panel)) (VP (VBD made) (NP (PRP$ its) (NNS decisions))))))))) (, ,) (NP (DT the) (NN review)) (VP (VBD was) (RB not) (VP (VBN designed) (S (VP (TO to) (VP (VB determine) (SBAR (IN whether) (S (NP (NP (JJ therapy-associated) (JJ adverse) (NNS effects)) (CC and) (NP (NNS harms))) (VP (VBD resulted) (PP (IN in) (NP (NP (JJ significant) (NNS changes)) (PP (IN in) (NP (JJ important) (NN health) (NNS outcomes))))))))))))) (. .)))
(ROOT (S (PP (IN In) (NP (NN addition))) (, ,) (NP (DT this) (NN guideline)) (VP (VP (VBD was) (RB not) (VP (VBN endorsed) (PP (IN by) (NP (NP (DT any) (JJ federal) (NN agency)) (CC or) (NP (JJ professional) (NN society)))) (PP (RB prior) (PP (TO to) (NP (NN publication)))))) (CC and) (SBAR (S (ADVP (RB thus)) (VP (VBZ is) (NP (NP (DT a) (NN departure)) (PP (IN from) (NP (JJ previous) (NN JNC) (NNS reports)))))))) (. .)))
(ROOT (S (NP (DT The) (NN panel)) (VP (VBZ anticipates) (SBAR (IN that) (S (NP (NP (DT an) (JJ objective) (NN assessment)) (PP (IN of) (NP (DT this) (NN report))) (PP (VBG following) (NP (NN publication)))) (VP (MD will) (VP (VB allow) (NP (NP (NP (JJ open) (NN dialogue)) (PP (IN among) (NP (VBG endorsing) (NNS entities)))) (CC and) (VP (VB encourage) (NP (NP (JJ continued) (NN attention)) (PP (TO to) (NP (NP (JJ rigorous) (NNS methods)) (PP (IN in) (NP (NN guideline) (NN development)))))) (, ,) (S (ADVP (RB thus)) (VP (VBG raising) (NP (DT the) (NN standard)) (PP (IN for) (NP (JJ future) (NNS guidelines)))))))))))) (. .)))
(ROOT (S (NP (NP (DT The) (NNS recommendations)) (VP (VBN based) (PP (IN on) (NP (NP (NNP RCT) (NN evidence)) (PP (IN in) (NP (DT this) (NN guideline))))))) (VP (VBP differ) (PP (IN from) (NP (NP (NNS recommendations)) (PP (IN in) (NP (NP (JJ other) (ADJP (RB currently) (VBN used)) (NNS guidelines)) (VP (VBN supported) (PP (IN by) (NP (NP (NN expert) (NN consensus)) (PRN (-LRB- -LRB-) (NP (NNP Table) (CD 6)) (-RRB- -RRB-)))))))))) (. .)))
(ROOT (S (PP (IN For) (NP (NN example))) (, ,) (NP (NN JNC) (CD 7) (CC and) (NP (JJ other) (NNS guidelines))) (VP (VBD recommended) (NP (NN treatment)) (PP (TO to) (NP (NP (NP (JJR lower) (NNP BP) (NNS goals)) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (NP (NN diabetes)) (CC and) (NP (NN CKD))))))) (VP (VBN based) (PP (IN on) (NP (JJ observational) (NNS studies))))))) (. .)))
(ROOT (S (ADVP (RB Recently)) (, ,) (NP (NP (JJ several) (NN guideline) (NNS documents)) (PP (JJ such) (IN as) (NP (NP (DT those)) (PP (IN from) (NP (DT the) (JJ American) (NNP Diabetes) (NNP Association)))))) (VP (VBP have) (VP (VBN raised) (NP (DT the) (JJ systolic) (NN BP) (NNS goals)) (PP (TO to) (NP (NP (NNS values)) (SBAR (WHNP (WDT that)) (S (VP (VBP are) (ADJP (JJ similar) (PP (TO to) (NP (NP (DT those)) (VP (VBN recommended) (PP (IN in) (NP (DT this) (JJ evidence-based) (NN guideline)))))))))))))) (. .)))
(ROOT (S (S (NP (NP (JJ Other) (NNS guidelines)) (PP (JJ such) (IN as) (NP (NP (DT those)) (PP (IN of) (NP (NP (DT the) (JJ European) (NNP Society)) (PP (IN of) (NP (NP (NNP Hypertension/European) (NNP Society)) (PP (IN of) (NP (NNP Cardiology)))))))))) (ADVP (RB also)) (VP (VB recommend) (NP (NP (DT a) (JJ systolic) (NN BP) (NN goal)) (PP (IN of) (NP (QP (JJR lower) (IN than) (CD 150)) (NN mm) (NN Hg)))))) (, ,) (CC but) (S (NP (PRP it)) (VP (VBZ is) (RB not) (ADJP (JJ clear)) (PP (IN at) (SBAR (WHNP (WHNP (WP what) (NN age)) (NN cutoff)) (S (PP (IN in) (NP (DT the) (JJ general) (NN population))) (NP (DT this) (NN goal)) (ADVP (RB specifically)) (VP (VBZ applies))))))) (. .)))
(ROOT (S (NP (DT This) (VBG changing) (NN landscape)) (VP (VBZ is) (ADJP (JJ understandable)) (VP (VBN given) (NP (NP (DT the) (NN lack)) (PP (IN of) (NP (JJ clear) (NNP RCT) (NN evidence))) (PP (IN in) (NP (JJ many) (JJ clinical) (NNS situations)))))) (. .)))
(ROOT (S (S (NP (PRP It)) (VP (VBZ is) (ADJP (JJ important)) (S (VP (TO to) (VP (VB note) (SBAR (IN that) (S (NP (DT this) (JJ evidence-based) (NN guideline)) (VP (VBZ has) (RB not) (VP (VBN redefined) (NP (JJ high) (NN BP))))))))))) (, ,) (CC and) (S (NP (DT the) (NN panel)) (VP (VBZ believes) (SBAR (IN that) (S (NP (NP (DT the) (CD 140/90) (NN mm) (NN Hg) (NN definition)) (PP (IN from) (NP (NN JNC) (CD 7)))) (VP (VBZ remains) (ADJP (JJ reasonable))))))) (. .)))
(ROOT (S (NP (NP (NP (DT The) (NN relationship)) (PP (IN between) (S (ADJP (RB naturally) (VBG occurring)) (SBAR (S (NP (NP (NN BP)) (CC and) (NP (NN risk))) (VP (VBZ is) (ADJP (JJ linear) (PP (IN down) (PP (TO to) (NP (ADJP (RB very) (JJ low)) (NN BP))))))))))) (, ,) (CC but) (NP (NP (DT the) (NN benefit)) (PP (IN of) (S (VP (VBG treating) (PP (TO to) (NP (DT these) (JJR lower) (NNS levels))) (PP (IN with) (NP (JJ antihypertensive) (NNS drugs)))))))) (VP (VBZ is) (RB not) (VP (VBN established))) (. .)))
(ROOT (S (PP (IN For) (NP (NP (DT all) (NNS persons)) (PP (IN with) (NP (NP (NN hypertension)) (, ,) (NP (NP (DT the) (JJ potential) (NNS benefits)) (PP (IN of) (NP (DT a) (JJ healthy) (NN diet)))) (, ,) (NP (NN weight) (NN control)) (, ,) (CC and) (NP (JJ regular) (NN exercise)))))) (VP (MD can) (RB not) (VP (VB be) (VP (VBN overemphasized)))) (. .)))
(ROOT (S (NP (DT These) (NN lifestyle) (NNS treatments)) (VP (VBP have) (NP (DT the) (JJ potential) (S (VP (TO to) (VP (VP (VB improve) (NP (NN BP) (NN control))) (CC and) (VP (ADVP (RB even)) (VB reduce) (NP (NN medication) (NNS needs)))))))) (. .)))
(ROOT (S (SBAR (IN Although) (S (NP (NP (DT the) (NNS authors)) (PP (IN of) (NP (DT this) (NN hypertension) (NN guideline)))) (VP (VBD did) (RB not) (VP (VB conduct) (NP (NP (NP (DT an) (NN evidence) (NN review)) (PP (IN of) (NP (NP (NN lifestyle) (NNS treatments)) (PP (IN in) (NP (NP (NNS patients)) (VP (VBG taking))))))) (CC and) (S (RB not) (VP (VBG taking) (NP (JJ antihypertensive) (NN medication))))))))) (, ,) (S (NP (PRP we)) (VP (VBP support) (NP (NP (DT the) (NNS recommendations)) (PP (IN of) (NP (DT the) (CD 2013) (NNP Lifestyle) (NNP Work) (NNP Group)))))) (. .)))
(ROOT (S (NP (NP (DT The) (NNS recommendations)) (PP (IN from) (NP (DT this) (JJ evidence-based) (NN guideline))) (PP (IN from) (NP (NP (NN panel) (NNS members)) (VP (VBN appointed) (PP (TO to) (NP (DT the) (NNP Eighth) (NNP Joint) (NNP National) (NNP Committee)))))) (PRN (-LRB- -LRB-) (NP (NNP JNC) (CD 8)) (-RRB- -RRB-))) (VP (VBP offer) (NP (NP (NNS clinicians)) (NP (NP (NP (DT an) (NN analysis)) (PP (IN of) (SBAR (WHNP (WP what)) (S (VP (VBZ is) (VP (VBN known))))))) (CC and) (VP (RB not) (VP (VBN known) (PP (IN about) (NP (NP (NN BP) (NN treatment) (NNS thresholds)) (, ,) (NP (NNS goals)) (, ,) (CC and) (NP (NN drug) (NN treatment) (NNS strategies)))) (S (VP (TO to) (VP (VB achieve) (NP (NP (DT those) (NNS goals)) (VP (VBN based) (PP (IN on) (NP (NP (NN evidence)) (PP (IN from) (NP (NNS RCTs))))))))))))))) (. .)))
(ROOT (S (ADVP (RB However)) (, ,) (NP (DT these) (NNS recommendations)) (VP (VP (VBP are) (RB not) (NP (NP (DT a) (NN substitute)) (PP (IN for) (NP (JJ clinical) (NN judgment))))) (, ,) (CC and) (SBAR (S (NP (NP (NNS decisions)) (PP (IN about) (NP (NN care)))) (VP (MD must) (ADVP (RB carefully)) (VP (VB consider) (CC and) (VP (VP (VB incorporate) (NP (DT the) (JJ clinical) (NNS characteristics))) (CC and) (NP (NP (NNS circumstances)) (PP (IN of) (NP (DT each) (JJ individual) (NN patient)))))))))) (. .)))
(ROOT (S (NP (PRP We)) (VP (VBP hope) (SBAR (IN that) (S (NP (DT the) (NN algorithm)) (VP (MD will) (VP (VP (VB facilitate) (NP (NN implementation))) (CC and) (VP (VB be) (ADJP (JJ useful) (PP (TO to) (NP (JJ busy) (NNS clinicians)))))))))) (. .)))
(ROOT (S (NP (NP (DT The) (JJ strong) (NN evidence) (NN base)) (PP (IN of) (NP (DT this) (NN report)))) (VP (MD should) (VP (VB inform) (NP (NN quality) (NNS measures)) (PP (IN for) (NP (NP (DT the) (NN treatment)) (PP (IN of) (NP (NP (NNS patients)) (PP (IN with) (NP (NN hypertension))))))))) (. .)))